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General introduction  
and aims of this thesis
Parts of the introduction are based on:
Hidradenitis suppurativa: a systematic review 
integrating inflammatory pathways into a cohesive 
pathogenic model
Frontiers in Immunology − accepted for publication
Hidradenitis suppurativa/acne inversa: a practical 
framework for treatment optimisation – systematic 
review and recommendations from the HS 
ALLIANCE working group
J Eur Acad Dermatol Venereol – in press
Surgical approaches to hidradenitis suppurativa 
management




Hidradenitis suppurativa (HS), also known as acne in versa, is a common chronic, 
recurrent, inflammatory follicular occlusive disease. Estimated prevalence of HS in 
Europe and North America range from <1% to 4%.1,2 The disease usually presents 
after puberty with painful, deep-seated inflamed lesions, predominantly at inverse 
body sites carrying terminal hairs such as the axillae, inguinal and anogenital re-
gions.3 Atypical areas including the nape, retro-auricular areas and the back can also 
be affected.4
Key symptoms of HS include chronic pain, discomfort, and a purulent, malodorous 
discharge.5 The major factors influencing the patients well-being are disease severity, 
the number of flares or affected skin areas, and the lesion location.6 The physical 
and psychological consequences of HS can profoundly reduce several aspects of 
patient’s quality of life. This is demonstrated by the affected scores of questionnaires 
for general health (EQ-5D and SF-36), dermatologic-specific quality of life (DLQI 
and Skindex), and sexual health.6-8 The impact of HS on general health (EQ-5D) 
can be compared with cerebrovascular stroke, diabetes mellitus or severe chronic 
obstructive pulmonary disease.6 In addition, rates of depression and anxiety among 
HS patients are significantly higher than in healthy controls.9 Collectively, this might 
explain the significantly increased completed suicide risk is in patients with HS.10
The pathogenesis of HS is not fully understood. Several factors contribute to the 
onset and maintenance of the disease. Genetic predisposition is a well-known endog-
enous factor, as demonstrated by a positive family history being reported by 30-40% 
of the patients.3 Exogenous risk factors include a positive smoking status and obesity.11 
In addition, HS is linked to a number of comorbid diseases. Data suggest that HS is 
most convincingly associated with the metabolic syndrome including the report of 
higher rates of diabetes mellitus, which may explain the significantly increased risk of 
adverse cardiovascular events.12-14 More recently, several immune mediated inflam-
matory diseases have been linked to HS, notably inflammatory bowel disease and 
spondyloarthropathy.12,15 HS can also occur in the context of auto-inflammatory syn-
dromes such as pyoderma gangrenosum, acne and suppurative hidradenitis (PASH).16
PATHOPHYSIOLOGY
Current evidence highlights a complex multifactorial pathogenesis.17 A key triggering 
factor is the occlusion of the hair follicle, caused by keratosis and hyperplasia of 
the follicular epithelium leading to cyst development.18,19 Subsequently, the cyst will 
rupture, causing a fierce immune response and inflammation that, depending on the 
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severity, may progress to abscess and sinus tract development and scarring.18,19  The 
name of the disease implies that sweating and bacterial infection are a fundamental 
part of the disease process. This is misleading and now considered a misnomer as no 
evidence has been found that HS is triggered by events in the apocrine or eccrine 
glands. Recent findings on the pathogenesis of HS and its syndromic forms are largely 
derived from four main lines of investigation: genetics, inflammatory markers, bac-
teriology including the microbiome, and physiological and environmental factors.
Genetics
Mutations in γ-secretase genes whose gene products act on many substrates including 
Notch,20 suggest that Notch or other substrates of γ-secretase and/or phosphoinositide 
3-kinase (PI3K) may play a role in the pathogenesis of HS.21 However, the functional 
significance of γ-secretase remains elusive. Interestingly, γ-secretase knock-out mice 
are characterised by a phenotype of multiple cutaneous cysts, a key feature of HS.22 
However, these mice did not exhibit skin inflammation,22 and nicastrin (NCSTN) 
mutations in HS did not enhance cytokine production in LPS-stimulated peripheral 
blood mononuclear cells.23
There is also evidence of mutations to the proline-serine-threonine phosphatase 
interacting protein 1 (PSTPIP1) gene in cases of PASH and pyogenic arthritis, pyo-
derma gangrenosum, acne and suppurative hidradenitis (PAPASH) syndromes.24,25 A 
mutation in the PSTPIP1 gene resulted in a case of pyoderma gangrenosum (PG), 
acne and ulcerative colitis (PAC), in which the associated elevated interleukin (IL)-
1β levels were responsive to the IL-1 receptor antagonist anakinra.26 PSTPIP1 is a 
cytoskeleton-associated adaptor protein, highly expressed in hemopoietic cells.26 The 
PSTPIP1 protein manifests its immunomodulatory effects through downregulation of 
CD2 adhesion, regulation of c-Abl tyrosine kinase activity, and interaction with other 
immunity-related proteins including the Wiskott–Aldrich syndrome protein (WASp)27, 
and pyrin and the familial Mediterranean fever (FMF) protein.26 Furthermore, a genetic 
analysis of auto-inflammation in PG and the syndromic form PASH identified muta-
tions in a range of auto-inflammatory genes (MEFV, NLRP3, NLRP12, NOD2, LPIN2 
and PSTPIP1), suggesting the involvement of inflammatory pathways such as NLRP 
inflammasomes, cystolic pattern recognition sensors, the innate immune system, and 
IL-1β signalling (PSTPIP1).16
The majority of HS cases appear to be non-familial, suggesting the existence of sep-
arate subsets and the need for stratification of patients diagnosed with HS.28 In a study 
of 139 unrelated patients with non-familial HS, single nucleotide polymorphisms of 
the IL-12Rb1 gene coding for the IL-12Rb1 receptor subunit did not genetically pre-
dispose to HS.29 However, their carriage was directly associated with the phenotype 
of HS, indicating the importance of the IL-12/23 pathway for the pathogenesis of 
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HS. Findings from a case-control study of two independent and genetically diverse 
cohorts of patients with non-familial HS from Greece (n = 163) and Germany (n = 
98) suggested that the copy number of the β-defensin gene cluster (DEFB) confers 
susceptibility for HS and modulates the disease phenotype.30
Inflammatory markers
Clear evidence suggests the involvement of pro-inflammatory cytokines in the im-
mune dysregulation of HS, with elevated levels of tumour necrosis factor (TNF)-α, 
IL-1ß, IL-6, IL-17 and interferon (IFN)-γ observed in HS lesions.17,31,32 The immune 
dysregulation is initiated by caspase-1 activity in the inflammasome which lead to 
the secretion of the pleiotropic cytokine IL-1β, thereby stimulating the infiltration 
of inflammatory cells and the induction of chemokines.33 As a result, a number of 
inflammatory markers, most of them related to the IL-17 pathway, have been found 
elevated in HS skin and serum on the mRNA and/or protein level.
Alterations in the skin have recently been reported for IL-1β16, CXCL-8/IL-816,34,  IL-
17/IL-17A16, IL-23p4035,  IL-3236, and IL-36/IL-36α/IL-36β/IL-36γ34,37. Data also indicate 
the involvement of T helper (Th) cells, which accumulate in HS lesions, in the patho-
genesis of HS.32,38 In addition, studies have shown that antimicrobial peptides (AMPs) 
are increased in HS lesions compared with the normal skin of HS patients.39 Keratino-
cytes isolated from HS patients exhibited a pro-inflammatory profile and a dysregulated 
production of AMPs such as HBD-2, psoriasin (S100A7) and calgranulin B (S100A8), 
indicating that the skin immune system is already activated in the steady state.40
Alterations in the serum have recently been reported for  IL-1β41, IL-641, CXCL-8/
IL-841, IL-1041, IL-12p7041 and IL-17/IL-17A41,42. In addition, TNF-α, S100A8, and 
S100A9 have been found to be upregulated in the circulation of HS patients.43,44 
Systemic inflammation is also demonstrated by elevated levels of c-reactive protein 
(CRP), erythrocyte sedimentation rate, neutrophils, and monocytes.41,45 A significant 
association between CRP levels and neutrophil count with HS disease severity has 
been reported.46 Lastly, the use of TNF-α inhibitors such as adalimumab and inf-
liximab have been associated with improvements in immune dysregulation in HS, 
which supports the importance of (local) molecular drivers in the pathogenesis of 
HS.3,47,48
Bacteriology and the microbiome
A number of studies investigated bacterial cultures from HS lesions and generated 
evidence for the involvement of microbes in the disease pathogenesis. A histological 
study of 42 patients with chronic HS identified bacterial aggregates (biofilms) in 67% 
of chronic lesional samples and in 75% of perilesional samples.49 The same author 
group conducted a case-control study of punch biopsy specimens and demonstrated 
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that the microbiome in patients with HS differs significantly from that in healthy 
controls in both lesional and non-lesional skin.50 A microbial analysis of lesional ver-
sus unaffected skin from 65 patients with HS identified anaerobic microbes in 83% 
lesions versus 53% control samples, and the microbiome varied with disease sever-
ity.51 These bacteria were associated with low pathogenicity. An extensive prospective 
microbiological study identified two opportunistic bacterial pathogens associated 
with HS lesions (S.lugdunensis and anaerobic actinomycetes).52 These pathogens can 
cause abscesses and severe infections. A cross-sectional study of 50 patients reported 
that bacterial colonisation was correlated with severity and localisation of HS le-
sions.53 Over two thirds (68.8%) of patients with both aerobic and anaerobic bacteria 
had the most severe grade of HS (Hurley stage III).
Physiological and environmental factors
Recent literature supports the involvement of previously suggested physiological 
and environmental risk factors, such as smoking and obesity, in HS.46,54,55 A postal 
follow-up survey study (N = 212) found the chance of remission from HS may be 
improved in non-smokers versus smokers, and in non-obese (body mass index [BMI] 
<30) versus obese patients.54 In contrast, a retrospective study of inflammatory serum 
markers in HS patients found no association between smoking status and HS severity, 
but smoking was associated with increased neutrophil counts.46 This study did find an 
association between increased BMI and HS severity whereas there was no correlation 
between BMI and neutrophil counts.
Related to obesity, an analysis of 14 obese patients with HS described the role 
of mechanical stress (for example on the abdomen at the level of the waistband) in 
promoting a ‘Koebner-like phenomenon’ in HS.55 The development of lesions at sites 
of traumatised but previously uninvolved skin highlights the importance of localised 
environmental factors in HS development. A hospital-based cross-sectional study 
conducted in the Netherlands reported a significantly higher average BMI in 106 
patients with HS than in 212 general dermatological patients.56 Among those patients 
identified as obese, bodyweight distribution was more peripheral in patients with HS 
than those without, consistent with enhanced friction due to overlapping skin folds.
The influence of hormones has been suspected in women with HS for more than 
60 years yet has not been proven.57 Kromann and colleagues reported no clear ef-
fect of pregnancy or menopause on HS symptoms.54 However, a substantial subset 
of women did experience HS-related alterations, with deterioration of HS around 
menses and amelioration of symptoms during pregnancy reported in 43% (n = 80) 
and 30% (n = 29) of the respondents, respectively.58 This study found a significant 




Integrated viewpoint on HS pathogenesis ‘sequence of events’
On the basis of the latest evidence, we are able to propose a three-stage sequence 
of events that contribute to the pathogenesis of HS. This integrated viewpoint is il-
lustrated schematically in Figure 1.
The first event is follicular occlusion with subsequent dilation. This may be driven 
by endogenous factors in individuals harbouring a genetic predisposition for an en-
hanced risk of infundibular keratinisation and cyst formation and/or follicular fragility. 
Exogenous factors such as smoking, mechanical friction and metabolic changes such 
as obesity –  which is associated with pseudoacanthosis – also contribute to occlu-
sion of the follicular isthmus. Furthermore, occlusion of the hair follicle may lead to 
a dysregulation of the homeostatic keratinocyte symbiosis and microbial dysbiosis, 
making the skin prone to a Th1/Th17-driven inflammatory disease.
The second event is rupture of the dilated follicle. The scattering of follicle content 
in the dermis including keratin fibres, commensal flora or pathogen- and damage-
associated molecular patterns (PAMPs/DAMPs) triggers an acute and severe immune 
response. The anatomical location, i.e. the inverse body areas, and enhanced me-
chanical friction at these predilection sites facilitates the inward rupture and exten-
sion of inflammation. We argue that the release of the follicular debris into the dermis 
results in simultaneous activation of multiple inflammatory pathways, particularly 
Th17/IL-23, the NLRP inflammasomes and innate receptors (toll-like receptors, TLRs 
such as TLR2). This is accompanied by histological alterations with a diverse cell 
infiltrate characterised by the mixed participation of monocytes, neutrophils, eosino-
phils, multinucleated giant cells, B-cells, plasma cells, T-cells, and natural killer cells, 
leading to an erythematous nodule or fluctuating abscess.
The third event is chronic inflammation with sinus tract or tunnel formation. Fol-
lowing follicular rupture, sequestered proliferating Ki-67+ epithelial strands promote 
continuous activation of the immune system. The presence of epithelial strands in 
the dermis, in addition to an imbalance in matrix metalloproteinases (MMPs) and 
tissue inhibitors of metalloproteinases (TIMPs), and increased activity of fibrotic fac-
tors such as transforming growth factor (TGF)-ß 1-2-3, may lead to scarring and the 
development of sinuses/tunnels or fistulae, a hallmark of chronic HS. These (partly) 
epithelialised intracutaneous cavities provide an excellent habitat for biofilm-pro-
ducing bacteria, which are able to continuously trigger inflammation with associated 
purulent drainage. Furthermore, we hypothesise that circulating pro-inflammatory 
cytokines and chemokines from chronic lesions may activate the immune system of 












































































































































































To date, there is no long-term cure for HS. In general, the main treatment goal is to 
improve patients’ quality of life. This can be achieved by reducing the inflammation-
related pain and purulent discharge, limiting the incidence and duration of flares, 
and removing chronic lesions using surgical techniques. As there are limited effec-
tive treatment options, there remains a large unmet medical need in this area. To 
date, only eight randomised controlled trials (RCTs) have investigated the efficacy 
of anti-inflammatory agents. The highest-level evidence available addresses the use 
of biologic therapies, especially adalimumab (anti-TNF-α), and topical and systemic 
antibiotics. The majority of the remaining evidence to guide management decisions 
is based on case reports, small cohort studies and expert opinion.
Anti-inflammatory antibiotics
The literature available on the use of antibiotics in HS is limited and largely restricted 
to retrospective studies. For Hurley stage I, topical clindamycin 1% is a possible 
therapy, especially in the absence of abscesses.59,60 If there are several lesions and 
frequent exacerbations, the therapeutic group of systemic tetracyclines may be con-
sidered.60 In Hurley stage II/III patients who have several active lesions, systemic 
clindamycin and rifampicin (dosage: 300 mg twice daily) should be administered.61-64 
A triple regimen of rifampicin (10 mg/kg once daily), moxifloxacin (400 mg once 
daily) and metronidazole (500 mg thrice daily) administered for up to 12 weeks, with 
metronidazole discontinuation after 6 weeks, may be an alternative option.65 To limit 
resistance, only one antibiotic of the same class should be used for a maximum of 12 
weeks. The S1 European and HS ALLIANCE guidelines recommend that antibiotics 
should be reintroduced in case of recurrence under the requirement that they were 
effective at the last time  of use.3 Of note, in HS, traditional microbiological sampling 
is not necessary as there is no evidence for infection as a causal factor. Moreover, 
antibiotics are prescribed in HS for their anti-inflammatory properties, rather than for 
their antibacterial action.
Biologics
Biologics targeting TNF-α have been most widely investigated in HS and adalimumab 
is the only registered drug for HS. Adalimumab should be considered as a first-choice 
biologic agent in moderate-to-severe HS after failure of conventional treatments.66-68 
Infliximab has also been shown to be effective and should be considered as a second-
line biologic for moderate-to-severe HS.69 Targeting IL-1 gave ambiguous clinical 
outcomes and is considered as third-line option. On the one hand anakinra proved 
to be efficacious in moderate-to-severe HS in a RCT, but on the other hand cases of 
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failure to anakinra therapy have been reported.70-72 Ustekinumab (anti-IL-12/23p40) 
is potentially effective for the treatment of moderate-to-severe HS.73 Secukinumab 
(anti-IL-17A) has demonstrated clinical improvement of HS in single cases,74,75 and 
the results of two RCTs (ClinicalTrials.gov Identifier: NCT02421172, NCT03248531)
investigating IL-17 antagonists are being awaited.
Surgical treatment
Surgery is indicated throughout all stages of the disease.76 The presence of inflam-
mation and suppuration determines the need for anti-inflammatory treatment before 
surgery, e.g. oral antibiotics or biologics. The required surgical intervention is chosen 
based on the nature of the symptoms, the type of lesions, the presence of sinus tracts, 
and the size of the area. The evidence for surgical therapies in HS is based on case 
series and cohort studies with differing methodologies and outcome definitions, im-
peding the mutual comparison of studies that investigate surgical techniques in HS.
To ensure the best patient outcomes, surgeons should select the appropriate surgical 
technique based upon operator experience and the individual needs of the patient. 
A small excision or deroofing can be used for recurrent nodules at fixed locations 
or sinus tracts in limited areas.77,78 Wide excision of an entire affected area (body 
surface are >1%), with removal of (non-)inflamed sinuses, nodules and scar tissue, is 
indicated for patients suffering Hurley III stage disease.79-81 Special attention should 
be paid to patients with perianal and/or perineal HS due to the possible existence 
of fistulas.82,83  In addition to electrosurgical (or cold steel techniques), ablative CO2 
laser treatment is an effective alternative method.84,85
Secondary intention healing is the preferred management after excisions in HS. 
Theoretically, secondary intention healing may reduce the rate of recurrence by al-
lowing the remaining aberrant keratinocytes or residual keratin fibres to escape from 
the wound. Trapping these remnant foci of diseased tissue by primary closure or re-
introduction of hair follicles in a predilection site by flap reconstruction may induce 
recurrence in the operated area. However, to date there is no literature available to 
support this hypothesis.
Other therapies
Various other treatments have been investigated in HS, but their applicability to wide-
spread practice and outcomes is currently unknown.86 Further research is warranted 
for these therapies. Systemic acitretin may be considered as a third-line therapy for 
patients with mild-to-moderate HS.87-90 The combination of oral zinc gluconate 30 
mg thrice daily and topical triclosan 2% twice daily is a treatment option in Hurley 
I-II patients.91 Systemic dapsone 50-200 mg daily induced improvement of HS in 
38% (9/24) of treated patients.92 Metformin at a maximum dose of 500 mg thrice 
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daily showed clinical amelioration of HS,93 and could therefore be an adjuvant treat-
ment in obese HS patients at risk for developing diabetes mellitus or the metabolic 
syndrome. Low-dose systemic corticosteroids (10 mg prednisolone equivalent per 
day) may be an effective adjunct in recalcitrant HS.94 Lastly, laser- and light-based 
treatments have shown promising results for patients with HS in different disease 
stages.86 These treatments include the use of intense pulsed light or Nd:YAG laser and 
external or intralesional photodynamic therapy.
Acute management of flares
Flares of disease, characterised by the acute onset of painful nodules or abscesses, are 
a hallmark of HS. Adequate management of flares is an essential part of the treatment 
strategy because acute lesions can be extremely painful and interfere heavily with 
daily life. Self-treatment of acute lesions can be performed by the application of 
resorcinol 15% cream thrice daily.95 Both the keratolytic and mild antiseptic prop-
erties of this topical agent has the potential to reduce levels of pain and achieve 
early clinical resolution of a treated boil. In a clinical setting, inflammatory nodules 
often benefit from intralesional corticosteroids by inhibiting the synthesis of pro-
inflammatory cytokines,96 whereas abscesses require incision and drainage to rapidly 
relieve symptoms of pain and pressure.97-99 Of note, incision and drainage should not 
be considered as a sole treatment because recurrence is almost inevitable.
AIMS OF THIS THESIS
In HS, rapidly evolving understanding of pathogenic mechanisms and clinical 
perspectives are needed to improve disease awareness, disease management, and 
ultimately improve patient outcomes. Because multiple facets of HS are not yet 
known, the outline of this thesis is not limited to only one aspect of the disease. Using 
a translational approach, we focused on clinical features and (immuno)pathogenic 
mechanisms as a rationale for the development of novel treatment strategies.
In our clinical experience a substantial proportion of patients reports itch, also known 
as pruritus. Therefore, the aim of Chapter 2 was to investigate the significance of HS-
related pruritus by determining the prevalence of pruritus, and exploring its impact 
on daily activities in a cohort of HS patients. In addition, a selection of serological 
and histological markers of pruritus were evaluated in a subpopulation.
Extensive inflammation is a clinical hallmark of HS and identification of important 
inflammatory markers in the pathogenesis of HS may help both therapeutic stratifica-
17
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tion. Consequently, in Chapter 3 we investigated the cytokine and chemokine profile 
in the plasma and lesional skin of HS patients.
Biologics targeting inflammatory mediators are now widely used for the treatment of 
HS in daily practice, but their clinical efficacy shows great inter-patient variability. 
For that reason, the aim of Chapter 4 was to determine the anti-inflammatory potency 
of currently available biologics for the treatment of HS in an ex vivo skin model using 
lesional HS biopsies.
High-quality evidence on HS treatment is limited, highlighting a significant unmet 
need for novel effective anti-inflammatory therapies. The aim of Chapter 5 was to in-
vestigate the efficacy of apremilast in patients with moderate HS using a randomised 
placebo-controlled trial design. In Chapter 5.1 the clinical efficacy, and short-term 
safety and tolerability of apremilast were evaluated. In Chapter 5.2, in a mode of ac-
tion study, we analysed the change in expression of inflammatory markers in lesional 
skin of patients receiving apremilast compared with placebo.
As follicular occlusion is the primary event in the HS pathophysiology, we hypoth-
esised that reducing the number of hair follicles would ameliorate the disease course. 
The aim of Chapter 6 was to evaluate two non-invasive techniques that (primarily) 
target the hair follicle in patients with mild HS. In Chapter 6.1 we assessed the effect 
of hair removal using a long-pulsed 1064-nm neodymium-doped yttrium aluminium 
garnet (Nd:YAG) laser. Lastly, in Chapter 6.2, the efficacy and safety of microwave 
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Pruritus is still a forgotten aspect of hidradenitis suppurativa (HS) and, to date, has 
never been adequately studied.
Objective
The aim of this study was to determine the prevalence, and explore the characteris-
tics, of pruritus in a well-defined cohort of HS patients.
Setting
An academic hospital-based cross-sectional study in The Netherlands.
Methods
A numeric rating scale (NRS, 0-10) was used to determine the prevalence of HS-related 
itch (NRS score ≥3). Candidate predictors for pruritus were subsequently determined 
using logistic regression models, and the impact of pruritus was assessed using a 
modified five-dimensional (5-D) itch scale. Associated serological and histological 
markers of pruritus were (semi-)quantitatively investigated in a subpopulation.
Results
The prevalence rate of pruritus in 211 HS patients was 57.3%, with a mean NRS score 
of 6.1 ± 2.0. Patients with a pruritus NRS score ≥3 had more HS-affected body sites 
than patients with a score <3 (p < 0.001). The occurrence of a pruritus NRS score 
≥3 was associated with Hurley III disease (odds ratio [OR] 7.73; p = 0.003) and HS-
related pain (OR 1.34; p < 0.001). Pruritus affected sleep and activities of daily living 
(ADL) in the majority of cases, with a mean (± SD) associated modified 5-D itch score 
of 13.7 ± 3.6 (on a scale from 5 to 25) in 52 HS patients. Histological examination 
showed that eosinophilic granulocytes were present in 25% (2/8) of the perilesional 
skin and 63% (10/16) of the lesional skin, while a perineural infiltrate was found in 
25% (2/8) and 69% (11/16) of the perilesional and lesional skin, respectively.
Conclusion
Pruritus is a frequent but underreported symptom in patients with HS. Its moderate-
to-severe intensity and significant impact on daily activities have great potential to 
impair patients’ quality of life.
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INTRODUCTION
Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, recurrent, 
inflammatory skin disease that mostly develops after puberty and predominantly oc-
curs in women, with a female-to-male ratio of 3 : 1.1,2 The estimated prevalence rate 
in Europe is approximately 1%.1 Risk factors for developing HS are smoking and 
overweight or obesity.3 The disease is characterised by deep-seated, inflamed nodules 
and abscesses, often followed by sinus tract formation, and is most commonly located 
in the flexural body sites carrying terminal hairs.4
Key symptoms of HS include acute and chronic pain, discomfort, and a purulent, 
foul-smelling discharge, which, overall, contribute to a poor quality of life.5,6 Previous 
clinical studies have mainly focused on these well-known symptoms,1,4,5 while less is 
known about the itch sensation, also known as pruritus. In 2011, a small qualitative 
study in which 12 HS patients were interviewed for the first time revealed that not 
only drainage, pain, and scarring but also itching have a significant psychosocial 
impact in HS patients.7
To date, one cross-sectional study demonstrated a positive association between 
disutility and itch in a cohort of 294 HS patients, using the EuroQoL-5D (EQ-5D) 
and a visual analogue scale (VAS) for itch, respectively.8 However, the prevalence 
and accompanying (psychosocial) factors of pruritus in HS have not been adequately 
investigated. The aim of this study was to determine the prevalence, and explore the 
characteristics, of pruritus in a cohort of HS patients. In addition, serological and 
histological markers of pruritus were evaluated in a subpopulation.
MATERIALS AND METHODS
Study design and population
This cross-sectional study consisted of consecutive male and female patients with 
a physician-verified diagnosis of HS who visited the department of Dermatology of 
the Erasmus University Medical Center in Rotterdam, The Netherlands. Each patient 
filled out a questionnaire relating to the intensity of pruritus and the pain caused by 
their HS. Patients with a limited understanding of the Dutch language, as well as 
patients with a concomitant skin disease that might cause pruritus (e.g. psoriasis, 
atopic dermatitis, chronic urticaria) were excluded.
Epidemiological and clinical parameters
Patients separately assessed the highest intensity of their HS-related pruritus and pain 
over the past 7 days on an 11-point numeric rating scale (NRS) ranging from 0 (no 
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itch/pain) to 10 (unbearable/extreme itch/pain).9 All patients with an NRS score ≥3 
were included in the prevalence analysis. It has previously been demonstrated that 
the minimal clinically important difference (MCID) for clinical improvement in itch 
ranks as a decrease of 2.7 points rated on the NRS in the last 3 days.10
Clinical parameters were collected during routine care and were derived from 
medical charts. HS severity was assessed using the Hurley classification of the worst 
affected body area,11 and the extent of disease activity was evaluated by the number 
of anatomical skin regions with inflammation. The presence of three or more papules/
pustules, one or more inflammatory nodules, one or more draining sinuses, or one or 
more abscesses per region (left and right separate) was considered as inflammatory 
active HS disease. Additionally, the NRS relating to pain was used as the patient-
reported outcome measure (PROM) of disease activity.
The impact of pruritus
Randomly selected patients with a pruritus NRS score ≥3 were asked to fill in a 
five-dimensional (5-D) itch scale, which is used to evaluate the impact of pruritus on 
daily activities and includes five domains − duration, degree, direction, disability, 
and distribution.12 The questionnaire was adapted through (1) translation into Dutch, 
and (2) explicitly mentioning the axillary and genital regions, with removal (i.e. points 
of contact with clothing) and merging (i.e. tops of feet and soles; palms and tops of 
hands; thighs and lower legs; forearms and upper arms) of non-relevant sections in 
the distribution domain. The latter was carried out to obtain better insight into the HS 
predilection areas, and resulted in 12, instead of 16, answer options (Supplementary 
Material). The outcomes of domains 1 to 4 are measured on a 5-point Likert scale.12 
The scoring system for the distribution domain was not adapted as it was not expected 
that HS patients without concomitant skin disease that might cause pruritus would 
have more than 12 skin regions with symptoms of itch. The overall 5-D score was 
calculated by adding up the individual scores of the five domains, resulting in scores 
ranging from 5 (no impact) to 25 (most severe impact on daily life).12
Serological analysis
A random subset of HS patients aged ≥18 years with a pruritus NRS score ≥3 was 
asked for a one-time collection of a blood sample in order to screen for other possible 
causes of pruritus.13,14 Tryptase, haemoglobin, bilirubin, creatinine, urea, thyroid-
stimulating hormone (TSH), and glycated haemoglobin (HbA1c) were assessed in 
serum.
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Histological analysis
Histopathological analysis was performed on 24 random HS skin samples (includ-
ing eight perilesional skin samples, and six early and ten chronic lesions) in order 
to evaluate potential skin-related mediators of pruritus. Large specimens of chronic 
inflamed skin were obtained from the excised skin of patients who had radical exci-
sion of their HS under general anaesthesia as this was considered waste material. In 
our clinic, HS lesions are excised with a healthy-appearing skin margin of 2 cm; this 
normal-appearing skin is denoted as perilesional skin. All early (i.e. newly emerging) 
HS lesions, as judged by both the HS patient and the dermatologist, were biopsied 
within 4 days after onset.
Three independent observers (ARJVV, KRvS, and EPP), blinded to the disease stage, 
assessed all skin samples, stained by haematoxylin and eosin (H&E), on the density 
of the infiltrate, followed by evaluation of eosinophilic granulocytes and perineural 
involvement within the infiltrate. The outcomes were scored in a semiquantitative 
manner using a global assessment on an ordinal scale from 0 to 3 (0 = none, 1 = 
mild, 2 = moderate, 3 = severe).15 Disagreements between the three observers were 
resolved through discussion until consensus was reached. The average overall score 
per category was calculated from the consensus score of the observers.
Statistical analysis
Statistical analyses were conducted using SPSS Statistics 21.0 (IBM Corporation, 
Armonk, NY). Patient characteristics were analysed using descriptive statistics, with 
continuous data presented as the mean ± standard deviation (SD) or median and inter-
quartile range (IQR), and categorical data presented as number (%). A Shapiro–Wilk 
test was performed to test whether continuous data were normally distributed. For 
the primary objective, i.e. the evaluation of patient characteristics between patients 
with and without pruritus, the parametric t test for normally distributed independent 
samples (two-sided), the non-parametric Mann–Whitney U test for non-normally 
distributed samples, and the Chi-square test or Fisher’s exact test for categorical data 
were applied. Candidate predictors for pruritus, based on both clinical experience 
and the literature, were subsequently determined using both univariable and mul-
tivariable logistic regression models, with pruritus (NRS score ≥3) as the dependent 
variable. In order to prevent overfitting of the regression analysis, we were restricted 
to using 9 degrees of freedom in the multivariate model, as the limiting sample size of 
patients without pruritus was 90 (Table 1).15 Data were presented as odds ratio (OR) 





The Medical Ethical Committee of the Erasmus University Medical Center in Rot-
terdam, The Netherlands, reviewed and approved the study protocol (reference MEC-
2016-092). Written informed consent for the serological and histological analysis was 
obtained from all subjects in accordance with the Declaration of Helsinki principles.





 (n = 121)
Pruritus NRS <3
 (n = 90) p-value
Age, years 38.0 [29-49] 38.0 [29-48] 39.0 [29-52] 0.39
Female sex 135 (64%) 78 (65%) 57 (63%) 0.87
BMI, kg/m² 28.5 ± 5.9 28.7 ± 5.8a 28.3 ± 6.0b 0.67
Diabetes mellitus 18 (9%) 10 (8%) 8 (9%) 0.87
Smoking statusc 0.05
Never smoked 37 (20%) 16 (13%) 21 (23%)
Present smoker 42 (62%) 83 (70%) 48 (54%)
Past smoker 131 (18%) 21 18%) 21 (23%)
Pack-yearsd 12.0 [7-23] 12.9 [6-22] 12.0 [7-26] 0.65
Positive family historye 80 (38%) 49 (41%) 31 (34%) 0.37
Use of systemic medication 64 (32%) 36 (30%) 28 (31%) 0.92
Skin type (Fitzpatrick)f 0.49
I 18 (9%) 14 (12%) 4 (5%)
II 126 (60%) 69 (57%) 57 (63%)
III 17 (8%) 11 (9%) 6 (7%)
IV 30 (14%) 17 (14%) 13 (14%)
V 11 (5%) 5 (4%) 6 (7%)
VI 9 (4%) 5 (4%) 4 (4%)
Duration of HS, years 14.0 [7-25] 15.0 [8-27] 13.0 [5-23] 0.22
HS disease severityg <0.001*
Hurley I 32 (15%) 13 (11%) 19 (21%)
Hurley II 140 (66%) 75 (62%) 65 (72%)
Hurley III 39 (19%) 33 (27%) 6 (7%)
Currently inflamed areash 1.5 ± 1.3 1.7 ± 1.4 0.9 ± 1.1 <0.001**
HS-related pain on NRS 6.3 ± 3.0 6.9 ± 2.5 5.0 ± 3.5 <0.001**
Data are expressed as mean ± SD, median [IQR], or n (%). * indicates significant at p = 0.05. ** indi-
cates significant at p = 0.001. a Missing n = 6. b Missing n = 9. c Missing n = 1. d Pack-year = (number of 
cigarettes smoked per day × number of years smoked) / 20. e A positive family history for HS-symptoms 
in first and second degree relatives. f Fisher’s exact test. g χ2-test. h Inflamed area = ≥3 papules/pustules 
or ≥1 inflammatory nodule  or ≥1 draining sinus or ≥1 abscess. BMI: body mass index. HS: hidradenitis 
suppurativa. NRS: numeric rating scale.
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RESULTS
Epidemiology of pruritus
A total of 231 HS patients were screened, of whom 20 were excluded (13 had a 
concomitant dermatological comorbidity causing itch, 5 had a limited understanding 
of the Dutch language, and 2 patients declined to take part in the study). The 211 
patients included in the study (64% female) had a median age of 38 years (range 
15-71) (Table 1). The prevalence rate (NRS score ≥3) of pruritus was 57.3% (121/211), 
with a mean (± SD) NRS score of 6.1 ± 2.0. For comparison, applying a cut-off value 
of a NRS score ≥1 resulted in a rate of 67.3% (mean NRS score of 5.4 ± 2.5). The 
mean intensity of itch in all 211 patients was rated at an NRS score of 3.7 ± 3.3. 
The occurrence of pain (NRS score ≥3) was more frequently reported, resulting in a 
prevalence rate of 83.4% and associated mean NRS score of 7.4 ± 1.8.
Patient characteristics
Comparison of the patient characteristics between patients with pruritus (NRS score 
≥3) and patients reporting no or negligible pruritus (NRS score <3) revealed no signifi-
cant differences, with the exception of HS disease activity/severity (Table 1). Patients 
with a pruritus NRS score ≥3 reported a higher level of HS-related pain (p < 0.001), 
had more affected body areas (p < 0.001), and had more severe disease according to 
the Hurley classification (p < 0.001) compared with patients reporting a pruritus NRS 
Table 2. Associations between patient characteristics and the occurrence of itch in 211 HS patients.
Characteristic Coding
Univariablea Multivariablea
OR (95% CI) p-value OR (95% CI) p-value
Age Continuous 0.99 (0.97-1.01) 0.33 0.97 (0.94-1.01) 0.10
Gender Male 1.05 (0.60-1.86) 0.87 0.75 (0.37-1.53) 0.75
Smoking status Never smoked Reference variable Reference variable
Present smoker 2.27 (1.08-2.76) 0.03* 2.02 (0.82-4.95) 0.13
Past smoker 1.31 (0.54-3.19) 0.55 1.26 (0.43-3.68) 0.67
Duration of HS (years) Continuous 1.02 (0.99-1.04) 0.20 1.04 (1.00-1.07) 0.38
HS severity Hurley I Reference variable Reference variable
Hurley II 1.69 (0.77-3.68) 0.19 1.78 (0.72-4.45) 0.22
Hurley III 8.04 (2.62-25) <0.001** 7.73 (2.01-27) 0.003*
Currently inflamed areas Continuous 1.70 (1.32-2.19) <0.001** 1.21 (0.92-1.58) 0.18
HS-related pain on NRS Continuous 1.35 (1.12-1.50) <0.001** 1.34 (1.18-1.52) <0.001**
* indicates significant at p = 0.05. ** indicates significant at p = 0.001. a Logistic regression analysis 
with pruritus NRS ≥3 as dependent variable: univariable model, unadjusted; and multivariable model, 
adjusted for factors and covariates in the model  (OR > 1 is a predictor for the occurrence of itch). CI: 
confidence interval. HS: hidradenitis suppurativa. NRS: numeric rating scale. OR: odds ratio.
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score <3 (Table 1). Candidate predictors for patients reporting a pruritus NRS score 
≥3 were Hurley stage III (OR 7.73; p = 0.003) and HS-related pain, with an OR of 
1.34 for each additional point on the NRS (p < 0.001) (Table 2). A higher number of 
currently inflamed areas was only associated with pruritus in the univariable analysis 
(OR 1.70; p < 0.001). In addition, patients who smoked tended to complain more 
about itch than patients who have never smoked (univariable analysis; OR 2.27; 
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Figure 1. The Modified 5-Dimensional Itch Scale of 51 hidradenitis suppurativa patients with a pruritus 
numeric rating scale score of ≥3. (a) Disability: the impact of itch on ADL and sleep in the past 2 weeks.
(b) Distribution of itch per body area in the past 2 weeks. ADL: activities of daily living, based on the 
highest outcome of the three subcategories in the questionnaire.
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The impact of pruritus
Fifty-two patients in the pruritus NRS score ≥3 group (n = 121) completed the 5-D 
itch scale; however, one incorrectly filled out questionnaire was excluded from the 
analysis. First, the most commonly reported pruritus characterisation was moderate 
(54%) to severe (27%) itching sensations for less than 6 hours per day (56%), which 
had not changed in the previous 2 weeks (48%). Second, pruritus, at least occasion-
ally, affected sleep and activities of daily living (ADL), i.e. leisure, social contact, 
housework, errands, and work/school, in 70% and 53% of patients, respectively 
(Figure 1a). The mean number of body areas affected by pruritus was 3.1 ± 2.5, with 
the inguinal/genital (67%) and axillary (52%) regions most frequently involved (Fig-
ure 1b). The overall modified 5-D itch score was 13.7 ± 3.6, i.e. HS-related pruritus 
had a moderate impact on daily activities.
Serological analysis
Serum pruritus markers were evaluated in 24 patients in the pruritus NRS score ≥3 
group (n  =  121). The mean serum values were within the normal range, with the 
exception of a lower haemoglobin level found in male patients (n = 5) (Table 3). Three 
outliers were detected: tryptase (19.3 µg/L) in one patient with a pruritus NRS score 
of 7, and HbA1c (91.0 and 57.0 mmol/mol) in two patients with pruritus NRS scores 
of 3 and 5, respectively.
Table 3. General serum pruritus markers of 24 HS patients with itch.
Serum pruritus marker Unit Mean ± SD Reference
Bilirubin µmol/L 6.0 ± 2.6 <17
Creatinine µmol/L 69.4 ± 16.8 55 - 115a
HbA1cb mmol/mol 38.9 ± 12.7 26 - 42
Haemoglobin     men (n = 5)       mmol/L 8.4 ± 1.2 8.6 - 10.5
                     women (n = 19) mmol/L 8.4 ± 0.6 7.5 - 9.5
Tryptase µg/L 5.4 ± 3.5 <11.4
TSH mU/L 1.6 ± 1.0 0.4 - 4.3
Ureab mmol/L 4.0 ± 1.5 2.5 - 7.5
a Upper limit dependent on ethnic origin, gender and age. b n = 1 missing. HbA1c: glycated haemoglo-
bin. SD: standard deviation. TSH: thyroid-stimulating hormone.
Histological analysis
The average semiquantitative scores for the three types of HS skin specimens are 
presented in Figure 2. Histological evaluation showed that inflammatory cell infiltra-
tion was present (i.e. score of 1-3) in 75% (6/8) of the perilesional samples, and 
100% (16/16) of both early and chronic lesional samples. Eosinophilic granulocytes 
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were present (i.e. score of 1–3) in 25% (2/8) of perilesional skin and 63% (10/16) of 
lesional skin (Figure 3a/b). A perineural infiltrate, mainly consisting of lymphocytes 
and a few neutrophils, was found in 25% (2/8) and 69% (11/16) of perilesional and 
lesional skin, respectively (Figure 3c/d).
DISCUSSION
For the first time, this explorative study evaluated the prevalence and clinical charac-
teristics of pruritus in a well-defined cohort of HS patients. We demonstrated a high 
prevalence rate of 57% (121/211 with an NRS score ≥3), with a mean NRS score of 
6.1 ± 2.0. This prevalence rate is substantially higher than the prevalence of itch in 
a healthy French population (29%) and a Norwegian national sample with several 
ethnicities (7%).16,17 A recently conducted study involving a general dermatological 
population of a German clinical practice reported a 36% prevalence rate of itch.18 
Compared with other inflammatory skin conditions, the 57% prevalence rate of 
pruritus in HS is similar to the rate in patients with psoriasis (49-90%),18,19 and lower 
than patients with burn injuries (67-93%)20,21 or chronic idiopathic urticaria (79%).22
The overall mean intensity of itch in this study (NRS score 3.7 ± 3.3) was similar to 
the pruritus VAS score of 3.7 ± 3.2 in a cohort of 294 HS patients.8 In addition, the 
mean modified 5-D itch score of 13.7 ± 3.6 in 51 HS patients is comparable with the 
5-D score in 51 patients with an inflammatory skin condition such as burn wounds 
(13.5 ± 3.2).12 Systemic diseases such as HIV/AIDS (n = 28; 16.8 ± 5.3), chronic liver 
disease (n = 63; 16.9 ± 4.7), and chronic kidney disease (n = 36; 18.2 ± 4.1) have 
shown higher 5-D itch scores.12 However, the majority (81%) of HS patients ranked 










General infiltrate Eosinophilic granulocytes Perineural infiltrate
Perilesional Early lesional Chronic lesional
Figure 2. Semiquantitative scores for histological markers of pruritus in three types of hidradenitis sup-
purativa lesions. A total of 24 samples were assessed: perilesional, n = 8; early lesional, n = 6; chronic 
lesional, n = 10. The y-axis indicates the average semiquantitative scores on an ordinal scale from 0 to 
3 (0 = none, 1 = mild, 2 = moderate, 3 = severe).
35
Pruritus in hidradenitis suppurativa
the severity of pruritus as moderate-to-severe on a 5-point Likert scale. Moreover, 
sleep and ADL were negatively impacted by pruritus in more than half of the patients.
Pruritus is a multidimensional phenomenon and is thought to signal danger from 
various environmental factors or physiological abnormalities. Therefore, it frequently 
accompanies various inflammatory skin conditions, including atopic dermatitis, pso-
riasis, chronic urticaria, and burn wound healing.23 To date, the aetiology of pruritus 
in skin diseases is only partially understood. A possible explanation for itching in 
HS patients is the presence of tryptase-positive mast cells, which were found to be 
increased in all stages of the disease, including perilesional skin.24 Increased serum 
levels of immunoglobulin (Ig)E have recently been reported in patients with HS.25 The 
latter, in combination with a dense infiltration of mast cells in HS, could trigger de-
granulation of these cells, releasing histamine and other mediators, such as proteases, 
causing pruritus. In addition, we found an influx of eosinophilic granulocytes and the 
presence of a perineural infiltrate (when nerve fibres were present) in the majority 
of prototypic HS lesions. An important phenomenon supporting the hypothesis of 
neurogenic inflammation is the finding of an abnormal innervation of the skin in 
psoriasis.26 As demonstrated in cutaneous T-cell lymphoma, interleukin (IL)-31 may 
play a role by exerting indirect effects on sensory nerves through keratinocytes to 





Figure 3. Two histological pruritus markers in hidradenitis suppurativa lesional skin. (a) Inflammatory 
infiltrate with influx of eosinophilic granulocytes (arrows); H&E, magnification ×20. (b) Closer view of 
eosinophilic granulocytes (arrows); H&E. (c) Perineural infiltration of the peripheral nerves (arrows) in 
overview; H&E, magnification ×5. (d) Infiltration of a peripheral nerve (arrow) by lymphocytes and a 
few neutrophils in detail; H&E, magnification ×20. H&E: hematoxylin and eosin.
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fibre neuropathy due to scar formation in the course of HS. Recurrent and chronic in-
flammation will destroy dermal nerves and subsequently enhance nerve regeneration 
and neovascularisation when inflammation has subsided. This type of neuropathic 
itch coincides with pain and may be caused by a disproportionate number of regen-
erating, unmyelinated C nerve fibres within HS lesions.28
The major strength of this explorative cross-sectional study is the recruitment of a 
relatively large number of physician-verified HS patients. As the occurrence of itch 
at a specific point in time is susceptible to confounders such as mental distress, use 
of systemic medication, and comorbidities,29 a comparator group and quality-of-life 
measurements, e.g. Dermatology Quality of Life Index (DLQI) or SKINDEX-29, are 
indicated for future research. Another strength is screening for common systemic 
causes of chronic recurrent itch that could interfere with the occurrence of HS-related 
itch. In addition, histopathological evaluation of two important skin-related mediators 
of pruritus have been performed, although the evaluation lacks information relating 
to the associated presence of pruritus. For future analysis, it would be interesting 
to evaluate specific itch-related biomarkers in the serum or skin lesions, such as 
eosinophilic granulocytes, thymus and activation-regulated chemokine (TARC), IL-2, 
IL-31, and substance P.
A limitation of this study could be the use of a non-validated, HS-modified 5-D itch 
scale. From a clinical point of view, the alteration of the distribution section was not 
expected to influence scoring as HS patients rarely have notable itch in distal, unaf-
fected body sites such as the hands and feet. Moreover, the body areas mentioned 
in the distribution domain of the adapted scale are more specific to HS-related itch 
(Supplementary Material). The modified 5-D itch scale, which could be validated for 
this application in future research, could therefore be a specialised and very useful 
tool for analysing pruritus in HS patients.
CONCLUSION
Pruritus is a frequent but underreported aspect of HS. Its moderate-to-severe intensity 
and significant impact on sleep and ADL have great potential to impair patients’ 
quality of life. Therefore, assessment of pruritus in both daily practice and clinical 
research settings, e.g. by using an NRS or VAS, together with the DLQI and EQ-5D, 
may form a helpful additional PROM to evaluate disease severity/activity and treat-
ment outcome.
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SUPPLEMENTARY MATERIAL
The modified 5D itch scale.
1. DURATION < 6 hours per day □ 1
During the last two weeks, how many 
hours have you been itching?
6-12 hours per day □ 2
12-18 hours per day □ 3
18-23 hours per day □ 4
Whole day □ 5
2. DEGREE Not present □ 1
Please rate the intensity of your itching 





3. DIRECTION Completely resolved □ 1
Over the past 2 weeks, has your itching 
gotten better or worse compared to the 
previous month?
Much better, but still present □ 2
Somewhat better, but still present □ 3
Unchanged □ 4
Worsened □ 5
4. DISABILITY Never affects sleep □ 1
A.  What was the impact of itching 
on your sleep over the last two 
weeks?
Occasionally delays falling asleep □ 2
Often delays falling asleep □ 3
Delays falling asleep and occasionally wakes me up at night □ 4
Delays falling asleep and frequently wakes me up at night □ 5
B.  Did the itching influence your 








C.  Did the itching influence your 








D.  Did the itching influence your 








5. DISTRIBUTION Head or scalp □ Abdomen □
Mark whether itching has been present 
in the following bodyparts over the 
past 2 weeks.
If a body part is not listed, choose the 
one that is closest anatomically.
Face □ Back □
Chest □ Groins and genitals □
Armpits □ Buttocks □
Arms □ Legs □
Hands □ Feet □
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A key element of hidradenitis suppurativa (HS) is an aberrant immune response. 
Identification of inflammatory markers is important for the clinical stratification of HS 
and may help refining treatment choices.
Objective
To simultaneously detect important cytokines and chemokines in respectively the 
plasma and lesional skin of patients with HS.  
Methods
A multiplex electrochemiluminescent immunoassay platform (Meso Scale Discovery) 
was used to quantify the in vivo protein levels of 30 cytokines and chemokines in 
twenty HS patients and ten healthy controls. Immunohistochemistry was performed 
for newly identified markers. Additionally, a correlation between individual plasma 
and lesional skin protein levels was calculated within the HS patients.
Results
In the circulation of HS patients, CCL-26 (eotaxin-3) was significantly elevated and 
CXCL-10 significantly lower compared with healthy controls. In the skin, protein 
levels of IL-16, IL-17A, CXCL-8, IL-12/23p40, CCL-4, and CXCL-10 were signifi-
cantly higher in HS patients than in controls. Immunohistochemistry demonstrated 
overexpression of CCL-4, CXCL-10, and CCL-26 in the HS infiltrate. There was no 
significant correlation between protein levels in patient plasma and lesional skin with 
correlation coefficients varying between −0.53 and +0.42.
Conclusion
The cytokine and chemokine profile of HS patients, including newly identified IL-16, 
CCL-4, CXCL-10 and CCL-26, reflects the ongoing skin inflammation in HS. The local 
and systemic upregulation of CCL-26 in HS patients can be linked to the high pruritus 
score in HS. Furthermore, our results demonstrate that plasma gives a limited reflec-
tion of the activated local cutaneous inflammatory milieu.
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INTRODUCTION
Hidradenitis suppurativa (HS) is an auto-inflammatory skin disease characterised by 
recurrent or chronic painful and pruritic inflammatory nodules, abscesses and sinus 
tracts in predominantly the axillary, inguinal and gluteal areas.1 Diagnosis at present 
is based largely on the clinical appearance and location of lesions, and their chronic-
ity. Well-known symptoms are acute and chronic pain, discomfort, and a purulent, 
foul-smelling discharge, which, overall, contribute to a decreased quality of life.2,3 
More recently, itch, also known as pruritus, was found to be a frequent and bother-
some symptom in HS patients.4,5
The pathogenesis of HS is complex with multiple factors contributing to the onset 
and progression of the disease including genetics, smoking, obesity, and mechanical 
friction.6  A key element of the HS pathophysiology is occlusion of the follicular infun-
dibulum and subsequent cyst formation, followed by rupture of the cyst inducing an 
acute inflammatory response. Hereby a broad range of immune cells such as T cells, 
natural killer (NK) cells, neutrophils, eosinophils, monocytes, and dendritic cells are 
recruited.4,7 Accordingly, elevated levels of multiple pro-inflammatory cytokines such 
as TNF-α, IL-1ß, IL-6, IL-8 (CXCL-8), and IL-17 have been detected in the skin and/or 
serum of HS patients.8-11 Unravelling the role of cytokines and chemokines in disease 
initiation and progression is important for the clinical and therapeutic stratification 
of HS. Identification of biomarkers in HS could help in personalising treatments, and 
may aid in monitoring the efficacy of treatments.
To date, no studies have investigated the inflammatory protein levels in the serum/
plasma and skin in parallel in a cohort of HS patients at a single time point. Therefore, 
the primary aim of this study was to simultaneously detect important cytokines and 
chemokines in respectively the plasma and lesional skin of patients with HS.
MATERIALS AND METHODS
Ethical statement
The research protocol was approved by the local Institutional Review Board (reference 
MEC-2013-337/NL45264.078.13). The collection of plasma and skin was conducted 
in the Department of Dermatology of the Erasmus University Medical Center and Sint 
Franciscus Hospital in Rotterdam, The Netherlands. All participants provided written 
informed consent in accordance with the Declaration of Helsinki principles for using 
their plasma and skin tissue in this study.
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Hidradenitis suppurativa patient and healthy control samples
Blood and skin samples were prospectively collected from 20 patients with a 
dermatologist-verified diagnosis of HS and 10 healthy controls. HS patients, of which 
10 were female, had a mean (± SD) age of 41.5 ± 10.6 years, a mean body mass 
index of 32.1 ± 7.6kg/m2, and a mean HS duration of 16.4 ± 10.9 years. Seventeen 
patients were current or past smokers. Disease severity was assessed according to 
Hurley staging: two patients suffered Hurley I, 14 patients suffered Hurley II, and 
four patients suffered Hurley III. The healthy control subjects consisted of otherwise 
healthy patients undergoing dermatologic and plastic surgery who had no family 
history of HS. Participants receiving any systemic immunomodulators or immuno-
suppressants, and non-HS patients with any significant inflammatory disease were 
excluded. Punch biopsies of 4 mm in diameter were obtained and immediately 
snap-frozen in liquid nitrogen. Skin samples of HS patients were taken from actively 
inflamed, non-fluctuating, indurated, erythemous lesions or plaques recurring on 
fixed locations. Venous blood was collected in vacuum EDTA tubes under sterile 
conditions, and after separation of the plasma samples were aliquoted and stored at 
−80oC until analysis.
In vivo protein quantification in skin homogenates
Plasma and skin samples were analysed using the Meso Scale Discovery (MSD) V-PLEX™ 
Human Cytokine 30-plex kit (K15054D; Meso Scale Discovery, Gaithersburg, MD) 
according to the instructions of the manufacturer. MSD assays use electrochemilumi-
nescent labels that allows for analysis of multiple analytes in a variety of sample types.12
The plasma and skin samples were thawed at room temperature. Skin biopsies were 
weighed, thereafter homogenised in 250 µL phosphate-buffered saline (PBS) and 
grinded using micro pestles. The homogenates were subsequently transferred to 1.5 
mL Eppendorf tubes and centrifuged at 13,000 g for 5 minutes at room temperature. 
Just before analysis, the plasma and supernatant samples were diluted two times for 
inflammatory cytokines and four times for chemokine analysis in sample diluents. The 
diluted samples were incubated on the MSD plates for two hours at room temperature 
with gentle shaking. The plates were rinsed and incubated for an additional two hours 
with detection antibodies. For CXCL/IL-8 two antibodies were used, both recognizing 
the same domain of its target. The difference between these antibodies relies on the 
dynamic range being measured. In addition to the regular antibody, the IL-8 HA 
(human antibody) has been validated for the MSD V-PLEX™ kit, and is recommended 
when high CXCL/IL-8 levels are anticipated.
After rinsing twice, read buffer T was added to each well and the plate was analysed 
using the Sector Imager 6000. Calibrator concentrations and skin and plasma samples 
were analysed in duplicates. The calibrator concentrations were plotted as log signal 
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unit on the vertical (Y) axis versus log concentration on the horizontal (X) axis using 
the MSD Workbench software. A weighted four parameter logistic fit (4PL) equation 
was used for curve fitting and back calculation of sample concentrations.
Immunohistochemistry
Three chemokines, which have not previously been reported to be overexpressed in 
HS patients, were additionally analysed by immunohistochemistry (IHC). First, paraf-
fin embedded tissue sections were heated at 60°C for 30 minutes, de-paraffinised, 
and rehydrated. Slides were subsequently placed in pH6 antigen retrieval buffer and 
heated at 95°C for 20 minutes in a hot water bath.  After cooling, slides were treated 
with 3% H2O2 (5 minutes) and blocked using 10% goat serum (30 minutes). Overnight 
incubation (4°C) was then performed using  the primary antibody at a concentration 
of 10µg/mL. Lastly, slides were washed, treated with secondary antibody, peroxidase 
(30 minutes) and diaminobenzidine substrate. The following antibodies were used: 
anti-CXCL10 (Thermofisher Scientific, cat#701225), anti-CCL4 (ThermoFisher Sci-
entific, cat#PA5-23681), anti-CCL26 (Thermofisher Scientific, cat# PA5-75690), and 
Rabbit IgG control (Lifespan Biosciences, cat#LS-C149375).
Statisical analyses
Plasma protein concentrations were expressed as picogram (pg) per mL. Protein 
levels of the skin samples were normalised for mg tissue dry weight (pg/mg). In case a 
protein level was below the detection limit, the lowest limit of quantification (LLOQ) 
was used for further calculations. If more than 50% of the samples per analysed 
protein in either the HS or healthy control group had values below the LLOQ, values 
were substituted by two categories: detectable versus non-detectable, i.e. above 
versus below the LLOQ, respectively.
For the primary objective either the Mann Whitney U test or Fisher’s exact test 
was used to assess the null-hypothesis that there was no difference in the levels 
of individual markers between healthy control and HS samples. For the secondary 
objective, to assess the correlation between individual plasma and skin protein lev-
els within the HS patients, we used the Spearman’s rho for the non-parametrically 
continuous variables and categorical variables (detectable versus non-detectable).13 
Alternatively, in case of a mismatch in the type of variable (continuous, categorical) 
between protein levels in skin and plasma, logistic regression models were used to 
estimate a Nagelkerke’s R-squared.
Statistical analyses were conducted using SPSS Statistics 24.0 (IBM Corporation, 
Armonk, NY). A two-sided p-value below 0.05 was considered significant. The level 
of significance was corrected by a false discovery rate using the Benjamini Hochberg 




Detection of cytokines and chemokines
In total, 30 plasma samples and 30 skin samples from 20 HS patients and 10 healthy 
controls were analysed by MSD multiplex assay. The protein levels for 30 inflamma-
tory markers in plasma and skin are summarised in Table 1 and Table 2, respectively. 
Table 1. Inflammatory protein expression in the plasma of healthy control subjects and HS patients.
Protein
pg/mL
NN (n = 10)
median (IQR) or x/total
HS (n = 20)





1 CXCL-10 (IP-10) 402.7 (328.7-550.5) 277.4 (236.0-328.8) 2.40 0.003*
2 CCL-26 (Eotaxin-3) 2/10 16/20 18 0.0041*
3 IL-12/23p40 132.7 (97.7-182.5) 104.0 (74.6-127.2) 1.30 0.055
4 IL-1α 1.8 (1.7-3.6) 4.2 (2.4-10.2) 0.62 0.055
5 CCL-4 (MIP-1β) 119.4 (66.6-176.0) 78.5 (59.9-102.5) 2.10 0.091
6 TNF-β 2/10 0/20 0.28 0.103
7 IL-1β 3/10 13/20 0.24 0.122
8 CCL-22 (MDC) 926.2 (716.5-1212.4) 1312.7 (1000.8-1538.6) 38 0.155
9 INF-γ 8.8 (5.3-14.0) 6.9 (4.8-8.9) 2.20 0.155
10 IL-15 2.0 (1.7-2.3) 1.7 (1.5-2.1) 0.32 0.198
11 IL-7 18.6 (14.8-24.2) 22.3 (17.0-30.3) 0.32 0.214
12 IL-10 0.3 (0.2-0.4) 0.2 (0.2-0.3) 0.16 0.231
13 CCL-3 (MIP-1α) 2/10 1/20 15.60 0.251
14 CXCL-8 (IL-8) 8.7 (7.2-9.7) 7.1 (6.0-9.1) 3.80 0.286
15 IL-16 208.0 (191.9-287.3) 257.9 (186.1-317.9) 4.20 0.475
16 CCL-11 (Eotaxin-1) 135.9 (95.6-181.4) 151.6 (118.5-210.1) 5.60 0.502
17 IL-6 1.3 (0.9-2.6) 1.1 (0.7-2.6) 0.36 0.530
18 IL-13 1/10 1/20 0.98 0.532
19 IL-17A 4/10 6/20 2.10 0.690
20 CCL-17 (TARC) 385.8 (222.6-511.6) 325.9 (259.9-653.7) 2.80 0.713
21 TNF-α 2.6 (2.3-3.2) 2.5 (2.2-3.0) 0.64 0.779
22 CCL-13 (MCP-4) 188.0 (160.3-234.8) 210.6 (120.9-238.3) 4.80 0.880
23 CCL-2 (MCP-1) 85.0 (75.3-99.1) 83.0 (62.9-114.9) 0.22 0.983
24 VEGF 140.1 (116.0-200.0) 155.0 (103.6-250.7) 7 0.983
25 IL-2 ND ND 0.68 -
26 IL-4 ND ND 0.38 -
27 IL-5 ND ND 0.40 -
28 IL-12p70 ND ND 0.74 -
29 GM-CSF ND ND 1.80 -
30 IL-8 HA ND ND 344 -
* Significant after correction with the Benjamini Hochberg test (p < 0.0042). HS: hidradenitis suppu-
rativa patients. IQR: interquartile range. LLOQ: lowest level of quantification. ND: not detected. NN: 
healthy controls. x: number of samples with a detectable value.
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In plasma, 20 of 30 (66.7%) analytes were detected. In the skin 25 of 26 (96.2%) 
proteins were detected, while four proteins (IL-4, IL-7, VEGF, GM-CSF) were not 
analysed because they have not been validated for skin-derived samples.
Table 2. Inflammatory protein expression in the skin of healthy control subjects and HS patients.
Protein
pg/mg skin tissue
NN (n = 10)
median (IQR) or x/total
HS (n = 20)
median (IQR) or x/total
Unadjusted
p-value
1 IL-16 10.90 (7.67-13.09) 57.54 (38.50-120.81) <0.001*
2 IL-17A 0/10 15/20 <0.001*
3 CXCL-8 (IL-8) 0.30 (0.21-1.30) 5.90 (1.25-19.48) 0.001*
4 IL-12/23p40 0.10 (0.08-0.17) 0.25 (0.14-0.47) 0.007*
5 CCL-4 (MIP-1β) 0.13 (0.08-0.15) 0.62 (0.19-1.83) 0.011*
6 CXCL-10 (IP-10) 0.66 (0.18-1.10) 1.80 (1.07-3.32) 0.011*
7 IL-8 HA 0/10 10/20 0.011*
8 TNF-β 1/10 9/20 0.101
9 CCL-3 (MIP-1α) 2/10 11/20 0.119
10 INF-γ 3/10 13/20 0.122
11 TNF-α 0/10 5/20 0.140
12 IL-1β 0.13 (0.07-0.18) 0.21 (0.08-0.73) 0.155
13 CCL-13 (MCP-4) 0.66 (0.53-0.72) 0.36 (0.25-0.66) 0.172
14 IL-10 0.009 (0.005-0.011) 0.006 (0.004-0.008) 0.183
15 CCL-17 (TARC) 2/10 9/20 0.246
16 IL-5 0.024 (0.019-0.039) 0.017 (0.013-0.029) 0.322
17 IL-1α 1.28 (0.92-2.10) 1.54 (0.86-4.40) 0.350
18 IL-2 0.035 (0.016-0.081) 0.031-0.023-0.039) 0.530
19 IL-6 0.26 (0.02-0.41) 0.08 (0.03-0.54) 0.530
20 CCL-2 (MCP-1) 3.13 (0.30-4.82) 1.43 (0.42-3.35) 0.588
21 IL-15 0.029 (0.026-0.039) 0.035 (0.026-0.045) 0.588
22 CCL-11 (Eotaxin-1) 4/10 11/20 0.700
23 CCL-22 (MDC) 1.80 (1.44-3.44) 1.82 (1.23-3.25) 0.983
24 IL-13 0/10 1/20 1.000
25 IL-12p70 3/10 6/20 1.000
26 CCL-26 (Eotaxin-3) ND ND  -
27 IL-7 NA NA  -
28 VEGF NA NA  -
29 IL-4 NA NA  -
30 GM-CSF NA NA  -
* Significant after correction with the Benjamini Hochberg test (p < 0.014). IL-8 HA (human antibody) 
has been validated for the MSD V-PLEX™ kit, and is recommended when high CXCL/IL-8 levels are 
anticipated. HS: hidradenitis suppurativa patients. IQR: interquartile range. LLOQ: lowest level of quan-
tification. NA: not analysed, not validated for skin samples. ND: not detected. NN: healthy controls. x: 
number of samples with a detectable value.
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Seven inflammatory markers were significantly elevated in HS patients
In plasma, CCL-26 was detected significantly more often in HS patients (16 of 20) 
compared with healthy controls (2 of 10), p = 0.004 (Table 1). Accordingly, the me-
dian CCL-26 level in HS patients was 24.9 pg/mL, interquartile range (IQR) 19.1-37.0 
(Figure 1). In contrast, CXCL-10 levels were significantly lower in HS patients, p = 
0.003. In addition, there was a trend for higher protein levels of IL-1α and lowered 
levels of IL-12/23p40 in HS patients. In lesional skin, IL-16 (p < 0.001), IL-17A (p 
< 0.001), CXCL-8 (p = 0.001), plus IL-8 HA (p = 0.011), representing very high 
CXCL-8 concentrations, IL-12/23p40 (p = 0.007), CCL-4 (p = 0.011), CXCL-10 (p = 
0.011) showed higher levels in HS patients compared with healthy controls (Table 
2, Figure 2). The median IL-17A protein concentration in lesional HS skin was 0.18 
pg/mg tissue (IQR 0.10-0.39). Besides CCL-4, CCL-3 (MIP-1α) was also detected in 
the majority (11/20) of HS lesional skin samples versus two of ten in the healthy 
control samples (p = 0.119). The elevated CCL-4 and CXCL-10 protein levels in HS 
lesions were confirmed by IHC (Figure 3). A strong staining of CCL-26 was observed 
in lesional skin, despite the fact that CCL-26 protein was not detected in lesional HS 
skin by the MSD multiplex assay (Table 2, Figure 3).
Weak correlations between protein levels in the plasma and lesional 
skin of HS patients
Of the 30 proteins, nine were not detected/analysed in either plasma or skin. In 16 ana-
lytes, a correlation coefficient (r) for protein concentrations in HS plasma and skin samples 
was calculated. In general, weak correlations between the protein levels in plasma and 
skin samples were observed: 13 analytes displayed a negative r (range −0.053 to −0.532), 


















































Figure 1. Levels of six elevated inflammatory proteins in lesional skin of HS patients in comparison 
with healthy control patients. (a) CCL-26 (p = 0.004). (b) CXCL-10 (p = 0.003), for NN one data point 
is out of the y-axis range. Horizontal bars display the median. ** p < 0.01. HS: hidradenitis suppurativa 
patients. LLOQ: lowest limit of quantification. NN: healthy controls.
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cytokines/chemokines in the lesional HS skin in which a correlation was calculated, 
showed a plasma-skin correlation coefficient of respectively r = 0.409 (CCL-4), r = −0.358 
(CXCL-8), r = −0.340 (CXCL-10). None of the correlations was statistically significant (p > 
0.05). Of note, CCL-2 (p = 0.016, unadjusted) and CCL-13 (p = 0.028, unadjusted) had 
no statistically significant plasma-skin correlations after correction for multiple testing. 
For IL-1ß, TNF-α, IFN-γ, CCL-11, CCL-17 there was a mismatch in the type of variable 
(continuous, categorical) in plasma and skin. The R-squared values for these five inflam-









































































































































































































































































Figure 2. Levels of six elevated inflammatory proteins in lesional skin of HS patients in comparison 
with healthy control patients. (a) IL-16 (p < 0.001). (b) IL-17A (p < 0.001). The LLOQ was used to calcu-
late the concentration of IL-17A in the healthy controls (0 of 10 detected). (c) CXCL-8 (p = 0.001). (d) IL-
12/23p40 (p = 0.007). (e) CCL-4 (p = 0.011). (f) CXCL-10 (p = 0.011). The Y-axis displays a logarithmic 
scale with the concentrations expressed as pg per mg skin tissue. Horizontal bars display the median. 
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DISCUSSION
In this study we simultaneously measured the protein levels of 30 important inflam-
matory markers, including Th1 and Th17 cytokines and chemokines, in the plasma 
and lesional skin of a well-defined cohort of HS patients. In the circulation, CCL-26 
was detected significantly more often in HS patients. In lesional skin, the levels of 
IL-16, IL-17A, IL-23p40, CCL-4, CXCL-8, and CXCL-10 were significantly elevated 
compared with healthy controls. Remarkably, only  weak correlations  were found 
between the protein levels in the plasma and skin of HS patients.
In plasma, the chemokine CCL-26 (also known as eotaxin-3 or MIP-4α) was a 
newly identified inflammatory marker in HS patients. Significant elevation of this 
chemokine in the serum has previously been reported in atopic dermatitis, cutaneous 
T-cell lymphoma and HIV-associated eosinophilic folliculitis, which are characterised 
by the infiltration of eosinophils, basophils, and specific subpopulations of T cells,14-16 
and all, like HS, diseases characterised by high pruritus scores.4
Table 3. Correlation between protein expression in plasma and skin of HS patients. None of the inflam-
matory markers were statistically significant after Benjamini Hochberg correction.
Protein
Coefficient (r)
plasma vs skin Unadjusted p-value
1 CCL-2 (MCP-1) −0.532 0.016
2 CCL-13 (MCP-4) −0.490 0.028
3 CCL-22 (MDC) 0.423 0.063
4 CCL-4 (MIP-1β) 0.409 0.073
5 CXCL-8 (IL-8) −0.358 0.121
6 CXCL-10 (IP-10) −0.340 0.143
7 IL-1α −0.275 0.240
8 CCL-3 (MIP-1α) −0.254 0.281
9 IL-12/23p40 0.198 0.402
10 TNF-ß −0.189 0.317
11 IL-17A −0.126 0.597
12 IL-6 −0.101 0.672
13 IL-16 −0.098 0.682
14 IL-10 −0.090 0.705
15 IL-15 −0.078 0.743
16 IL-13 −0.053 0.826
r: correlation coefficient (range -1, +1) calculated using the Spearman rho test. Nine markers were not 
tested for a correlation as these markers were not detected in either skin or plasma: IL-2, IL-4, IL-5, IL-7, 
IL-12p70, IL-8-HA, CCL-26, VEGF, GM-CSF.
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No cytokines were found upregulated in the circulation despite the inclusion of 
severe cases of HS with 18 of 20 patients with Hurley stage II and III disease severity. 
Previously, increased serum levels of general inflammatory markers including (high 
sensitive) CRP, erythrocyte sedimentation rate, neutrophils, monocytes, and IgE have 
been demonstrated in HS patients.8,10,17,18 In addition, six studies have reported on 
specific inflammatory serum markers in HS, of which IL-6, IL-17A, TNF-α, TNF-α 
receptor I, soluble IL-2 receptor, S100A8, S100A9 and MMP-8 have been found to be 
upregulated compared with healthy controls.8,10,19-22
Our results obtained in the skin confirm previous findings demonstrating over-
expression of IL-17 pathway-associated cytokines and chemokines such as IL-17A, 
IL-23p40 and CXCL-8 in HS.11,23,24 However, some previously published results, that 
showed significant upregulation of TNF-α, IL-1ß and IL-10 in (peri)lesional HS skin, 
could not be confirmed statistically.24,25 This can be explained by the different ap-
proaches as in the current study  biopsies were homogenised for in situ assessment, 
while van der Zee et al. and Kelly et al. cultured the skin biopsies for 24 and three 
hours respectively. This step of ex vivo culturing of skin samples allows for a prolonged 
production of cytokines that may lead to higher cytokine levels in the culture media. 
Interestingly, CCL-26 was found in abundance in the HS infiltrate by IHC, but was not 
detected in skin homogenates, possibly because CCL-26 is too strongly bound to its 
receptor on the many eosinophils present in the HS infiltrate.4
Upregulation of CXCL-10 in the skin is a remarkable finding, because only limited 
levels of IFN-γ, despite the significant T cell infiltration, have been detected in lesional 
HS skin. The interleukin IL-16 and chemokines CCL-4 and CXCL-10 are produced by 
many cell types including macrophages, dendritic cells, B cells, mast cells, eosino-
phils and T lymphocytes, and play a crucial role in the induction and modulation of 
immune responses during infection and inflammation.26,27 In the context of a strong 
upregulation of CXCL-8, IL-17A and IL-23, we hypothesise that IL-16, CCL-4 and 
CXCL-10 may participate in the recruitment of leucocyte subsets, especially neu-
trophils, eosinophils, monocytes and dendritic cells, into the inflamed lesional HS 
skin.28,29 The importance of neutrophils in the pathophysiology of HS is underlined by 
the increased levels of CXCL-8 that can be cleaved by neutrophil elastase to activate 
Th17 cells to produce bioactive IL-17.30 Furthermore, it has been demonstrated that 
activated neutrophils induce chemotaxis of Th17 cells by a reciprocal cross-talk.31
The poor correlation between cutaneous cytokine and chemokine protein levels 
was reflected by all coefficients except for CCL-2 being below (+/−)0.50, i.e. a low 
to negligible correlation.13 Moreover, most of the analytes demonstrated a negative 
(inverse) correlation between expression in plasma and skin. The overexpression of 
CXCL-10 in HS lesions might explain the lower plasma levels as CXCL-10 could have 
been attracted from the circulation into lesional skin and bound by target cells to fuel 
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local inflammation. A similar observation was reported in a recent study, in which 
plasma concentrations of complement factor C5a and C5b9 were higher among 
patients with mild disease than those with moderate or severe HS.32 Collectively, our 
findings indicate that enhanced levels of cytokines and chemokines in lesions of HS 
patients is generally not reflected in the plasma or serum.
Our study has several strengths including the in parallel assessment of inflammatory 
markers in skin and plasma using a sensitive and accurate detection technique. Limi-
tations of this study are the limited sample size, which did not allow for a subgroup 
analysis by Hurley disease severity,  and the use of a predefined panel of 30 cytokines 
and chemokines, which did not measure all previously reported HS-biomarkers in-
cluding antimicrobial peptides. Lastly, the cross-sectional study design did not allow 
for analysis of cytokine- and chemokine modulation by anti-inflammatory therapies.
In conclusion, CCL-26 is a newly identified inflammatory marker that is upregulated 
in the circulation of HS patients. Besides previously demonstrated overexpression of 
IL-17A, IL-23p40, CXCL-8 in HS lesions, this study found IL-16, CCL-4, CXCL-10 and 
CCL-26 as novel and potentially important players in the pathogenesis of HS. The 
local and systemic upregulation of CCL-26 in HS patients can be linked to the high 
pruritus score in HS. Furthermore, our results demonstrate that plasma gives a limited 
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Biologics targeting inflammatory mediators are able to clinically improve hidradenitis 
suppurativa (HS). However, their clinical efficacy shows great inter-patient variability 
in daily practice.
Objective
To investigate the anti-inflammatory potency of currently available biologics for the 
treatment of HS in an ex vivo skin culture system using lesional HS biopsies.
Methods
Lesional skin samples of ten HS patients and normal skin samples of five healthy con-
trols were cultured ex vivo and exposed to prednisolone or biologics targeting TNF-α, 
IL-17A, IL-12/23p40, or CD20,  respectively adalimumab, infliximab, secukinumab, 
ustekinumab, and rituximab. Real-time quantitative PCR and cytokine bead arrays 
were used to measure the inhibitory effect of the biologics on cytokines and antimi-
crobial peptides (AMPs).
Results
The relative mRNA expression of all tested cytokines and AMPs was significantly 
downregulated by all anti-inflammatory agents (p < 0.0001). The release of the 
pro-inflammatory cytokines TNF-α, IFN-γ, IL-1ß, IL-6, and IL-17A was significantly 
inhibited by adalimumab, infliximab, ustekinumab, prednisolone (all p < 0.0001) 
and rituximab (p = 0.0071) but not by secukinumab (p = 0.0663). In addition, adalim-
umab, infliximab, and prednisolone reduced the levels of a broader mix of individual 
cytokines than secukinumab, ustekinumab, and rituximab.
Conclusion
This ex vivo study suggests that TNF-α inhibitors and prednisolone are the most  pow-
erful inhibitors of pro-inflammatory cytokines and AMPs in HS lesional skin, which is 
in accordance with our clinical experience in patients with HS.
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INTRODUCTION
Hidradenitis suppurativa (HS) is a chronic skin disease characterised by painful, 
deep-seated, inflamed nodules, abscesses, and in later stages sinus tracts.1 Occlusion 
of the hair follicle with subsequent rupture, followed by a fierce local inflammatory 
response, are considered primary pathogenic events. The aberrant innate immune 
response is characterised by the upregulation of various pro-inflammatory cytokines 
and antimicrobial peptides (AMPs).2
Several studies have found elevated mRNA and protein levels of tumour necrosis 
factor (TNF)-α in lesional and perilesional HS skin.3,4 Targeting TNF-α with adalim-
umab and infliximab has been shown to be clinically efficacious in HS in randomised 
placebo-controlled trials.5-7 In addition, upregulation of interleukin (IL)-1ß, IL-17A, 
and IL-23 in HS lesions point to the importance of the IL-17 pathway in the pathophysi-
ology of HS.8-10 However, targeting IL-1 in HS gave ambiguous clinical outcomes. In a 
randomised controlled trial anakinra proved to be efficacious in moderate-to-severe 
HS, yet cases of failure on anakinra therapy have been reported.11-13
Most recently IL-17 has been targeted in two clinical trials in HS (NCT02421172, 
NCT03248531), but the results have not yet been released. Treatment with 
secukinumab or ustekinumab induced amelioration of HS in a few individual cases 
and case series.14-16 In addition, enhanced levels of AMPs in lesional HS skin have 
been described for S100A7 (psoriasin), S100A8, S100A9, human ß-defensin (HBD)-
2, HBD-3 and LL-37.17-19 Upregulation of these AMPs in HS lesional skin is mainly 
driven by IL-17.18
Chronic HS lesions are characterised by a marked increase in the number of 
CD20+, CD79A+ B cells, and CD138+ plasma cells.20 One case report described a 
clear improvement in HS after treatment with rituximab for concomitant idiopathic 
carpotarsal osteolysis syndrome.21 This highlight the contribution of these B and 
plasma cells to the inflammatory process in HS.
Although biologics targeting inflammatory mediators are now widely used for the 
treatment of HS, their clinical efficacy shows great inter-patient variability. Our ex 
vivo skin culture system is a fast and simple method to simultaneously investigate 
and compare the effect of biologics in fresh human lesional skin samples.22 It ap-
proaches the in vivo situation by maintaining the patients’ skin architecture and 
allows close monitoring of the events following response to immunostimulators or 
suppressors in the same experiment.23 Therefore, this study sought to investigate the 
anti-inflammatory potency of currently available biologics used for the treatment of 




Ethics and informed consent
HS lesional skin was collected from excised skin after HS surgery conducted in the 
department of Dermatology of the Erasmus University Medical Center in Rotterdam, 
The Netherlands from October 2017 through February 2018. According to the opt-
out principle used in the Erasmus University Medical Center no informed consent is 
required for the use of excised tissue for research purposes as this is considered waste 
material. Control skin samples were obtained from healthy individuals in the Sint 
Franciscus Hospital in Rotterdam, The Netherlands. All healthy volunteers provided 
written informed consent for the use of their excised skin in this study.
Hidradenitis suppurativa patients
Ten HS patients, five males and five females, with chronic, active disease (seven 
Hurley stage II, three Hurley stage III) requiring surgical excision under general or 
sedative anaesthesia were included. HS lesional skin samples were obtained from the 
inguinogenital area in 5 of these 10 patients, axillae in 4, and from the gluteal area in 
1 patient. The mean (± SD) age was 43.7 ± 7.4 years, the mean body mass index was 
30.3 ± 6.5 kg/m2, and 7 of 10 patients were current smokers. Eight patients received a 
stable (≥ 28 days) dose of systemic antibiotics for their HS at the time of surgery. None 
of the patients had been using immunosuppressive or immunomodulatory therapies 
(e.g. biologics) for at least two months prior to surgery.
Healthy control skin
Healthy skin samples were obtained from the submammary and abdominal waste 
material of five women who underwent breast or abdominal reduction surgery. We 
argue that skin from these regions is suitable  as a control samples because the in-
framammary and abdominal folds are predilection sites for HS. The control subjects 
were otherwise healthy and had no family history of HS, and were not using any 
immunosuppressive or immunomodulatory treatment at the time of surgery.
Biopsy procedure
A total of seven fresh 4-mm punch biopsies per subject were taken. HS lesional skin 
biopsies were obtained from the same palpable infiltrate, and at least 1 cm away from 
the excision border. Abscesses were not biopsied to avoid sampling only the roof of the 
abscess. Each biopsy was weighed prior to culture as described in an earlier publication.4 
HS biopsies had a mean weight of 32.4 ± 6.6 mg, which was significantly heavier than 
biopsies from healthy skin with a weight of mean 16.1 ± 3.0 mg (p < 0.001). This potential 
confounder was addressed by normalising all protein levels for the mg tissue.
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Ex vivo skin culture
The 4-mm biopsies were immediately cultured in a transwell system (Netwell; Co-
star, Cambridge, MA) as described previously.22,23 In brief, samples were placed in 
punched-out holes in the transwell membrane of a 12-well plate with the epidermis 
exposed to the air and the dermis immersed in 1 mL Iscove’s modified Dulbecco’s 
medium (Gibco, Paisley, U.K.) containing 0.5% human AB serum, penicillin (100 
U/mL) and streptomycin (100 U/mL) with or without an anti-inflammatory agent. 
Biologics and prednisolone were separately added to the culture media resulting 
in the following seven conditions: (i) culture media as negative control; (ii) pred-
nisolone 100 µg/ml as positive control; (iii) adalimumab 30 µg/ml; (iv) infliximab 
20 µg/ml; (v) secukinumab 30 µg/ml; (vi) ustekinumab 10 µg/ml; (vii) rituximab 200 
µg/ml. The concentrations of the monoclonal antibodies were a multiple of the re-
ported trough levels in patients with plaque psoriasis (adalimumab24,25, infliximab25, 
ustekinumab26, secukinumab27), and CD20+ B cell malignancies (rituximab28). Skin 
biopsies were incubated for 24h at 37°C in an atmosphere of 5% CO2 and 98% 
humidity. Subsequently, the biopsies were placed in 250 µL lysis buffer containing 
1% ß-mercaptoethanol. Both the supernatants and the biopsies were transferred to a 
polypropylene tube and stored at −20°C until further analysis.
Gene expression analysis
Total mRNA was extracted using the GenElute Mammalian Total RNA Miniprep Kit 
(Sigma-Aldrich, St. Louis, MA). RNA was treated with 0.1 U/μL DNAse (Invitrogen) 
and cDNA was subsequently synthesised using 1 μg total RNA template, with Super-
Script II reverse transcriptase, random hexamer primers (Invitrogen) and oligo(dT)15 
(Promega). Primers and probes were designed and chosen using ProbeFinder Sofware 
and the Universal Probe library (Roche Applied Science, Indianapolis, IN).  ABL1 
was chosen as a reference housekeeping gene.29 Real-time quantitative PCR (qPCR) 
was performed for 12 genes using the ViiA7 sequence-detection system (Applied 
Biosystems): TNF-α, IL-1ß, IL-6, CXCL-8/IL-8, IL-12p19, IL-17A, IFN-α/MxA, S100A7, 
S100A8, S100A9, LL37, and HBD-2. Gene expression was analysed with QuantStudio 
Real-Time quantitative PCR Software version 1.3 (Applied Biosystems, Waltham, MA).
Protein quantification
Eighteen inflammation-related cytokines were simultaneously measured in the super-
natant using a customised bead-based Multi-Analyte Profiling assay (Luminex, R&D 
systems, Minneapolis, MN): CCL-20, TNF-α, IFN-γ, IL-1ß, IL-1R1, IL-5, IL-6, IL-10, 
IL-12/23p40, IL-17A, IL-17E, IL-18, IL-19, IL-22, IL-27, IL-31, IL-33, and IL-36ß. As-
says were used according to the manufacturers’ protocol. A dilution factor of 2 was 




The relative mRNA expression and protein production per sample compared with 
culture media (negative control) was calculated for every condition. Protein levels 
were normalised according to input weight and expressed in picogram (pg)/mL/mg 
tissue weight. The lower limit of quantification was imputed when protein concentra-
tions in the supernatant (pg/mL) were below limit of detection. The Kruskal-Wallis 
test, i.e. a one-way ANOVA on ranks, was used to compare the variance in mRNA 
and protein levels per inflammatory marker. If another condition stochastically 
dominated one other condition, the Dunnett’s post-test was subsequently used to 
separately test conditions versus culture media (pairwise comparisons). We chose 
this approach in order to increase power. A two-sided p-value lower than 0.05 was 
considered significant. The level of significance for the relative mRNA expression and 
protein production was separately adjusted by the Benjamini Hochberg procedure 
for multiple comparisons. A correlation between relative mRNA and protein levels 
per cytokine was calculated using the Spearman rho test for non-normally distributed 
continuous variables. GraphPad Prism version 6 (GraphPad Software, La Jolla, CA) 
was used for all statistical analyses.
RESULTS
Sample flow for analysis
In total, samples of ten HS patients and five healthy controls were analysed by real-
time qPCR. Supernatants of one HS patient were excluded from protein analysis 
because of erroneous sample processing, resulting in samples of nine HS patients 
with protein data. For control skin, supernatants of three healthy volunteers were 
analysed by Luminex assay. However, protein levels were below level of detection or 
in the very low range of the calibration line in these control samples (data not shown). 
Therefore, samples of the other two patients were not analysed.
Significant downregulation of gene expression of cytokines and AMPs 
by prednisolone and different biologics
The relative changes in mRNA expression of the 12 genes in HS samples includ-
ing significance levels are shown in Table 1. The overall median inhibitory effect on 
the mix of cytokines and AMPs per condition was: prednisolone 0.57 (interquartile 
range [IQR] 0.34-1.03); adalimumab 0.51 (0.33-0.92); infliximab 0.53 (0.32-0.78); 
secukinumab 0.56 (0.29-0.99); ustekinumab 0.64 (0.44-1.00), rituximab 0.73 (0.50-
1.19). Remarkably, the inhibitory impact on AMPs was stronger for the biologics 
than for prednisolone (Table 1, Figure 1). Prednisolone, adalimumab and infliximab 
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significantly inhibited IL-1β. Expression of CXCL-8/IL-8 was significantly downregu-
lated by adalimumab, infliximab, secukinumab, and ustekinumab. Messenger RNA 
levels of two other important pro-inflammatory cytokines, TNF-α and IL-23p19, 
were not significantly downregulated by any of the biologics or prednisolone. Gene 
expression of members of the S100 family and HBD-2 was significantly reduced by 
adalimumab, infliximab, secukinumab and ustekinumab (Table 1). In healthy control 
skin, only prednisolone, adalimumab and infliximab significantly downregulated 
mRNA expression of the mix of tested cytokines and AMPs (Supplementary Table 1, 
Supplementary Figure 1).
Significant ex vivo reduction in TNF-α, IFN-γ, IL-1ß, IL-6, and IL-17A 
protein levels of in HS lesional skin
In total, 18 cytokines were measured. Six cytokines were not detected in the majority 
of HS samples throughout all conditions: IL-1RI, IL-5, IL-12/23p40, IL-22, IL-31, and 
IL-33. Relative changes in protein production including significance levels for the 
other 12 cytokines are shown in Table 2. The overall median (IQR) effect on cytokines 
per condition was: prednisolone 0.51 (0.28-0.64); adalimumab 0.78 (0.54-0.91); 






















































































































































































































Figure 1. Anti-inflammatory impact on the relative mRNA expression of the mix of cytokines and 
AMPs in HS lesional skin, n = 10. All agents displayed significant inhibition of both cytokine and AMP 
mRNA expression except for the effect of RTX on cytokine mRNA expression. One data point is out of 
the y-axis range. Horizontal bars display the median. Media, culture media; PRED, prednisolone 100 
µg/mL; ADA, adalimumab 30 µg/mL;  IFX, infliximab 20 µg/mL; SEC, secukinumab 30 µg/mL; UST, 
ustekinumab 10 µg/mL; RTX, rituximab 200 µg/mL.
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infliximab 0.70 (0.49-0.94); secukinumab 0.85 (0.69-0.95); ustekinumab 0.71 (0.57-
0.79); rituximab 0.81 (0.70-0.94). Specifically the release of TNF-α, IFN-γ, IL-1ß, 
IL-6, and IL-17A was significantly inhibited by all tested drugs with the exception of 
secukinumab (Figure 2). In addition, prednisolone significantly inhibited the release 
of TNF-α, IFN-γ, IL-1ß, IL-6, IL-17A, IL-10, and IL-25/17E. As expected adalimumab 
and infliximab almost completely neutralised TNF-α levels in the supernatants (Figure 
3). Of note, for the two important cytokines TNF-α and IL-17A we observed  both a 
strong intra- and inter-patient variability among all biologic conditions (Figure 3).
Great variation in correlation between mRNA expression and protein 
production levels in HS samples
The cytokines IL-1ß, IL-6, IL-17A, and TNF-α, were measured by both real-time qPCR 
and Luminex. There was great variation in the correlation between mRNA and protein 
levels of these individual cytokines (Figure 4). A high correlation between mRNA and 
protein levels was found for IL-17A (r = 0.86; p < 0.0001), while the correlation for 
TNF-α was almost zero (r = 0.04; p = 0.7480).























Figure 2. Anti-inflammatory impact on protein production of all cytokines and five important cytokines 
as measured by Luminex, n = 9. Important inflammatory cytokines: TNF-α, IFN-γ, IL-1ß, IL-6, IL-17A. 
Twelve data points are out of the y-axis range. Horizontal bars display the median. Media, culture 
media; PRED, prednisolone 100 µg/mL; ADA, adalimumab 30 µg/mL;  IFX, infliximab 20 µg/mL; SEC, 
secukinumab 30 µg/mL; UST, ustekinumab 10 µg/mL; RTX, rituximab 200 µg/mL.
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DISCUSSION
In this study we show that the commercially available biologics used in daily prac-
tice for the treatment of HS (adalimumab, infliximab, ustekinumab and rituximab), 
significantly inhibited mRNA and protein expression of various cytokines and AMPs 
in lesional HS skin, cultured ex vivo for 24 hours. Moreover, the anti-inflammatory 
effect of prednisolone and all biologics, except secukinumab, is the strongest on 
TNF-α, IFN-γ, IL-1ß, IL-6, and IL-17A, which are important cytokines in the patho-
genesis of HS. In addition, prednisolone and TNF-α inhibitors seem the most effective 
in reducing the release of a broader range of pro-inflammatory cytokines and AMPs 
in lesional HS skin.
The strongest evidence in patients with moderate-to-severe HS has been docu-
mented for anti-TNF agents adalimumab and infliximab.5,30-32 We confirmed the pre-
viously reported decrease of ex vivo IL-1ß protein levels after adalimumab treatment 
on the mRNA level.7 As TNF-α is a multifunctional cytokine with numerous actions, 
a simultaneous downregulation of other cytokines, such as IL-6 and cytokines of the 
IL-1 family, could also explain the results of the anti-TNF agents in our study.9,33 Our 
translational findings correspond with the observed efficacy of TNF-α inhibitors in HS 
daily practice. Inter-patient variability in the response to biologics could explain why 
some HS patients are clinically good responders while others show a lesser response.
TNF-α











































Figure 3. Inter- and intra-patient variability demonstrated by fluctuating protein levels of TNF-α and 
IL-17A, n = 9. (a) TNF-α. Connected dots represent one patient.  High intra-patient variability as dem-
onstrated by the fluctuating per patient protein levels between conditions. Low inter-patient variability 
for conditions PRED, ADA, IFX. (b) IL-17A. Connected dots represent one patient. Very high (more 
than TNF-α) intra-patient variability. Low inter-patient variability for conditions PRED. Media, culture 
media; PRED, prednisolone 100 µg/mL; ADA, adalimumab 30 µg/mL;  IFX, infliximab 20 µg/mL; SEC, 
secukinumab 30 µg/mL; UST, ustekinumab 10 µg/mL; RTX, rituximab 200 µg/mL.
Chapter 4
68
Remarkably, secukinumab did not reduce the IL-17 protein levels in the same 
way as adalimumab and infliximab reduced that of TNF-α. Unfortunately, IL-12p40 
protein, an important indicator of the IL-17 pathway, fell below the level of detection 
in the Luminex assay. It could be that other cytokines such as TNF-α and IL-1ß, not 
being blocked by secukimumab in this culture system were still able to induce pro-
duction of IL-17. Moreover, levels of IL-17A were in the lower range of detection in 
most patients. Another explanation may be that the anti-IL-17A antibodies used in the 
Luminex assay detect a different epitope of IL-17A than recognised by secukinumab. 
The lower mRNA expression of AMPs, IL-6 and CXCL-8 may be considered as the 
result of blocking of IL-17A bioactivity by secukinumab.
The pan-cytokine inhibitory characteristics of prednisolone were demonstrated by 
inhibition of multiple cytokines on both the mRNA and protein level, which sup-
ports the efficacy of systemic and intralesional corticosteroids for acute HS flares in 
clinical practice.34 However, prolonged high-dose systemic corticosteroids are not 


























































Figure 4. Correlation between the relative protein production (y-axis) and mRNA (x-axis) expression 
of HS lesional skin, n = 9. (a) IL-1ß. (b) IL-6. (c) IL-17A. (d) TNF-α. Values on x-axis and y-axis display 
the relative production and expression values of a cytokine. Abbreviations: r, correlation coefficient; p, 
p-value according to Spearman rho test.
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recommended as HS rapidly flares after tapering, especially after a long course.35 
Nonetheless, low-dose systemic prednisolone could be a valuable adjunct therapy 
for recalcitrant HS.36
Rituximab was the only biologic without a significant inhibitory effect on individual 
inflammatory mRNA and protein levels. This is not surprising as B cell blockade in 
inflammatory diseases acts via inhibition of antibody production, antigen presenta-
tion and indirectly via cytokine reduction.37 Therefore, the presence of the complete 
immune system is required for B cell blockade to be effective. Moreover, HS is con-
sidered primarily a disease of a deficient innate immunity. On the other hand, chronic 
HS lesions are full of B cells and plasma cells, indicating that adaptive humoral 
immunity is also activated in longstanding HS.20,38
The impact of biologics on AMP expression has never been investigated in lesional 
HS skin. Our findings indicate a potential supporting role for AMPs in HS pathophysi-
ology as it is known that AMPs are capable of activating keratinocytes and attracting 
innate immune cells to amplify the local immune response.39 Cytokines produced 
by innate and adaptive immune cells, such as TNF-α, IL-17, and IL-12, drive AMP 
production in the keratinocytes.40-42 Moreover, AMPs can be activated by damage- 
and pathogen-associated molecular patterns (DAMPs/PAMPs) after follicle rupture 
with the release of keratin fibres and skin commensals in the dermis.
Although it is assumed that levels of mRNA and protein have a one-to-one correla-
tion, the absence of correlation between TNF-α mRNA and its protein levels has been 
previously reported.43-45 In addition, other factors such as the half-life of proteins and 
the degradation and stability of mRNA may vary widely.43,46,47
Major strengths of our study are the use of a standardised ex vivo transwell culture 
system and weighing each biopsy in order to normalise all protein levels for mg tissue 
weight. Cytokines were evaluated on both mRNA and protein level, including four 
cytokines that were assessed for validation purposes. Furthermore, the use of healthy 
control skin from regions that are suitable to function as control samples further 
increases the validity of our study. Possible limitations include the relatively small 
sample size, lack of dose-response relationships, and AMPs which have only been 
evaluated on the mRNA level.
In conclusion, prednisolone, adalimumab, infliximab, ustekinumab and rituximab 
significantly inhibited the expression levels of a selected panel of inflammatory cyto-
kines and AMPs in ex vivo lesional skin of HS patients. The ex vivo model will enable 
studies with combinations of  biologics, or targeting of novel important cytokines, 
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SUPPLEMENTARY MATERIAL
















































































































































Supplementary Figure 1. Relative mRNA expression of all cytokines (5) and all AMPs (5) in healthy 
control skin, n = 5. Two data points are out of the y-axis range. Horizontal bars display the median. 
Media, culture media; PRED, prednisolone 100 µg/mL; ADA, adalimumab 30 µg/mL;  IFX, infliximab 20 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Apremilast for moderate  
hidradenitis suppurativa:  
results of a randomised controlled trial
A.R.J.V. Vossen
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E.P. Prens





Effective anti-inflammatory treatments for hidradenitis suppurativa (HS) are limited.
Objective
To evaluate the efficacy and short-term safety of apremilast in patients with moderate 
HS.
Methods
A total of 20 patients with moderate HS were randomised in a 3 : 1 ratio to receive 
blinded treatment with apremilast, 30 mg twice daily, or placebo for 16 weeks. The 
primary outcome was the Hidradenitis Suppurativa Clinical Response at week 16. 
Linear mixed effects modelling (analysis of covariance) was used to assess secondary 
clinical outcomes between treatment groups.
Results
The Hidradenitis Suppurativa Clinical Response was met in 8 of 15 patients in the 
apremilast group (53.3%) and none of 5 patients in the placebo group (0%) (p = 
0.055) at week 16. Moreover, the apremilast-treated patients showed a significantly 
lower abscess and nodule count (mean difference, −2.6; 95% confidence interval, 
−6.0 to −0.9; p = 0.011), NRS for pain (mean difference, −2.7; 95% confidence 
interval, −4.5 to −0.9; p = 0.009), and itch (mean difference, −2.8; 95% confidence 
interval, −5.0 to −0.6; p = 0.015) over 16 weeks compared with the placebo-treated 
patients. There was no significant difference in the Dermatology Life Quality Index 
over time between the 2 treatment groups (mean difference, −3.4; 95% confidence 
interval, −9.0 to 2.3; p = 0.230). The most frequently reported adverse events in 
the apremilast-treated patients were mild-to-moderate headache and gastrointestinal 
symptoms, which did not result in dropouts.
Limitations
Small number of patients, relatively short study duration.
Conclusion
Apremilast, at a dose of 30 mg twice daily, demonstrated clinically meaningful ef-
ficacy and was generally well tolerated in patients with moderate HS.
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INTRODUCTION
Hidradenitis suppurativa (HS) is a chronic, recurrent, autoinflammatory skin disorder 
with an estimated prevalence of approximately 1% of the general population.1 The 
disease occurs more frequently in females and usually presents during adolescence 
with painful, itchy, deep-seated, inflamed nodules, abscesses, and sinus tracts pre-
dominantly in the axillae and inguinal and anogenital regions.1,2 Disease severity 
can be categorised into 6 stages, ranging from clear (stage 0) to very severe (stage 6) 
according to the Hidradenitis Suppurativa Physician’s Global Assessment (HS-PGA).3 
HS may progress over time, supporting the need for early intervention.
Currently, first-line therapies for moderate HS include anti-inflammatory oral anti-
biotics such as the tetracyclines and the combination of clindamycin and rifampicin.4 
Second-line treatment includes adalimumab, which is the only registered treatment 
for moderate-to-severe HS that provides clinically meaningful improvements.5 Other 
biologic therapies have not been extensively studied in patients who have HS or are 
currently in the early stages of its clinical development.6 Taken together, the high-
quality evidence on HS treatment is limited, highlighting a significant unmet need for 
novel effective anti-inflammatory therapies.
Recently, in a small case series, 5 of 6 patients with moderate-to-severe HS treated 
with apremilast, 30 mg twice daily for 3 months, showed a promising response.7 In 
addition, the clinical efficacy of apremilast for patients with moderate-to-severe pso-
riasis and psoriatic arthritis has previously been proved in multiple clinical trials.8-10 
Apremilast is an orally administered small molecule drug that specifically inhibits 
phosphodiesterase 4 and modulates the expression of a variety of proinflammatory 
and anti-inflammatory mediators.11-13 As apremilast targets phosphodiesterase 4 in 
several inflammatory cell types involved in the pathogenesis of HS, such as T cells, 
natural killer cells, neutrophils, monocytes, and dendritic cells, we hypothesised that 
it might have a beneficial effect in patients with HS.
The objective of this double-blind randomised placebo-controlled trial was to 
investigate the clinical efficacy and short-term safety and tolerability of apremilast in 
patients with moderate HS. We specifically chose a study population with moderate 
HS because the clinical efficacy of apremilast in psoriasis (as measured by reaching 
a 90% improvement in baseline Psoriasis Area Severity Index score) is lower than 
that of most anti-tumour necrosis factor-α agents and certainly lower than that of the 





Patients who were at least 18 years of age with moderate HS, defined as a HS-PGA 
score of 3, were enrolled. Additionally, patients were required to have at least 4 in-
flammatory lesions (i.e. abscesses, draining sinuses/tunnels, or inflammatory nodules 
in at least 2 anatomic locations). Patients receiving systemic antibiotics or immuno-
suppressive and/or immunomodulating therapy were required to stop treatment at 
least 28 days before baseline and until the end of study. Patients were excluded if they 
had minimal, mild, severe, or very severe disease severity according to the HS-PGA 
scale; any clinically significant active systemic disease or infection; a diagnosis of or 
suspected Crohn’s disease; a history of major psychiatric illness requiring hospitalisa-
tion within the past 3 years; a malignancy or history of malignancy (except for treated 
basal or squamous cell skin carcinoma or early forms of cervical carcinoma with 
no recurrence in 5 years); open wounds remaining after surgical treatment; prior 
treatment with apremilast; or a contraindication for apremilast.
Screening
Once a patient was considered eligible for the study, the following screening pro-
cedures were performed: (1) medical history and physical examination; (2) chest 
radiograph; (3) serologic testing for HIV, hepatitis B and C virus, tuberculosis (Quan-
tiFERON) and (in women) a serum pregnancy test; and (4) clinical laboratory analysis 
to determine haemoglobin level, white blood cell count, absolute neutrophil count, 
platelet count, serum creatinine level, alanine aminotransferase level, and alkaline 
phosphatase level.
Study design
This study was an investigator-initiated clinical trial (EudraCT 2016-000859-27; 
NCT03238469) that was conducted in the department of Dermatology of the Erasmus 
University Medical Center Rotterdam, The Netherlands, approved by the local medi-
cal ethics committee (NL.57003.078.16), and implemented according to the Decla-
ration of Helsinki principles. All patients provided written informed consent before 
enrolment. Eligible patients were randomly assigned to treatment with apremilast at 
a dose of 30 mg twice daily (n = 15) or placebo tablets with an appearance, packag-
ing, and labelling identical to that of apremilast (n = 5). An independent statistician 
generated the randomisation scheme on the basis of the anticipated group size with 
a ratio of 3 to 1 by using R Statistical Software (R Foundation for Statistical Comput-
ing, Vienna, Austria). Treatment was allocated by using the sequential randomisation 
code provided and guarded by the trial pharmacist. Patients, care providers, and 
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those assessing the outcomes were blinded to treatment allocation. Apremilast was 
dose-escalated over the first week of treatment (10 mg on day 1, with increases of 10 
mg/d) until the target dose of 30 mg twice daily had been reached. The duration of 
the treatment period was 16 weeks. Study visits were scheduled for screening and at 
week 0 (baseline), week 2, week 4 (early response), week 8, week 12, and week 16 
(end of study).
Outcome measures
The primary outcome was the percentage of patients reaching the Hidradenitis Sup-
purativa Clinical Response (HiSCR) at week 16, which was defined as at least a 50% 
reduction in total abscess and inflammatory nodule (AN) count, with no increase 
in abscess count and no increase in draining sinus count relative to baseline.15,16 At 
every visit, a physical examination (including a lesion count) was performed. Second-
ary clinical outcomes included the HiSCR at week 4, total lesion count, AN count, 
and Dermatology Life Quality Index (DLQI) score17; the patient’s assessment of pain, 
itch, and disease burden on a numeric rating scale (NRS) ranging from 0 (no itch, 
pain, or burden) to 10 (unbearable/extreme itch, pain, and/or burden); and clinical 
photographs. Both physician-reported outcomes and patient-reported outcomes were 
collected at all visits. Safety assessments were conducted from screening until the 
end of the study. Adverse events (AEs) and vital signs were evaluated at each visit, and 
clinical laboratory measurements were evaluated at weeks 2, 8, and 16.
Statistical analyses
No statistical sample size was calculated.18 Sample size estimations were based on 
previous exploratory clinical trials in HS.19,20 Clinical efficacy and safety outcomes 
were analysed in the intention-to-treat population according to the randomised group 
assignments. The proportion of patients achieving HiSCR was analysed by Fisher’s 
exact test at week 4 and week 16 (primary outcome). Missing outcomes in terms 
of the HiSCR of 2 patients at week 16 were imputed by last observation carried 
forward. To assess response over 16 weeks of treatment, the total lesion count, AN 
count, and DLQI score, as well as the patient’s global assessment on pain, itch, and 
disease burden, were analysed by linear mixed effects modelling using analysis of 
covariance with the fixed factor treatment*time, the baseline value as covariate, and 
first-order autoregressive as best fitting covariance structure. Exactly the same model 
was subsequently used to separately evaluate the treatment arms relative to baseline 
for an impression of the short-term (week 4) and final response to treatment (end of 
the study [week 16]). Secondary outcomes were not statistically compared at time 
points to increase the power. Missing data for the analysis of covariance modelling 
were not imputed, nor were they carried forward. Post hoc analysis did not show 
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significant differences between the approach of no data imputation and the approach 
of last observation carried forward. Safety data were analysed by descriptive statistics 
for all patients who received at least 1 dose of the study drug. Statistical analyses 
were conducted with SPSS Statistics 24.0 (IBM Corporation, Armonk, NY). A 2-sided 
p-value less than 0.05 was considered significant.
RESULTS
Patients
Enrolment occurred between February and August 2017, and a 16-week follow-up 
was completed in December 2017. In total, 21 patients were randomised, of whom 
20 received at least 1 dose of study medication and were included in the intention-
to-treat population. Of these, 18 (90%) completed the week 16 follow-up visit (Figure 
1). Of the 15 patients receiving apremilast, 2 (13%) discontinued the study: 1 patient 
discontinued between week 4 and week 8 because of personal circumstances (travel 
distance in combination with divorced parents), and the other discontinued at week 
8 on account of adverse effects. None of the 5 patients in the placebo arm dropped 
out. The baseline characteristics for the intervention groups are depicted in Table 1.
15 assigned apremilast 5 assigned placebo 
20 randomised 
1 excluded 
- withdrawal of consent 
21 screened 
2 discontinued 
- 1 adverse event 
- 1 personal reasons 





5 completed 13 completed 
Figure 1. Flow chart of patient enrolment and the study procedure.
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Primary efficacy outcome
Of the 15 patients allocated to treatment with apremilast, 8 (53.3%) achieved a posi-
tive HiSCR at week 16 compared with none of the patients in the placebo group (p 
= 0.055) (Figure 2). The last observation was carried forward for the dropout after 
week 4 (negative HiSCR) and the dropout at week 8 (positive HiSCR). At week 4, 10 
of 15 patients receiving apremilast (66.7%) achieved a positive HiSCR versus none 
of the patients in the placebo group (p = 0.033). A decrease in the proportion of 
patients treated with apremilast who achieved an HiSCR was observed from week 2 
(an HiSCR in 11 of 15 patients) with a stabilisation between week 12 and 16 (a HiSCR 
in 8 of 15 patients). A characteristic example of the clinical response of a patient 
treated with apremilast is provided in Figure 3.
Secondary efficacy outcomes
Over 16 weeks of treatment, the patients receiving apremilast showed a significantly 
lower AN count (mean difference, −2.6; 95% confidence interval, −6.0 to −0.9; p = 
0.011) (Figure 4) and significantly lower NRS scores for pain (mean difference, −2.7; 
95% confidence interval, −4.5 to −0.9; p = 0.009) (Figure 5), itch (mean difference, −2.8; 
95% confidence interval, −5.0 to −0.6; p = 0.015), and disease burden (mean difference, 
Table 1. Baseline characteristics.
Characteristic Apremilast (n = 15) Placebo (n = 5)
Mean age ± SD, y 35.7 ± 13.0 33.4 ± 8.2
Women, n (%) 12 (80) 5 (100)
Race, white, n (%) 15 (100) 4 (80)
Mean history of HS ± SD, y 21.6 ± 13.0 16.0 ± 7.1
Prior HS antibiotics treatment, n (%) 13 (87) 4 (80)
Prior HS biologics treatment, n (%) 4 (27) 2 (40)
Mean BMI ± SD, kg/m2 32.7 ± 6.7 32.8 ± 5.3
Current smokers, n (%) 11 (73) 5 (100)
Mean current daily cigarette consumption ± SD 17.7 ± 8.2 19.6 ± 11.4
Mean total lesion count ± SD † 6.9 ± 2.3 7.2 ± 2.6
Mean AN count ± SD ‡ 6.1 ± 1.7 5.8 ± 2.4
Mean DLQI ± SD, (0-30) 14.6 ± 7.6 11.8 ± 5.9
Mean NRS for pain ± SD, (0-10) 6.4 ± 2.4 5.8 ± 2.2
Mean NRS for itch ± SD, (0-10) 5.0 ± 2.9 6.8 ± 3.0
Mean NRS for disease burden ± SD,  (0-10) 6.2 ± 2.1 7.0 ± 3.0
Values as mean ± standard deviation or number (percentage). † Total number of abscesses, draining 
sinuses/tunnels, and inflammatory nodules. ‡ Total number of abscesses and inflammatory nodules. AN: 
abscess and inflammatory nodule. BMI: body mass index. DLQI: Dermatology Life Quality Index. HS: 
hidradenitis suppurativa. NRS: numeric rating scale. SD: standard deviation.
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−1.8; 95% confidence interval, −3.7 to −0.01; p = 0.049) than did patients in the placebo 
group. The total lesion count demonstrated a trend toward significant improvement in 
the apremilast group (mean difference, −2.6; 95% confidence interval, −5.5 to 0.2; p = 
0.064). There were no differences in DLQI score over time between the treatment groups 
(mean difference, −3.4; 95% confidence interval, −9.0 to 2.3; p = 0.230).
The mean changes from baseline by treatment group for the secondary clinical 
outcomes at week 4 (early response) and week 16 (end of study) are summarised in 
Table 2. In the apremilast group the treatment outcomes observed at week 16 did 
(a) (b) (c)
Figure 3. Example of a patient in the apremilast treatment group: baseline (a), at week 4 (early re-
sponse) (b), and at week 16 (end of study) (c). Arrows indicate index lesions (i.e. inflammatory nodules 
that were larger than 10 mm in diameter and painful by palpation at baseline. Note that all the deep-

















Placebo HiSCR + Apremilast HiSCR +
Figure 2. Percentage of patients in both treatment groups reaching the hidradenitis suppurativa clinical 
response (HiSCR) relative to baseline during the treatment period. Fisher’s exact test was performed at 
week 4 (p = 0.033) and at week 16 (p = 0.055). † Last observation carried forward for 1 HiSCR non-
achiever as a result of dropping out. ‡ Last observation carried forward for 1 HiSCR achiever as a result 
of dropping out.
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not further improve as compared with those at week 4 except for itch. In the placebo 
group all outcomes except the NRS for disease burden deteriorated at the end of 


























Figure 4. Mean estimated abscess and inflammatory nodule (AN) count from baseline until week 16 
according to linear mixed effects modelling (analysis of covariance). Mean estimated difference for 
apremilast vs placebo: −2.6; 95% confidence interval, −6.0 to −0.9; p = 0.011. Bars display standard 



























Figure 5. Mean estimated level of pain from baseline until week 16 according to linear mixed effects 
modelling (analysis of covariance). Mean estimated difference for apremilast vs placebo: −2.7; 95% 





In total, 38 AEs were reported in the apremilast group versus 11 AEs in the placebo 
group (p = 0.514). An overview of the AEs is shown in Table 3. Most of the AEs 
were mild-to-moderate, and none was classified as a serious AE. One patient in the 
apremilast group discontinued study participation because of unbearable muscle 
and joint pain that occurred a few days after the first dose of study medication. A 
poststudy exploratory genetic analysis of cytochrome P450 family 3 subfamily A 
member 4 gene (CYP3A4) and cytochrome P450 family 1 subfamily A member 2 
(CYP1A2) polymorphisms, which are important for the metabolism of apremilast, 
showed normal expression in this patient, implying that differential metabolism could 
not explain the AE. In all, 6 patients in the apremilast group versus 2 patients in 
the placebo group had ongoing AEs at the end of the study. The ongoing AEs in 
the patients receiving apremilast after 16 weeks were diarrhoea (n = 2), headache, 
nonspecific rash, increased fatigue, and a depressed feeling. At telephone follow-up 
8 weeks after the end of study, these events were resolved without sequelae. There 
were no clinically significant changes in laboratory parameters.
Table 2. Mean estimated change from baseline for treatment outcomes at week 4 and week 16.
Characteristic Apremilast* (n = 15) Placebo* (n = 5)
Week 4
Total lesion count† −2.8 (−4.6 to −1.1) −0.4 (−3.5 to 2.6)
AN count‡ −2.7 (−4.3 to −1.1) +0.6 (−2.2 to 3.4)
DLQI (0-30) −3.8 (−7.2 to −0.4) +0.8 (−5.1 to 6.7)
NRS for pain (0-10) −2.1 (−3.5 to −0.8) +1.6 (−0.7 to 3.9)
NRS for itch (0-10) −0.7 (−2.0 to 0.6) +2.0 (−0.3 to 4.3)
NRS for disease burden (0-10) −1.8 (−3.0, −0.6) +1.1 (−1.0 to 3.2)
Week 16
Total lesion count† −2.0 (−3.9 to −0.2) +1.4 (−1.7 to 4.4)
AN count‡ −2.2 (−3.9 to −0.5) +2.0 (−0.8 to 4.8)
DLQI (0-30) −2.3 (−5.9 to 1.3) +4.2 (−1.7 to 10.1)
NRS for pain (0-10) −0.8 (−2.2 to 0.6) +2.2 (−0.1 to 4.5)
NRS for itch (0-10) −1.1 (−2.5 to 0.3) +2.4 (0.1 to 4.7)
NRS for disease burden (0-10) −1.0 (−2.3 to 0.3) +0.9 (−1.2 to 3.0)
* Mean estimated change from baseline at week 4 and week 16 for with corresponding 95% confidence 
intervals for outcome values according to linear mixed effects modelling (analysis of covariance). † Total 
number of abscesses, draining sinuses/tunnels, and inflammatory nodules. ‡ Total number of abscesses 
and inflammatory nodules. DLQI: Dermatology Life Quality Index. NRS: numeric rating scale.
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DISCUSSION
The main finding from this study was a clinically meaningful improvement of moder-
ate HS after treatment with apremilast at a dose of 30 mg twice per day for 16 weeks. 
Apremilast significantly decreased disease activity as measured by the AN count, 
and 53.3% of patients receiving apremilast achieved the HiSCR in comparison with 
none of the patients receiving placebo. In addition, apremilast for 16 weeks was well 
tolerated by patients with moderate HS. 
The response to treatment in this study was evaluated primarily by the HiSCR.15 This 
validated efficacy end point has previously been used in 4 randomised controlled 
trials in HS.5,16,21 The proportion of HiSCR responders in our study is within the range 
of HiSCR achievers in these previous studies: consecutively, 54.5% (adalimumab 
every week during 16 weeks of treatment [N = 147, of whom 43 received placebo]), 
Table 3. Adverse events.
Characteristic
Apremilast (n = 15)
n (%) E*
Placebo (n = 5)
n (%) E*
Headache 7 (47) 8 1 (20) 2
Diarrhoea 7 (47) 7 1 (20) 1
Nausea 4 (36) 4 1 (20) 1
Common cold 4 (36) 4 1 (20) 1
Vomiting 2 (13) 2 0 (0) 0
Nonspecific rash 2 (13) 2 0 (0) 0
Excessive joint and muscle pain 1 (7) 1^ 0 (0) 0
Back pain 1 (7) 1 0 (0) 0
Increased fatigue 1 (7) 1 0 (0) 0
Depressed feeling 1 (7) 1 0 (0) 0
Pyelonephritis 1 (7) 1 0 (0) 0
Mycosis of the vulva 1 (7) 1 0 (0) 0
Increased itch 1 (7) 1 0 (0) 0
Sore throat 1 (7) 1 0 (0) 0
Elevation in serum ALT level† 1 (7) 1 0 (0) 0
Decrease in serum haemoglobin level‡ 1 (7) 1 1 (20) 1
Nonspecific gastrointestinal symptoms 1 (7) 1 1 (20) 1
Dry mouth 0 (0) 0 1 (20) 1
Hair loss 0 (0) 0 1 (20) 1
Self-reported fever of unknown origin 0 (0) 0 1 (20) 1
Flare of herpes labialis 0 (0) 0 1 (20) 1
* Number of patients with at least one adverse event (n), percentage of patients with at least one adverse 
event  (%), and number of adverse events (E).  ALT: Alanine Transaminase. † Self-limiting elevation of 2-3 
times the upper limit. ‡ Below lower limit according to local laboratory threshold. ̂  Reason for dropout.
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41.8% ([PIONEER I] adalimumab every week during 12 weeks of treatment (N = 
307, of whom 154 received placebo]), 58.9% ([PIONEER II] adalimumab every week 
during 12 of weeks treatment [N = 326, of whom 163 received placebo]), and 60.0% 
(the monoclonal antibody MABp1 during 12 weeks of treatment [N = 20, of whom 
10 received placebo]). Of note, in these trials patients with moderate-to-severe HS 
were enrolled and 3 of 4 studies were larger. Although a 1-to-1 comparison is inap-
propriate, the aforementioned results demonstrate that our findings are in line with 
the currently reported response rates.
Interestingly, the time to clinical response was much faster than that with apremilast 
in psoriasis, in which case an increasing proportion of patients achieving a 75% 
improvement in baseline Psoriasis Area Severity Index score has been observed up 
to 52 weeks after start of treatment.22 This might potentially be explained by differ-
ences in underlying pharmacodynamic patterns, as HS auto-inflammatory pathology 
is initiated by an aberrant innate immune response followed by participation of the 
adaptive immune system that involves a broader array of cell types than in psoriasis 
pathophysiology.
Patients’ assessment of HS-related pain and itch fluctuated during treatment, pos-
sibly reflecting the natural course of the disease, as the AN count does not take into 
account the size or severity of individual lesions. The DLQI score improved in the 
apremilast-treated patients but exhibited even larger variability during the study. An 
explanation might be the small number of patients studied and the fact that quality 
of life could have been affected by other (personal) circumstances in addition to the 
HS disease activity.
Treatment with apremilast at a dose of 30 mg twice daily was generally well tol-
erated, with the majority of the AEs rated mild-to-moderate. The safety profile of 
apremilast observed in this study is consistent with previous findings from larger 
trials in patients with psoriasis and psoriatic arthritis.23,24 However, the number of 
patients included in our study was small, and the current safety results may not be 
representative for a larger population.
The evidence-based literature available on nonbiologic therapies in HS is limited 
and largely restricted to retrospective studies or expert opinion.4 Therefore, recom-
mendations for optimal medical management of HS are challenging. Although the 
efficacy of apremilast in HS must still be confirmed in larger studies, we believe 
that apremilast could be considered as a new treatment option for moderate HS 
after failure of conventional treatments, such as the combination of clindamycin and 
rifampicin. Currently, adalimumab is the first-choice agent in moderate-to-severe 
HS after failure of conventional treatments.5 However, there may be advantages of 
apremilast over oral antibiotics and biologic therapies. It is well established that 
continuous antibiotic treatment can induce bacterial resistance, limiting its use for 
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chronic purposes, whereas subcutaneous administration and relatively frequent labo-
ratory monitoring can pose an additional burden for patients who are treated with 
adalimumab. Another problem with the use of tumour necrosis factor-α antagonists 
such as adalimumab and infliximab is the risk of formation of antidrug antibodies, 
with neutralisation of the therapeutic effect over time.25
The major strength of this study is its randomised, double-blind, placebo-controlled 
design. In addition, the risk of inter-rater variability for the physician-reported out-
comes was minimised by using only 2 clinical assessors. Limitations of our study are 
the small number of included patients, the study’s relatively short duration, and the 
lack of data beyond the end of treatment. Missing HiSCR data were handled by using 
last observation carried forward in 2 patients taking apremilast, which potentially 
increased the effect of attrition bias. Furthermore, the AEs headache, diarrhoea, nau-
sea, and vomiting were common in the apremilast group, which could have partially 
unblinded the observers.
In conclusion, the results from this study indicate that oral apremilast is a promising 
treatment option with good short-term safety and tolerability and that it could be a 
valuable addition to the armamentarium for the treatment of HS. Studies with larger 
populations and longer follow-up are needed to further elucidate the efficacy and 
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Treatment with apremilast has demonstrated clinically meaningful improvement in 
moderate hidradenitis suppurativa (HS).
Objective
To evaluate the change in expression of inflammatory markers in lesional skin of HS 
patients receiving apremilast 30 mg twice daily (n = 15) for 16 weeks compared with 
placebo (n = 5).
Methods
At baseline 5-mm punch biopsies were obtained from an index lesion (HSL) and 
non-lesional skin (HSN) as control in the same anatomical area. Subsequent HSL 
samples were taken as close as possible to the previously biopsied site at week 4 
and week 16. After sampling, biopsies were split; one half was processed for in vivo 
mRNA analysis using real-time quantitative PCR; the other half was cultured for ex 
vivo protein analysis using a proximity extension assay (Olink). Linear mixed effects 
models were calculated to compare the levels of inflammatory markers in HSL skin 
between apremilast and placebo over time.
Results
At baseline, 17 proteins with a fold change >2 in HSL versus HSN skin were identified 
in 20 patients. The top 5 were IL-17A (5), S100A12, CST5, IL-12/23p40, and CD6 (1) 
with respective fold changes ranging from 6.6 to 1638 (FDR < 0.044). Linear mixed 
effects models for 75 assays were calculated. Protein levels of S100A12 decreased 
during treatment in the apremilast group compared with the placebo group (p = 
0.014, FDR = 0.186). None of the 14 genes exhibited significant changes in expres-
sion over time. However, an evident downward trend in relative mRNA expression of 
IL-17A and IL-17F was demonstrated in patients receiving apremilast.
Conclusion
We did not detect statistically significant changes in inflammatory markers in 
lesional skin of HS patients receiving apremilast compared with placebo, despite 
clinical improvement in the apremilast group. Nonetheless, S100A12 and IL-17A 
were significantly elevated in HS lesional skin and showed a decrease in response 
to apremilast. The translational model in clinical trials involving HS clearly needs 
further improvement.
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INTRODUCTION
Hidradenitis suppurativa (HS) is a chronic, recurrent, auto-inflammatory skin disorder 
with limited effective treatment options.1 Recently, treatment with apremilast for 16 
weeks has demonstrated clinically meaningful improvement in moderate HS. In this 
study (NCT03238469; EudraCT 2016-000859-27) twenty patients with moderate 
HS (HS-PGA score of 3) were randomised in a 3 : 1 ratio to receive blinded treat-
ment of apremilast 30 mg twice daily or placebo, respectively. Demographic and 
disease characteristics were similar between treatment arms. The mean age of the 
study population was 35 years (range 21-64), most patients were female (17/20) and 
current smokers (16/20), the mean (± SD) BMI was 32.7 ± 6.2, and the mean abscess 
and inflammatory nodule (AN) count was 6.0 ± 1.8. The objective of this translational 
study was to evaluate the change in expression of inflammatory markers in lesional 




This investigator-initiated trial was approved by the medical ethics committee of the 
Erasmus University Medical Center Rotterdam, The Netherlands (NL.57003.078.16). 
All patients provided written informed consent for study participation and use of their 
skin biopsies.
Biopsy procedure
At baseline, two 5-mm punch biopsies were taken: one was obtained from an ery-
thematous, indurated, inflamed lesion, i.e. the index lesion (HSL), and one from the 
normal-appearing, unaffected non-lesional skin (HSN) in the same anatomical area 
(Figure 1). Subsequent HSL skin samples were taken as close as possible to the previ-
ously biopsied index site at week 4 (early response) and week 16 (end of study). After 
sampling, biopsies were split whereby one half was processed for mRNA analysis of 
the biopsy, representing the in vivo gene expression, and the other half was cultured 
for ex vivo protein analysis. The supernatants and the biopsies in 250 µL lysis buf-
fer containing 1% ß-mercaptoethanol were transferred to a polypropylene tube and 
stored at −20°C until further analysis.
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Ex vivo skin culture and protein quantification
After sampling, half of the 5-mm biopsy was cultured for 24h at 37°C in an atmosphere 
of 5% CO2 and 98% humidity in a transwell system (Netwell; Costar, Cambridge, 
MA) as previously described.2,3 In short, samples were placed in a 12-well plate with 
the epidermis exposed to the air and the dermis immersed in 1 mL Iscove’s modi-
fied Dulbecco’s medium (Gibco, Paisley, U.K.) containing 0.5% human AB serum, 
penicillin (100 U/mL) and streptomycin (100 U/mL). A broad spectrum of 92 inflam-
matory markers was measured in the supernatant using the Olink Proseek Multiplex 
Inflammation panel (Olink Proteomics, Uppsala, Sweden).
In vivo gene expression
Total RNA was isolated using the GenElute Mammalian Total RNA Miniprep Kit 
(Sigma-Aldrich, St. Louis, MA), treated with 0.1U/μL DNAse (Invitrogen), and cDNA 
was synthesised with SuperScript II reverse transcriptase, random hexamer primers 
(Invitrogen) and oligo(dT)15 (Promega). Primers and probes were designed and cho-
sen using ProbeFinder Software and the Universal Probe Library (Roche Applied Sci-
ence, Indianapolis, IN). ABL1 was used as housekeeping gene. Real-time quantitative 
PCR for 14 genes (IFN-γ, TNF-α, IL-1ß, IL-6, IL-8, IL-10, IL-23p19, IL-12/23p40, IL-17A, 
IL-17F, IL-31, CXCL-10, CCL-5, and MPO) was performed with the ViiA7 System and 
using the QuantStudio Real-Time PCR Software version 1.3 (Applied Biosystems, 
Waltham, MA).
(a) (b) (c)
Figure 1. Biopsy procedure in a patient with a good clinical response to apremilast. Note that all deep-
seated lesions have resolved. Erythematous lesions seen at week 16 are scars and superficial folliculitis.
(a) Baseline. A 5-mm punch biopsy was obtained from an erythematous, indurated, inflamed lesion 
(arrow pointing to index lesion). An additional 5-mm punch biopsy of the non-lesional skin was taken 
from the same anatomical area to serve as control (circle within the square). (b) Week 4 and (c) Week 
16. Subsequent skin samples were taken as close as possible to the previously biopsied index site (small 
circles within dashed line).
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Statistical analysis
Protein data are presented as normalised protein expression (NPX), which are log2-
transformed arbitrary units. Relative mRNA expression levels for week 4 and week 
16 were calculated using the 2-ΔΔCT method using a baseline value of 1 for each 
individual sample.4 First, differentially expressed proteins at baseline were explored 
by calculating a fold change with the median NPX of HSL skin divided by the median 
NPX of HSN skin. If the fold change was more than 2, a Wilcoxon signed rank test 
was subsequently used to pairwise compare protein levels between HSL and HSN 
skin. Second, linear mixed effects models and associated ANOVA for repeated mea-
sures were calculated to compare inflammatory protein and mRNA expression levels 
between apremilast and placebo over time. Fixed effects were treatment, time and 
treatment*time. Third, the Spearman’s rho was used to assess translational linkage, 
i.e. correlation between the levels of inflammation and the AN count. A two-sided 
p-value below 0.05 was considered significant. P-values were adjusted for multiple 
testing within each test using the Benjamini-Hochberg approach. Statistical analyses 
were conducted in R Statistical Software version 3.5 (R Foundation for Statistical 
Computing, Vienna, Austria) using the lmerTest package.
RESULTS
At baseline, 17 proteins with a fold change >2 were identified (Table 1). The top-5 
were IL-17A (5), S100A12, CST5, IL-12p40, and CD6 (1) with respective fold changes 
ranging from 6.6 to 1638 (FDR < 0.044). Out of 92 Olink assays, 75 were included in 
the linear mixed effects models. The removed assays had less than 25% detectability 
for among others TNF-α and IFN-γ. Only the protein levels of S100A12 decreased 
over time in the apremilast versus placebo group. However, this was not statistically 
significant after correction for multiple testing (p = 0.014, FDR = 0.186; Figure 2).
None of the 14 genes analysed by linear mixed effects models yielded significant 
differences. Only the relative mRNA expression of IL-17A and IL-17F demonstrated 
an evident but nonsignificant downward trend in patients receiving apremilast versus 
placebo (p > 0.05; Figure 3). In addition, there was no correlation between S100A12 
protein levels or IL-17A/F mRNA expression and the favourable clinical response in 
the apremilast group as measured by the AN count (data not shown).
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median IQR median IQR FDR %
1 CD6 1638 3.5 2.0 - 4.1 0.002 0.0 - 0.2 3.4 e-07 0.018 None
2 IL-12p40 38 0.9 0.5 - 1.8 0.024 0.0 - 0.1 7.2 e-06 0.038 7.5
3 CST5 23 0.9 0.6 - 1.1 0.041 0.0 - 0.1 6.1 e-07 0.024 1.1
4 S100A12 11 4.5 3.1 - 6.3 0.4 0.4 - 0.8 2.7 e-05 0.041 20.0
5 IL-17A 6.6 3.1 1.8 - 3.8 0.5 0.5 - 0.6 2.9 e-05 0.044 26.3
6 TNFSF14 4.5 3.4 2.5 - 4.1 0.8 0.4 - 1.0 1.0 e-06 0.029 6.3
7 AXIN1 4.4 1.9 1.7 - 2.1 0.4 0.4 - 0.5 8.8 e-07 0.026 8.8
8 β-NGF 3.2 1.1 0.6 - 1.4 0.3 0.3 - 0.6 5.8 e-04 0.047 15.0
9 TNFSF11 3.1 2.2 1.2 - 3.3 0.7 0.7 - 0.7 4.6 e-07 0.021 28.8
10 CD244 3.0 2.7 2.3 - 3.1 0.9 0.9 - 0.9 1.1 e-07 0.012 23.8
11 CD5 3.0 7.3 5.9 - 7.6 2.5 2.2 - 2.6 1.3 e-08 0.003 None
12 TNFRSF9 2.9 6.4 5.2 - 7.6 2.2 1.8 - 2.7 1.3 e-08 0.006 1.3
13 OSM 2.9 6.4 6.0 - 7.8 2.2 1.3 - 3.4 4.0 e-06 0.035 3.8
14 SIRT2 2.8 5.0 4.5 - 5.4 1.8 1.5 - 1.9 1.9 e-07 0.015 5.0
15 GDNF 2.7 2.9 2.0 - 3.8 1.1 0.8 - 1.2 1.6 e-06 0.032 5.0
16 IL-18R1 2.3 4.2 3.6 - 5.2 1.8 1.7 - 2.0 1.3 e-08 0.009 None
17 ST1A1 2.1 1.5 0.8 - 1.8 0.7 0.5 - 1.2 1.3 e-02 0.050 10.0
Missing data: samples with NPX-values below background level throughout all samples, i.e. HSN and 
HSL baseline, HSL week 4 and HSL week 16. Unadj. p-value: unadjusted p-value by Wilcoxon signed 
rank, NPX HSL vs. NPX HSN.  Adj. p-value (FDR): adjusted p-value Benjamini Hochberg test, NPX HSL 
vs. NPX HSN. FDR: false discovery rate. HSL: HS lesional. HSN: HS nonlesional. IQR: interquartile 
range. NPX: normalised protein expression, a high NPX value corresponds with a high protein con-
centration.
Figure 2. Protein levels of S100A12 in patients receiving apremilast (n = 15) and placebo (n = 5), linear 
mixed effect model: p = 0.014, FDR = 0.186. Relative expression: expression on t = 4 and t = 16 relative 
to baseline using the 2−ΔΔCT method with a baseline value of 1 for each individual sample. Data at week 
16 for two patients receiving apremilast are missing as these two patients discontinued after respectively 
week 4 and week 8. NPX, Normalized Protein eXpression; t, week.
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DISCUSSION
This translational study aimed to identify inflammatory skin markers in response to 
apremilast 30 mg twice  daily for 16 weeks in patients with moderate HS, which 
showed positive clinical results in a previously published study. Only S100A12 pro-
tein levels and IL-17A and IL-17F mRNA expression showed a clear but nonsignificant 
decrease in patients receiving apremilast compared with placebo.
S100A12 (calgranulin C, EN-RAGE) is a pro-inflammatory, calcium-binding antimi-
crobial protein that interacts with the receptor for advanced glycation end products 
(RAGE) and is overexpressed in various inflammatory skin diseases, e.g. psoriasis.5,6 
Previously, S100A8 and S100A9 (calprotectin or calgranulin A/B) have been dem-
onstrated to be elevated in the serum and lesional skin of HS patients.7,8 It is known 
(a)
(b)
Figure 3. Relative mRNA expression levels of IL-17A and IL-17F in patients receiving apremilast (n = 
15) and placebo (n = 5), linear mixed effect model: p > 0.05. (a) IL-17A. At t = 16 in the apremilast 
group: one data point is out of the y-axis range. (b) IL-17F. At both t = 4 and t = 16 in the apremilast 
group one data point is out of the y-axis range. Data at week 16 for two patients receiving apremilast 




that IL-17 is a potent inducer of S100A8 and S100A9 in keratinocytes.9,10 The other 
way around, S100A12 stimulates T cells to produce IL-17A.11 Thus, elevated levels 
of IL-17A and S100A12 in HSL skin at baseline and the responsiveness of these in-
flammatory markers to apremilast treatment is not surprising. Moreover, apremilast’s 
impact on the Th17 pathway was recently demonstrated by the significant reduction 
of IL-17A and IL-17F protein levels in the plasma of psoriasis patients.12
The nonsignificant findings using a broad panel of inflammatory markers may be 
explained by the regression to the mean phenomenon, particularly at the individual 
level.13 The highly inflammatory index lesions could have spontaneously improved 
over time in the context of the fluctuating nature of the disease, especially in the 
placebo group. The effect of regression to the mean increases with larger measure-
ment variability.13 Expanding the number of biopsies from index lesions, representing 
several degrees of inflammation, would theoretically be a solution. However, taking 
more biopsies in the same patients would not be feasible for ethical reasons.
Another explanation for the decreased levels of inflammation over time in both 
groups could be that the inflammatory infiltrate of the index lesion was gradually re-
duced by successively taking biopsies from the same nodule. Moreover, the  substrate 
for the foreign body inflammation such as hair fragments and keratin fibres, may have 
also been (partially) removed by the biopsy procedure.14 Furthermore, this exploratory 
study might be underpowered which may also have resulted in nonsignificant results.
Previously, two prospective uncontrolled studies investigating infliximab and 
ustekinumab in HS were also unable to link translational data to the clinical re-
sponse.15,16 However, in these studies only inflammatory markers in serum were 
investigated. Strengths of our study include the placebo-controlled trial design, the 
use of skin (target organ) instead of serum or plasma, and the standardised biopsy 
procedure of an index lesion. A limitation is the small study population.
In conclusion, this translational study investigating apremilast in moderate HS did 
not detect statistically significant changes in important inflammatory markers in le-
sional skin compared to placebo over 16 weeks of treatment, despite positive clinical 
findings. Nonetheless, related S100A12 and IL-17A were significantly elevated in 
HSL skin and showed a decline only in the apremilast group. In addition, our findings 
highlight the challenge of assessing pharmacodynamics in the skin in a highly fluc-
tuating inflammatory disease. A better translational model in clinical trials involving 
HS has yet to be developed.
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To the Editor:
Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disorder of 
the hair follicle and is characterised by painful, deep-seated inflammatory nodules 
and abscesses.1 The disease is difficult to treat, and current medical therapies focus 
on reducing inflammation rather than preventing flare-ups or sustaining remission.2 
In HS, occlusion of the hair follicle, caused by infundibular keratosis and hyperplasia 
of the infundibular epithelium, is considered to be the primary event.3,4 We hypoth-
esised that targeting the hair follicle with laser hair removal would ameliorate the 
disease. The aim of this case series was to evaluate the effect of hair removal using 
a long-pulsed 1064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser 
on the course of the disease in patients with mild HS.
The laser treatments were performed between July 2011 and December 2016 in 
the Dermatology department of the Erasmus University Medical Center (Rotterdam, 
The Netherlands). A questionnaire was sent to assess patient-reported outcomes. The 
primary outcome was the number of HS flares per month, and secondary outcomes 
were disease severity on a numeric rating scale (NRS) ranging from 0 (no suffer-
ing) to 10 (extreme/unbearable suffering), overall treatment satisfaction (NRS: 0 very 
dissatisfied; 10 very satisfied), and decrease of hair growth in the treated area (quar-
tile grading scale). Descriptive statistics were used to report the outcomes with the 
mean (± SD) or number (%). For comparison of the number of monthly flares and the 
disease severity before and after treatment, the Fisher’s exact test and the Wilcoxon 
signed rank test were used, respectively. A two-sided p-value of 0.05 was considered 
significant. Statistical analysis was performed using IBM SPSS Statistics Version 21.0 
(Armonk, NY: IBM Corp).
Twenty-seven HS patients with the follicular sub-phenotype and mild disease (HS 
Physician Global Assessment score of 2, Hurley stage I-A) who had undergone hair 
removal using the Nd:YAG laser were identified from our records. Two patients were 
excluded as they had received suboptimal therapy of less than three treatments. The 
questionnaire was sent to the remaining 25 patients: two patients refused participa-
tion and eight patients did not respond to the invitation, resulting in 15 completed 
questionnaires. Ten men and five women, aged 34.1 ± 10.1 years with a body mass 
index of 25.1 ± 3.7 were included in the analysis. Twelve patients (80%) were current 
or ex-smokers, and eleven patients (73%) had skin types of II–III on the Fitzpatrick 
scale. Patients were most often treated in the inguinal/genital area and received ap-
proximately ten treatments on average. The laser settings that were used are shown 
in Table  1. Three patients received stable systemic co-medication for HS prior to (≥ 
28 days) and during the course of the laser hair removal (clindamycin 300 mg twice 
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daily and rifampicin 600 mg once daily, minocycline 100 mg once daily, and acitretin 
25 mg once daily). None of these treatments statistically affected the study outcomes.
Nd:YAG depilation resulted in a decrease in the number of monthly flares (p = 
0.019) (Table 2). In addition, the mean HS disease severity after depilation was 
significantly lower than before therapy, NRS 6.4 ± 2.8 versus NRS 3.6 ± 3.5 (p = 
0.010) respectively. The majority of patients reported a 51-75% decrease of hair 
growth after treatment. Overall treatment satisfaction was rated with a NRS score 
of 6.7 ± 2.4, and two-thirds of the patients would recommend laser-assisted hair 
removal to other HS patients.
Three studies have previously demonstrated improvement of HS after 1064 nm 
Nd:YAG treatment. These studies focused mainly on targeting the inflammatory 
lesions (inflammatory nodules, abscesses, and sinuses).5-7 Treatment involved two 
to three pulses on the lesions, and the anatomic area also a single pass. We used 
a different approach by destroying the hair follicles with the intention of altering 
the course of the disease. Because of this difference in approach, our HS patients 
were less severely affected than those in previous studies (Hurley II and III disease). 
Moreover, in the previous studies patients received fewer treatments (maximum four 
sessions), and the follow-up period was relatively short (maximum two months).5-7 
One study investigated the efficacy of intense pulsed light (IPL) in Hurley stage II and 
III HS patients; this showed significant improvement in the modified Sartorius score 
after a follow-up at twelve months.8
Table 1. Characteristics of treatment by laser hair removal.
Type of laser 1064 nm Nd:YAG^
Range of settings Nd:YAG 30-60 J/cm2




     Axillary 5
     Inguinal/genital 10
     Gluteal/perianal 6
     Other* 3
Mean number of treatments ± SD 9.8 ± 9.4
Mean interval ± SD, weeks 5.6 ± 0.1
Mean follow-up ± SD, months 14.9 ± 14.1
^ One patient received 8 treatments with Nd:YAG followed by 11 treatments with Intense Pulsed Light 
(IPL). † Twelve patients received 2 passes, one patient received mostly 2 passes, and two patients re-
ceived 1 pass.  * Neck, thorax, thigh. SD: standard deviation.
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A major strength of our study is that we focused, to the best of our knowledge, for 
the first time on disease prevention and used the number of flares as an outcome 
measure. Another strength is the relatively long follow-up period of more than one 
year. However, this survey-based case series is likely to be underpowered, and the 
findings we obtained could be biased due to natural fluctuation of the disease course. 
Other limitations are a possible recall bias and the absence of physician-reported 
outcomes such as counts of abscesses and nodules.
In conclusion, our results suggest that laser hair removal could be a novel therapeu-
tic approach to prevent disease progression or ameliorate the disease, especially in HS 
patients with the follicular sub-phenotype. We believe that prospective randomised 
controlled trials are warranted to confirm the mechanism of action and long-term 
efficacy of laser hair removal in mild HS.
Table 2. Patient-reported outcomes on the area(s) treated by Nd:YAG (N = 15).
Before treatment* After treatment p-value
Flares per month, n 0.019 ^
    <1 4 8
     1 2 0
     2 1 3
     3 3 3
     >3 / continuous inflammation 5 1
Mean NRS for HS disease severity ± SD, (0-10) 6.4 ± 2.8 3.6 ± 3.5 0.010 †
Decrease of hair growth after Nd:YAG
     0-25% 1 (7%)
     26-50% 5 (33%)
     51-75% 7 (47%)
     75-100% 2 (13%)
Mean NRS for pain due to Nd:YAG ± SD, (0-10)  5.4 ± 2.6
Mean NRS for overall treatment satisfaction ± SD, (0-10) 6.7 ± 2.4 
Recommendation of laser depilation to other HS patients, 
n (%)
     yes 10 (67%)
     doubt 4 (26%)
     no 1 (7%)
NRS: numeric rating scale (0-10). HS: hidradenitis suppurativa. SD: standard deviation * Average num-
ber of flares before treatment based on period 6 months prior to treatment. ^ Fisher’s exact test. † Wil-
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Microwave ablation in mild hidradenitis suppurativa
To the Editor:
Hidradenitis suppurativa (HS) is a common chronic, recurrent, autoinflammatory skin 
disease of the hair follicle with limited treatment options.1 No definitive treatment 
exists for this debilitating entity. MiraDry (Miramar Labs Incorporated, Santa Clara, 
CA) is a microwave device targeting the eccrine and apocrine sweat glands as well as 
hair follicles through thermolysis in the dermal-hypodermal junction.2,3 We hypoth-
esised that this noninvasive ablative technique could potentially improve the clinical 
symptoms of HS by reducing the number of hair follicles (primary action) and the 
destruction of the inflammatory cell infiltrate (secondary action) in HS lesions. We, 
therefore, evaluated the efficacy and safety of miraDry treatment for mild axillary HS 
in a randomised intrapatient-controlled trial. Ethical approval was given by the IRB of 
the Erasmus University Medical Center (MEC-2017-390).
We aimed to include 20 HS patients for random allocation to a single miraDry 
treatment (5.8 GHz, energy level 5, manufacturer-recommended settings) of 1 axilla 
under tumescent anaesthesia. Patients were required to have a total of 3-5 abscesses or 
nodules per axilla with ≤1 abscess or draining sinus. Additional inclusion and exclu-
sion criteria are available at https://www.clinicaltrials.gov (identifier NCT03238469). 
The primary outcome was a left-right comparison of the axillary areas using the 
Hidradenitis Suppurativa Clinical Response (HiSCR). Secondary outcomes included 
a numeric rating scale on pain per axilla, treatment satisfaction, and a hair follicle 
count. Two independent blinded observers performed lesion counts at baseline and 
3 months after the procedure.
Only 9 of 20 HS patients were tested; negative clinical outcomes during the re-
cruitment period made it pertinent for us to do an interim analysis, resulting in the 
decision to discontinue the study. One of the randomised patients did not tolerate the 
miraDry treatment due to extreme pain during the procedure, despite the use of sev-
eral local anaesthetics. Of the 8 patients who concluded the miraDry treatment (all 
women, median age 31.5, interquartile range [IQR] 28.0-39.0 years), 7 completed 
the 3-month follow-up; 1 patient dropped out because of worsening of HS symptoms 
in the axilla treated by miraDry. Two patients achieved the HiSCR in the miraDry-
treated axilla, and 2 patients achieved the HiSCR in the comparator axilla (p = 1.00) 
(Table 1). In total, 5 of 8 patients showed worsening of their disease after miraDry 
treatment, with an increase in the abscess and nodule and sinus count (Figure 1). 
Patients suffered from active lesions for a median (IQR) of 43.0 (4.0-90.0) days in 
the miraDry-treated axilla versus a median of 5.5 (2.0-26.0) days in the contralateral 
axilla (p = 0.14). After 3 months, the median numeric rating scale score for pain in 
the miraDry-treated axilla was 7.0 (2.0-8.0) versus 0 (0-5.0) for the untreated axilla 
Chapter 6.2
114
(p = 0.07). One patient developed cellulitis of the upper arm after miraDry treatment, 
requiring antibiotic treatment, which was classified as a severe adverse event.
We observed that the number of hair follicles after 3 months was numerically lower 
in the miraDry-treated axilla, median 4.0 (3.0-5.0)/cm2, a 50.9% decrease from base-
line, compared with the untreated counterpart, median 8.5 (6.0-10.0)/cm2, a 2.0% 
decline from baseline (p = 0.07). Because the miraDry device targets the dermal zone 
rather than a particular structure, its nonselectivity might have resulted in the poor 
study outcomes. Accordingly, we argue that the microwave energy is able to rupture 
pre-existing and subclinical or microscopic HS precursor lesions (cysts), subsequently 
resulting in an intense inflammatory response beyond the initially visible lesions.
Although the intervention was completed in only 8 patients, our findings indicate 
that microwave ablation using the miraDry device has no apparent clinical benefit 
and could even be harmful in patients with mild HS. Commercial miraDry clinics 
in the Netherlands also observed a few cases of flaring of the disease in HS patients 
(personal communication: Dr A. Roopram and Dr W. Venema - May 2018). Taken 
together, we question the utility of microwave ablative therapy in patients with HS in 
clinical practice.
(a) (b)
Figure 1. Baseline condition (a) and 3-month response (b) to miraDry treatment in the left axilla of 
patient 5 with hidradenitis suppurativa.
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General discussion
CONCLUSIONS AND GENERAL DISCUSSION
Hidradenitis suppurativa (HS) is a chronic, recurrent skin disease harbouring a com-
plex pathogenesis that is not yet fully understood. By identifying the latest publica-
tions on the pathophysiology of HS, our systematic review has collated substantial 
evidence that HS is an immune-mediated inflammatory disease (IMID) with both 
endogenous and exogenous factors contributing to the onset and progression of the 
disease.
Firstly, genetic factors play a key role in causing HS. Mutations in a range of genes, 
including NCSTN mutations in the γ-secretase complex and PSTPIP1 mutations, are 
directly associated with auto-inflammatory disease.1-4 However, the majority of HS 
cases appear to be non-familial, suggesting the existence of separate subsets and the 
need for stratification within patients diagnosed with HS.5 Secondly, the simultane-
ous activation of multiple inflammatory pathways (inflammasome, Th1/Th17, toll-like 
receptor signalling) result in the upregulation of cytokines and chemokines, includ-
ing TNF-α and a range of interleukins, which are connected to auto-inflammatory 
mechanisms in the pathogenesis of HS.6-8 Thirdly, there is an alteration in the local 
microbiome of normal-appearing versus lesional skin.9-12 Data also suggest that 
bacterial aggregates are associated with inflammation of chronic HS lesions, and it is 
proposed that they most likely occur as a secondary event, possibly due to predispos-
ing local anatomical changes such as sinus tracts (tunnels), keratinous detritus and 
dilated hair follicles.9 Finally, enhancement of HS risk and severity occurs via a range 
of physiological and environmental factors like smoking, obesity and mechanical 
friction.13-16
As there are multiple gaps in HS knowledge, the aim of this thesis was not restricted 
to one single facet of the disease. Instead, we took a broader approach and focused 
on both clinical and translational aspects of HS. Four key themes have emerged from 
this thesis. First, pruritus or itch is a frequent and bothersome symptom in patients 
with HS. We detected several pathophysiological substrates that could explain the 
occurrence of HS-related pruritus. Second, the overexpression of chemokines and 
cytokines in HS lesional skin reflects a chronic, activated local inflammatory milieu, 
indicating the need for effective anti-inflammatory HS therapies. Third, the potency 
and efficacy of novel anti-inflammatory agents for HS were demonstrated in respec-
tively laboratory and clinical trial settings. Fourth, two treatment strategies (primarily) 




Importance of the symptom itch including possible pathophysiological 
substrates
Key symptoms of HS are acute and chronic pain, discomfort, and a purulent, foul-
smelling discharge, which overall contribute to a decreased quality of life.17,18 Previ-
ous clinical studies have mainly focused on these well-known symptoms, while less 
is known about pruritus.17,19,20 Therefore, we determined the prevalence and explored 
the characteristics of pruritus in a cohort of HS patients. In Chapter 2 we found a high 
prevalence rate of 57% in 211 HS patients, who reported a mean (± SD) NRS score 
(range 0-10) of 6.1 ± 2.0 in the past 7 days. The majority (81%) of patients ranked the 
severity of pruritus as moderate-to-severe on a five-point Likert scale. Moreover, sleep 
and ADL were negatively impacted by pruritus in more than half of the patients. The 
mean modified 5-D itch score of 13.7 ± 3.6 in 52 HS patients is comparable with 
the 5-D score in 51 patients with an inflammatory skin condition like burn wounds 
(13.5 ± 3.2).21
The prevalence rate we found in HS was similar in a Spanish cohort of 191 HS 
patients (59%),  and higher than a Polish cohort of 103 HS patients (42%).22,23 How-
ever, Matusiak et al. did not report the VAS/NRS cut-off point for determination of the 
prevalence rate in their HS patients (N = 103).22 In comparison with other dermato-
logic conditions, the rate in our cohort was similar to that in patients with psoriasis 
(49-90%),24,25 although in the past psoriasis was considered a non-pruritic disease. 
The rate of pruritus in HS patients is lower than patients suffering burn injuries (67-
93%)26,27 or chronic idiopathic urticaria (79%).28
In our study, the degree of pruritus was positively correlated with pain intensity, 
number of HS-affected areas, and active smoking. In addition, we found a significant 
correlation between the intensity of pruritus and DLQI scores (N = 422, r = 0.47, 
p = 2.0 e-24, unpublished data) in a subpopulation of the HiScreen Registry, con-
sisting of HS patients from the department of Dermatology in the Erasmus MC and 
DermaHaven. A similar correlation (r = 0.48) was found in the study of Matusiak et al 
(N = 103).22 Furthermore, pruritus scores were responsive to anti-inflammatory treat-
ment, as shown by the significant different trends of NRS scores for patients receiving 
apremilast versus patients receiving placebo (Chapter 5.1).
The occurrence of pruritus from HS lesions could be explained by inflammatory 
cell infiltration, especially the influx of eosinophils and the presence of neurogenic 
inflammation (Chapter 2). Moreover, protein levels of β-nerve growth factor were 
significantly elevated in lesional skin versus non-lesional skin in the same anatomi-
cal area of 20 HS patients (Chapter 5.2). Nerve growth factor is known to increase 
neuropeptide levels. These upregulated neuropeptides, such as substance P and 
calcitonin gene-related peptide, are associated with neurogenic inflammation and 
the hypersensitive perception of pruritus.29,30
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Another explanation for the report of pruritus by HS patients is the presence of 
tryptase-positive mast cells, which were found to be increased in all stages of the dis-
ease including perilesional skin.31 In Chapter 3 we found overexpression of CCL-26 
(eotaxin-3) in the circulation and lesional skin of HS patients. Additionally, increased 
serum levels of IgE have been reported in patients with HS.32 The latter two findings in 
combination with a dense infiltration of mast cells in HS could trigger degranulation 
of these cells, releasing histamine and other mediators, such as proteases, which 
causes pruritus. Levels of IL-2, CCL-11, and CCL-17 (TARC), all inflammatory mark-
ers that are associated with pruritus, were not elevated in HS plasma and lesional 
skin (Chapter 3). However, the cause of pruritus in HS is probably multifactorial. 
Other possible mechanisms leading to itch are a small fibre neuropathy as a result of 
scar formation,33 irritant contact dermatitis due to maceration or purulent discharge 
of HS lesions, and alteration in the signalling of mammalian target of rapamycin 
(mTOR).34,35
Overexpression of chemokines and cytokines reflects chronic 
inflammation
An aberrant immune response, characterised by the overexpression of several mark-
ers of inflammation, is an important element of the HS pathophysiology. Unravelling 
the role of cytokines and chemokines in disease initiation and progression is essential 
for the clinical and therapeutic stratification of HS. In Chapter 3 we showed that the 
in vivo protein levels of IL-12/23p40, IL-16, IL-17A, CXCL-8, CXCL-10, CCL-4, and 
CCL-26 were significantly higher in HS patients compared with healthy controls. 
A limitation was the small sample size, which did not allow for subgroup analysis 
by Hurley stage disease severity. Interestingly, there was no significant correlation 
between protein levels in patient plasma and lesional skin. The question is whether 
pathway and drug target discovery in plasma or serum is useful in HS. In another 
study (Chapter 5.2), ex vivo protein levels of multiple inflammatory markers includ-
ing IL-12/23p40, IL-17A and S100A12 (calgranulin C) were significantly elevated in 
lesional skin versus non-lesional skin in 20 patients suffering moderate HS.
Our results obtained in lesional skin confirm previous findings demonstrating over-
expression of IL-17 pathway-associated cytokines and chemokines such as IL-17A, 
IL-12/23 and CXCL-8 in HS.36-38 In the context of a strong upregulation of S100A12, 
CXCL-8, IL-17A and IL-23, we hypothesise that IL-16, CCL-4 and CXCL-10 may par-
ticipate in the recruitment of leucocyte subsets, especially neutrophils, eosinophils, 
monocytes and dendritic cells, into the inflamed HS skin.39,40 The significance of 
neutrophils in the HS pathogenesis is highlighted by the (very) high levels of CXCL-8 
that can be cleaved by neutrophil elastase to activate Th17 cells to produce bioactive 
IL-17.41 Furthermore, it has been demonstrated that activated neutrophils induce che-
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motaxis of Th17 cells by a reciprocal cross-talk.42 Some previously published results 
that showed upregulation of TNF-α, IL-1ß and IL-10 in (peri)lesional HS skin could 
not be reproduced.38,43 This can be explained by the different methodologies used. In 
our study (Chapter 3), biopsies were homogenised for in situ analysis, while van der 
Zee et al. and Kelly et al. cultured the skin specimens for 24 and 3 hours respectively, 
and measured cytokines in the supernatant.38,43
The evidence presented above supports HS as a chronic inflammatory skin disorder 
associated with alterations in predominantly the innate immune system. An informal 
literature review was additionally conducted to consider our (Chapter 3 and Chapter 
5.2) and previous findings in relation to the immunopathogenesis of other established 
IMIDs such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriasis 
and psoriatic arthritis, pyoderma gangrenosum, and Behçet’s disease. Although these 
IMIDs are characterised by different pathogeneses, they also share common immuno-
logical mechanisms and activated inflammatory pathways (Table 1). The most striking 
similarity among these diseases is that of aberrations in the innate immune response. 
Several cytokines are systemically-raised in many of these IMIDs, particularly those 
implicated in the Th1 and Th17 responses, including TNF-α, IFN-γ, IL-12/23, IL-17, 
IL-1β and other cytokines of the IL-1 family such as IL-36.44-48 Several of the pro-
inflammatory cytokines have also been shown to be upregulated in HS (e.g. IFN-γ6, 
IL-2, TNF-α7,46 and TNF-β6), and are produced by Th1 cells, implicating the Th1 path-
way in the pathogenesis of HS. Understanding the distinct and shared immunologic 
characteristics of IMIDs will aid the development of effective treatments to target the 
pathogenic mechanisms involved and to modify the disease course.
Novel anti-inflammatory treatments in laboratory and clinical settings
Most evidence to guide management decisions for HS is based on small cohort studies, 
case reports, and expert opinion.49 This is illustrated by the low number (only eight) of 
randomised controlled trials that have investigated the efficacy of anti-inflammatory 
agents in HS. First-line treatments encompass oral antibiotics with anti-inflammatory 
properties, mainly tetracyclines and the combination of clindamycin and rifampi-
cin.19 Second-line therapies include anti-TNF-α biologics such as adalimumab, 
which is the only registered drug for moderate-to-severe HS with clinically relevant 
improvements.50 Other biologic therapies such as secukinumab (anti-IL-17A) and 
ustekinumab (anti-IL-12/23p40) have not widely been studied in patients with HS or 
are in the early stages of clinical development.51 Moreover, very little is known about 
small molecule drugs that modulate the production of pro- and anti-inflammatory 
cytokines in HS. Taken together, there is limited high-quality evidence on HS treat-
ment indicating a significant need for novel efficacious anti-inflammatory therapies.
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Table 1. Key cytokines of established immune mediated inflammatory diseases in relation to hidrad-
enitis suppurativa.
Disease Disease overview Key^ cytokine profile References
HS Inflammatory skin disease 




IL-1β, 6, CXCL/IL-8,12, 
17, 23, IFN-γ, TNF-α
Banerjee et al., 2017; Boer, 2017; 
Calderon-Castrat et al., 2016; Di 
Caprio et al., 2017; Hessam et al., 
2015; Jimenez-Gallo et al., 2017; 
Kromann et al., 2014; Marzano et 
al., 2017; Marzano et al., 2013; 
Nomura et al., 2013; Thomi et al., 
2017; Xiao et al., 2016; Zhang et 
al., 2013
CD Imbalance between gut 
microbiome and host 
immune system with genetic 
background
Th1, Th17
IL-1β, 6, 12, 17, 23, 
IFN-γ, TNF-α
Hugot et al., 2001; Ogura et al., 
2001; Park et al., 2017
UC Imbalance between gut 
microbiome and host 
immune system with genetic 
background
Th2, Th17
IL-1β, 6, 12, 13, 17, 23 
TNF-α
Park et al., 2017
AS Imbalance between gut 
microbiome and host 
immune system with genetic 
background
Th17
IL-6, 17, 22, 23, 26, 
IFN-γ, TNF-α
Brown, 2017; Gooren et al., 2000; 
Jethwa and Bowness, 2016; Li and 
Brown, 2017; O’Rielly et al., 2016; 
Sparks and Costenbader, 2014; 
Videm et al., 2014
Psoriasis Inflammatory skin 
disease with genetic and 
immunological background
Th1, Th17
IL-2, 17, 22, 23, 26, 
TNF-α, IFN-γ
El-Boghdady et al., 2017; Ho et al., 
2005; Love et al., 2012; Nguyen 
et al., 2018; Ogawa et al., 2017; 
Strange et al., 2010
PsA Inflammatory arthritis 
associated with psoriasis 





PG Inflammatory, ulcerating, 
neutrophilic skin disease 
with genetic, immunological, 
and environmental 
background
IL-1β, 17, TNF-α Al Ghazal et al., 2012; Marzano 
et al., 2017; Shavit et al., 2017; 




inflammatory, vasculitis with 
genetic, immunological, and 
environmental background
Th1, Th17
IL-6, 11, 17, 21, 22, 
26, TNF-α, Chitinase3-
like1, gp130/sIL -6Rb, 
sTNF-R1, sTNF-R2
Hemminki et al., 2012; Lopalco 
et al., 2017; Scherrer et al., 2017; 
Thomsen and Sorensen, 2010
^ Data summarise key cytokines of these diseases but many other genes, cells types and mediators are 
involved in the pathogenesis. AS: ankylosing spondylitis. CD: Crohn’s disease. HS: hidradenitis suppu-
rativa. PG: pyoderma gangrenosum; PsA, psoriasis and psoriatic arthritis; UC, ulcerative colitis.
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In an ex vivo disease model, we evaluated the anti-inflammatory effects of 
currently available biologics targeting TNF-α, IL-17A, IL-12/23p40, and CD20. 
Adalimumab, infliximab, secukinumab, ustekinumab and rituximab in addition to 
prednisolone significantly inhibited a selection of pro-inflammatory cytokines and 
antimicrobial peptides in HS lesional skin (Chapter 4). Furthermore, adalimumab, 
infliximab and prednisolone reduced the levels of a broader mix of individual cy-
tokines than secukinumab, ustekinumab, and rituximab. These findings correspond 
with the observed efficacy of both TNF-α inhibitors, and systemic and intralesional 
corticosteroids in the treatment of HS patients in daily practice.50,52,53 Moreover, the 
inter-patient variability in the response to the biologics could explain why some HS 
patients are successfully treated while others show a lesser response. Interestingly, in 
our ex vivo  assay, secukinumab did not inhibit protein concentration of respectively 
IL-17 in the same way as adalimumab and infliximab reduced that of TNF-α. Unfor-
tunately, IL-12p40 protein, an important indicator of the IL-17 pathway, fell below 
the level of detection in the multiplex assay. However, the lower mRNA expression 
of the AMPs, IL-6 and CXCL-8 can be considered as the indirect result of block-
ing the bioactivity of IL-17A and IL-12/23p40 by secukinumab and ustekinumab, 
respectively. Rituximab was the only biologic without a significant inhibitory effect 
on individual inflammatory mRNA and protein levels. This is not surprising as B cell 
blockade in inflammatory diseases acts via inhibition of antibody production, antigen 
presentation and indirectly via cytokine reduction.54
In conclusion, our ex vivo skin culture system represents an adequate model for 
studies in search of novel candidate drugs for the treatment of HS, and to personalise 
the treatment in specific patients. Future ex vivo studies could focus on dose-response 
relationships, combinations of monoclonal antibodies or bi/trifunctional antibodies, 
and biologics in combination with low dose prednisolone.
In a clinical setting, we studied the efficacy and tolerability of apremilast at a dosage 
of 30 mg twice daily in patients with moderate HS. A clinical response as measured 
by the HiSCR50 was met in 8 of 15 (53.3%) patients in the apremilast group and 
none of 5 patients (0%) in the placebo group at week 16 (Chapter 5.1). This response 
rate is within the range of the proportion of HiSCR50 achievers reported in four 
studies which have investigated biologics in patients suffering moderate-to-severe 
HS; 41.8% to 60.0%.50,55,56 In addition, patients treated with apremilast showed a 
significantly lower abscess and nodule count, and levels of pain and pruritus over 16 
weeks compared with placebo-treated patients. Although the DLQI improved in the 
apremilast-treated patients, its trend over time was not significantly different between 
the treatment arms, possibly because of the large variability observed. Furthermore, 
treatment with apremilast was generally well tolerated, similar to the safety data from 
larger trials in patients with psoriasis and psoriatic arthritis.57,58
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We believe that apremilast is a valuable option after failure of conventional treat-
ments such as the combination of clindamycin and rifampicin. Moreover, apremilast 
may have the following potential advantages over both antibiotics and biologics. A 
drawback of recurrent or long-term antibiotic treatment is the risk of inducing bacte-
rial resistance.  A problem with the use of TNF-α antagonists such as adalimumab 
and infliximab is the risk of anti-drug antibody formation with neutralisation of the 
therapeutic effect over time.59
In Chapter 5.2 we aimed to detect changes in the expression of important inflam-
matory markers in lesional skin between the two treatment arms. Although we did 
not observe significant differences, related S100A12 and IL-17A were significantly el-
evated in lesional skin and showed a decline only in the apremilast group. Moreover, 
in psoriasis, the significant reduction of IL-17A and IL-17F plasma protein levels after 
apremilast treatment highlights its impact on the Th17 pathway.60 Our nonsignificant 
results could be explained by several determinants. First, the regression to the mean 
phenomenon should be considered as a possible cause as the highly inflammatory 
index lesions could have spontaneously improved over time in the context of the 
fluctuating nature of the disease, especially in the placebo group. Second, the inflam-
matory infiltrate and substrates for the foreign body inflammation were gradually 
reduced by successively taking biopsies from the same nodule. Third, the small and 
possibly underpowered study population could have resulted in the nonsignificant 
findings. Previously, two open label studies investigating respectively infliximab and 
ustekinumab in HS patients neither found a change in inflammatory protein serum 
levels after treatment, nor could link translational data to the clinical response.61,62 In 
conclusion, assessing pharmacodynamics (in the skin) in a highly fluctuating inflam-
matory disease remains challenging. A better translational model in clinical trials 
involving HS has yet to be developed.
Modifying the disease course by targeting the hair follicle yielded 
ambiguous results 
Current treatment strategies primarily focus on treating the consequences rather 
than preventing flare-ups or sustaining remission. Because follicular occlusion is 
considered to be the primary event in the pathogenesis of HS, we hypothesised that 
targeting the hair follicle would ameliorate the disease. Therefore, two non-invasive 
techniques that could potentially improve the symptoms and clinical course of HS 
were separately studied: hair reduction using the 1064-nm neodymium-doped yt-
trium aluminium garnet (Nd:YAG) laser and microwave ablation (miraDry).
Three previous studies that used the Nd:YAG laser in HS primarily focused on 
targeting the inflammatory lesions rather than destroying the hair follicles.63-65  We 
retrospectively evaluated the effect of Nd:YAG depilation of a whole anatomic area 
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in 15 patients with Hurley stage I and HS-PGA 2. Because of the different approach 
in using the Nd:YAG laser, our HS patients were less severely affected than those in 
previous studies (Hurley II and III disease severity). Treatment with Nd:YAG resulted 
in a significant decrease in the number of patient-reported monthly flares after a 
follow-up period of on average more than one year  (Chapter 6.1). In addition, mean 
HS disease severity after depilation as measured by a NRS was significantly lower 
in comparison with before therapy. Two-thirds of the patients would recommend 
Nd:YAG depilation to other HS patients. These results suggest that laser hair removal 
could be a novel therapeutic approach to prevent disease progression or ameliorate 
the disease, especially in HS patients with the follicular sub-phenotype.66 However, 
our findings could be biased due to natural fluctuation of the disease course as 
there was no control group. Other study limitations are a possible recall bias and 
the absence of physician-reported outcomes such as an abscess and nodule count. 
Prospective randomised controlled trials are warranted to confirm the mechanism of 
action and long-term efficacy of laser hair removal in mild HS.
Recently, non-invasive microwave ablation (MWA) using the miraDry device have 
demonstrated promising results for permanent reduction of axillary hairs.67 There may 
be advantages of MWA over light- and laser-based methods. MWA requires only 1 
or 2 sessions to achieve 70% reduction of hair growth,67 while light- and laser-based 
methods often require 6 to 10 sessions to realise such results. Moreover, outcomes of 
MWA are independent of skin type and hair colour.67
We hypothesised that MWA could potentially improve the symptoms of HS by 
reducing the number of hair follicles (primary action) and the destruction of the in-
flammatory cell infiltrate (secondary action) in HS lesions. Therefore, in Chapter 6.2, 
we evaluated the efficacy and safety of MWA for mild axillary HS in a randomised 
intrapatient-controlled trial. Only 9 of 20 planned HS patients were included because 
the study was prematurely terminated due to negative clinical outcomes. In total, 8 
patients completed the three month follow-up, of which 5 showed worsening of their 
disease after microwave ablative therapy. Commercial miraDry clinics in The Neth-
erlands also observed a few cases of flaring of the disease in HS patients (personal 
communication).
As the miraDry device targets a zone rather than a particular structure, its non-
selectivity might have resulted in the poor study outcomes. Accordingly, we argue 
that the microwave energy is able to rupture pre-existing and subclinical or micro-
scopic HS precursor lesions (cysts), subsequently resulting in an intense inflamma-
tory response beyond the initially visible lesions. In addition, the development of 
HS-like lesions such as abscesses and nodules are a relatively frequent complication 
of miraDry treatment in otherwise healthy subjects with axillary hyperhidrosis.68 We 
used miraDry energy level 5 (manufacturer’s recommended setting) corresponding 
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with an energy delivery time of 3.0 seconds. Although the delivery time in level 1 
(lowest setting) is only 0.6 seconds shorter than level 5 (highest setting), the effect on 
hair reduction using the lowest setting has never been reported. In conclusion, our 
findings indicate that MWA using the miraDry device has no apparent clinical benefit 
and may even be harmful in patients with mild axillary HS. Therefore, we question 
the utility of microwave ablative therapy in patients with HS in clinical practice.
FUTURE PERSPECTIVES
Pathomechanisms
Despite the rising number of publications on HS in the recent years, there are still many 
questions to be addressed. Therefore, further research in various arenas is warranted 
to ultimately improve the management and treatment of patients with HS and related 
syndromic conditions. Large gaps remain in the understanding of the pathogenesis of 
HS. Genetic research should aim to add more detail to the proposed mechanism by 
which loss of function of NCSTN or of other γ-secretase proteins causes familial HS, 
and to better stratify patients with HS. Immunologic studies should focus on molecular 
drivers of tissue inflammation and injury in HS and the relationship between the HS 
cytokine profile and disease activity. Next generation sequencing methods will help 
unravelling the genome, transcriptome, and proteome of HS patients. Furthermore, 
microbiome research is needed to better characterise the disruption to the microbial 
ecosystem and to elucidate whether the disruption causes the disease or whether the 
disease causes the dysbiosis. High-throughput metagenomic methods can make this 
work possible. Finally, it will be important to focus research on the interaction of 
environmental factors and immunogenetic factors.
Immunogenetic research in progress
In 2017, we reported a novel NCSTN mutation in a three-generation Dutch family 
with HS.69 In HS, 83% (30/36) of the previously reported sequence variants in the 
γ-secretase complex are scattered throughout the extracellular domain of the NCSTN 
gene without particular hotspots,70 indicating a critical role for NCSTN in the stability 
of the γ-secretase complex.71 Because the nicastrin protein exhibits multiple conserved 
residues and is for 88% (63/72 amino acids) homologous to the murine counterpart, 
we used the microarray dataset of the Immunological Genome Project (ImmGen) 
to perform a thorough dissection of the expression and function of NCSTN in the 
immune system. In short, the expression data of the NCSTN  gene were normalised as 
part of the ImmGen pipeline by Robust Multichip Average as described by Jojic et al.72 
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Gene Expression Omnibus data were subsequently log2-transformed and signatures 
for 16 cell lineages (both hematopoietic and mesenchymal) were calculated.
Wildtype NCSTN appeared to be upregulated in myeloid cells like monocytes 
and macrophages, and mesenchymal cells such as fibroblastic reticular cells and 
fibroblasts (Figure 1). We hypothesise that mutated NCSTN variants could affect the 
function of these cell lineages, ultimately leading to an aberrant immune response, 
especially in the skin. In addition, ARNT, PPARδ and CAPNS1 were identified in 
the 25 highest co-expressed genes with NCSTN (Figure 2). The ARNT gene encodes 
the aryl hydrocarbon receptor nuclear translocator protein. The aryl hydrocarbon 
receptor (AhR) is involved in the induction of several enzymes that participate in 
xenobiotic metabolism, including dioxin and polycyclic aromatic hydrocarbons 
which are present in cigarette smoke.73 PPARδ facilitates AhR signalling, enhances 
fatty acid catabolism, and induces keratinocyte differentiation.74,75 Calpain-like pro-
teases process the precursor form of IL-1α into the biologically active mature form, an 
important pro-inflammatory cytokine in epithelial and myeloid cells.76,77
In summary, the associated immunobiological functions of NCSTN, ARNT and 
PPARδ link genetics to the environment, which are smoking, the metabolic syndrome, 
and the skin microbiome.78 Because we observed a positive association between 
pack years of smoking and disease severity in the three affected family members, 
we are investigating the role of AhR ligands and its relation to bacterial products in 





Figure 1. Wildtype NCSTN expression in hematopoietic and mes-
enchymal cell lineages. The colour intensity correlates with the de-
gree of change. (a) Myeloid signature with upregulation in mono-
cytes, macrophages, non-lymphoid dendritic cells, and neutrophils. 
(b) Upregulation of stromal cells and typically fibroblastic reticular 
cells and fibroblasts. BEC: blood endothelial cell. FRC: fibroblastic 
reticular cell. LEC: lymphatic endothelial cell. 
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Chapter 1 is the general introduction and provides the main objectives of this the-
sis. Hidradenitis suppurativa (HS) is a chronic, debilitating, autoinflammatory skin 
disease with a prevalence rate of approximately 1% in Europe. HS usually presents 
in the adolescence with inflammatory nodules and abscesses, followed by sinus 
tract formation and scarring in predominantly the inverse body areas such as the 
axillae and groins. Key symptoms of HS include pain, discomfort, and a purulent, 
foul-smelling discharge. The physical and psychological consequences of the disease 
can profoundly reduce several aspects of patient’s quality of life. Although the patho-
physiology of HS is not fully understood, follicular occlusion is supposed to be the 
key triggering event. This is followed by dilatation and subsequent rupture of the hair 
follicle causing an intense immune response. Exogenous factors such as smoking, 
obesity, and mechanical friction in addition to genetic predisposition and alterations 
in the microbiome may contribute to the onset and progression of the disease. Rap-
idly evolving understanding of pathogenic mechanisms and clinical perspectives are 
needed to improve disease awareness, disease management, and ultimately improve 
patient outcomes. Because multiple facets of HS are not yet known, the outline of 
this thesis was not limited to only one aspect of the disease. We focused on clinical 
features and (immuno)pathogenic mechanisms as a rationale for the development of 
novel treatment strategies.
In Chapter 2 we determined the prevalence, and explored the characteristics of 
pruritus in a well-defined cohort of patients with HS. The prevalence of HS-related 
itch (NRS score ≥3) in 211 patients was 57.3%. Patients with a pruritus NRS score ≥3 
suffered more HS-affected body sites (p < 0.001), more often Hurley stage III disease 
severity (p < 0.001), and higher levels of HS-related pain (p < 0.001) compared with 
patients reporting a NRS score <3. In a subpopulation (n = 51), the most commonly 
reported characterisation of pruritus was moderate (54%) to severe (27%) itching 
sensations for less than 6 hours per day (56%), which had not changed in the previous 
2 weeks (48%). Histological examination on 24 random HS skin samples showed that 
eosinophilic granulocytes were present in 25% (2/8) of the perilesional skin and 63% 
(10/16) of the lesional skin, while a perineural infiltrate was found in 25% (2/8) and 
69% (11/16) of the perilesional and lesional skin, respectively. Our results suggest 
that pruritus is a frequent but underreported aspect of HS. Its moderate-to-severe 
intensity and consequential impact on sleep and activities of daily living have great 
potential to impair patients’ quality of life. Therefore, standardised assessment of 
pruritus (e.g. using a NRS or VAS) in both daily practice and clinical research settings, 
Chapter 8
142
together with the DLQI and EQ-5D, may form a helpful additional patient-reported 
outcome measure to evaluate disease severity/activity and treatment outcome.
In Chapter 3 we measured the in vivo protein levels of 30 important markers of 
inflammation, including Th1 and Th17 cytokines and chemokines, in the plasma and 
(lesional) skin of 20 HS patients and 10 healthy controls using a multiplex electroche-
miluminescent immunoassay platform (Meso Scale Discovery). In the circulation of 
HS patients, CCL-26 (eotaxin-3) was significantly elevated and CXCL-10 significantly 
lowered compared with healthy controls. In lesional skin, protein levels of IL-16, 
IL-17A, CXCL-8, IL-12/23p40, CCL-4, and CXCL-10 were significantly higher than in 
controls. Additionally, immunohistochemistry demonstrated overexpression of CCL-
4, CXCL-10, and CCL-26 in the HS infiltrate. Interestingly, there was no significant 
correlation between protein levels in patient plasma and lesional skin with correla-
tion coefficients varying between −0.53 and +0.42. In conclusion, the cytokine and 
chemokine profile of HS patients, including newly identified IL-16, CCL-4, CXCL-10 
and CCL-26, reflects the ongoing skin inflammation in HS. Moreover, the local and 
systemic upregulation of CCL-26 in HS patients can be linked to the high pruritus 
score in HS. Lastly, our results demonstrate that cytokine and chemokine levels in 
plasma give a limited reflection of the activated local cutaneous inflammatory milieu.
In Chapter 4 we sought to quantify the anti-inflammatory potency of currently avail-
able biologics targeting TNF-α, IL-17A, IL-12/23p40, or CD20 in an ex vivo disease 
model. Real-time quantitative PCR and cytokine bead arrays were used to measure 
the inhibitory effects of adalimumab, infliximab, secukinumab, ustekinumab, and 
rituximab in addition to prednisolone (positive control) on cytokines and AMPs in HS 
lesional skin compared to healthy control skin. The relative mRNA expression of all 
tested cytokines and AMPs was significantly downregulated by all anti-inflammatory 
agents (p < 0.0001). The release of the important pro-inflammatory cytokines TNF-α, 
IFN-γ, IL-1ß, IL-6, and IL-17A was significantly inhibited by adalimumab, infliximab, 
ustekinumab, prednisolone (all p < 0.0001), and rituximab (p = 0.0071), but not 
by secukinumab (p = 0.0663). Moreover, adalimumab, infliximab and prednisolone 
reduced the levels of a broader mix of individual cytokines than secukinumab, 
ustekinumab, and rituximab. Our results suggests that TNF-α inhibitors and predniso-
lone are the most powerful inhibitors of pro-inflammatory cytokines and AMPs in HS 
lesional skin. Lastly, our ex vivo skin culture system represents an adequate model for 
studies in search of novel candidate drugs for the treatment of HS and to personalise 
the treatment in specific patients.
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In Chapter 5.1 we evaluated the efficacy and short-term safety of apremilast in 
patients with moderate HS. Apremilast is a small molecule drug that specifically 
inhibits phosphodiesterase 4, thereby modulating the expression of a variety of pro-
inflammatory and anti-inflammatory mediators. A total of 20 patients with moderate 
HS were randomised in a 3 : 1 ratio to receive blinded treatment with apremilast, 
30 mg twice daily, or placebo for 16 weeks. The Hidradenitis Suppurativa Clinical 
Response (HiSCR) was met in 8 of 15 patients in the apremilast group (53.3%) and 
none of 5 patients in the placebo group (0%) (p = 0.055) at week 16. Moreover, the 
apremilast-treated patients showed a significantly lower abscess and nodule count 
(mean difference, −2.6; 95% CI, −6.0 to −0.9; p = 0.011), NRS for pain (mean dif-
ference, −2.7; 95% CI, −4.5 to −0.9; p = 0.009), and itch (mean difference, −2.8; 
95% CI, −5.0 to −0.6; p = 0.015) over 16 weeks compared with the placebo-treated 
patients. There was no significant difference in the DLQI over time between the two 
treatment arms (mean difference, −3.4; 95% CI, −9.0 to 2.3; p = 0.230). The most 
frequently reported adverse events in the apremilast-treated patients were mild-to-
moderate headache and gastrointestinal symptoms, which did not lead to dropouts. 
Concluding, apremilast is a promising new treatment option for HS. Studies with 
larger populations and longer follow-up are needed to further elucidate the efficacy 
and safety profile of apremilast in HS.
In Chapter 5.2 we assessed the change in expression of inflammatory markers in 
lesional skin of HS patients receiving apremilast 30 mg or placebo twice daily for 16 
weeks. At baseline, 5-mm punch biopsies were obtained from an index lesion (HSL) 
and non-lesional skin (HSN) in the same anatomical area. Subsequent HSL samples 
were taken as close as possible to the previously biopsied site at week 4 and week 16. 
After sampling, biopsies were split; one half was processed for in vivo mRNA analysis 
using real-time quantitative PCR and the other half was cultured for ex vivo protein 
analysis using a proximity extension assay (Olink). At baseline, 17 proteins with a 
fold change >2 in HSL versus HSN skin were identified in 20 patients. The top-5 were 
IL-17A (5), S100A12, CST5, IL-12/23p40, CD6 (1) with fold changes ranging from 
6.6 to 1638, respectively (FDR < 0.044). Protein levels of S100A12 decreased during 
treatment in the apremilast group compared with the placebo group (p = 0.014, FDR 
= 0.186). None of the 14 genes exhibited significant changes in expression over time, 
although an evident downward trend in relative mRNA expression of IL-17A and 
IL-17F was demonstrated in patients receiving apremilast. Our findings highlight the 




In Chapter 6.1 we evaluated the effect of hair removal using a long-pulsed 1064-nm 
Nd:YAG laser on the course of the disease in a case series of 15 patients with mild 
HS. A questionnaire was used to assess several patient-reported outcomes. Nd:YAG 
depilation resulted in a decrease in the number of monthly flares (p = 0.019). In 
addition, the mean (± SD) HS disease severity after depilation was significantly lower 
than before therapy, NRS 6.4 ± 2.8 versus NRS 3.6 ± 3.5 (p = 0.010), respectively. 
The majority of patients reported a 51-75% decrease of hair growth after treatment. 
Overall treatment satisfaction was rated with a NRS score of 6.7 ± 2.4, and two-
thirds of the patients would recommend Nd:YAG depilation to other HS patients. 
Our results suggest that laser hair removal could be a novel therapeutic approach to 
prevent disease progression or ameliorate the disease, especially in HS patients with 
the follicular sub-phenotype. However, the findings we obtained could be biased due 
to natural fluctuation of the disease course. We believe that randomised controlled 
trials are warranted to confirm the mechanism of action and long-term efficacy of 
laser hair removal in mild HS.
In Chapter 6.2 we evaluated the efficacy and safety of microwave ablative therapy 
using the miraDry device for mild axillary HS in a randomised intrapatient-controlled 
trial. Only 8 of 20 HS patients completed miraDry treatment; negative clinical out-
comes during the recruitment period resulted in the decision to discontinue the study. 
Two patients achieved the HiSCR in the miraDry-treated axilla, and two patients 
achieved the HiSCR in the comparator axilla (p = 1.00). In total, 5 of 8 patients showed 
worsening of their disease after miraDry treatment. Moreover, the median (IQR) NRS 
score for pain in the miraDry-treated axilla was 7.0 (2.0-8.0) versus 0 (0-5.0) for the 
untreated axilla after 3 months (p = 0.07). The number of hair follicles after 3 months 
was numerically lower in the miraDry-treated axilla, median 4.0 (3.0-5.0)/cm2, a 
50.9% decrease from baseline, compared with the untreated counterpart, median 
8.5 (6.0-10.0)/cm2, a 2.0% decline from baseline (p = 0.07).  We argue that the 
microwave energy is able to rupture pre-existing and subclinical or microscopic HS 
precursor lesion (cysts), subsequently resulting in an intense inflammatory response.
Taken together, we question the utility of microwave ablative therapy in patients with 
HS in clinical practice. 
In Chapter 7 we provided a general overview of the main findings, discussed the 
clinical implications of these findings, and suggested directions for future research. 
Four key themes have emerged from this thesis. Firstly, pruritus or itch is a frequent 
and bothersome symptom in patients with HS. Several pathophysiological substrates 
could explain the occurrence of HS-related pruritus. Secondly, the overexpression of 
chemokines and cytokines in HS lesional skin reflects a chronic, activated local in-
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flammatory milieu, indicating the need for effective anti-inflammatory HS therapies. 
Thirdly, the potency and efficacy of novel anti-inflammatory agents for HS were dem-
onstrated in respectively laboratory and clinical trial settings. Fourthly, two treatment 
strategies (primarily) targeting the hair follicle yielded ambiguous results in mild HS. 
Further research in various arenas is needed to ultimately improve the management 













Hoofdstuk 1 is de algemene inleiding en geeft de belangrijkste doelstellingen van 
dit proefschrift. Hidradenitis suppurativa (HS) is een chronische, invaliderende, auto-
inflammatoire huidziekte met een prevalentie van ongeveer 1% in Europa. HS open-
baart zich meestal in de adolescentie met inflammatoire nodi en abcessen, gevolgd 
door sinusvorming en littekens in voornamelijk de lichaamsplooien, zoals oksels 
en liezen. De belangrijkste symptomen van HS zijn pijn, ongemak en een etterige, 
riekende afscheiding. De fysieke en psychologische gevolgen van de ziekte kunnen 
verschillende facetten van de kwaliteit van leven van de patiënt ingrijpend verminde-
ren. Hoewel de pathofysiologie van HS niet volledig bekend is, wordt verondersteld 
dat folliculaire occlusie een belangrijke activerende gebeurtenis in de pathogenese 
is. Na occlusie volgt dilatatie met daaropvolgende ruptuur van de haarfollikel, welke 
een intense immuunrespons veroorzaakt. Exogene factoren zoals roken, obesitas 
en mechanische wrijving kunnen naast genetische aanleg en veranderingen in het 
microbioom bijdragen aan het ontstaan  en de progressie van de ziekte. Toenemend 
inzicht in pathogene mechanismen en klinische inzichten zijn nodig om het ziekte-
bewustzijn, therapieën en uiteindelijk de behandelresultaten van patiënten met HS te 
verbeteren. Omdat meerdere aspecten van HS nog niet bekend zijn, is de hoofdlijn 
van dit proefschrift niet beperkt tot slechts één aspect van de ziekte. We hebben ons 
gericht op klinische kenmerken en (immuno)pathogene mechanismen als basis voor 
de ontwikkeling van nieuwe behandelstrategieën.
In Hoofdstuk 2 hebben we de prevalentie van pruritus met bijbehorende kenmer-
ken onderzocht in een goed gedefinieerd cohort HS patiënten. De prevalentie 
van HS-gerelateerde jeuk (NRS-score ≥3) bij 211 patiënten was 57.3%. Patiënten 
met een pruritus-NRS-score ≥3 hadden meer aangedane anatomische regionen (p 
< 0.001), vaker Hurley stadium III ziekte-ernst (p < 0.001) en hogere niveaus van 
HS-gerelateerde pijn (p < 0.001) vergeleken met patiënten die een NRS-score <3 
rapporteerden. In een subpopulatie (n = 51) was de meest gerapporteerde typering 
van pruritus: matig (54%) tot ernstige (27%) jeukende sensaties gedurende minder 
dan 6 uur per dag (56%), wat niet veranderd was in de afgelopen 2 weken (48%). 
Histologisch onderzoek van 24 willekeurige HS huidbiopten toonde aan dat eosino-
fiele granulocyten aanwezig waren in 25% (2/8) van de perilaesionale huid en 63% 
(10/16) van de laesionale huid, terwijl een perineuraal infiltraat werd aangetroffen 
in respectievelijk 25% (2/8) en 69% (11/16) van de perilaesionale en laesionale 
huid. Onze resultaten suggereren dat pruritus een vaak voorkomend symptoom van 
HS is. De matige tot ernstige intensiteit van pruritus en de bijkomende invloed op 
slaap en dagelijkse activiteiten kunnen de kwaliteit van leven van patiënten met HS 
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verminderen. Het gestandaardiseerd uitvragen van jeuk (bijvoorbeeld met een NRS 
of VAS) kan naast de DLQI en EQ-5D een nuttige aanvullende patiënt-gerapporteerde 
uitkomstmaat zijn om de ziekte-ernst/activiteit te evalueren in de dagelijkse praktijk 
en in studieverband.
In Hoofdstuk 3 hebben we de in vivo eiwitniveaus gemeten van 30 belangrijke inflam-
matoire markers, waaronder Th1- en Th17-cytokines en chemokines, in het plasma en 
de (laesionale) huid van 20 HS patiënten en 10 gezonde controles. Hiervoor maakten 
wij gebruik van een multiplex elektrochemiluminescent immunoassay-platform 
(Meso Scale Discovery). In het plasma van HS patiënten was CCL-26 (eotaxine-3) 
significant verhoogd en CXCL-10 significant lager dan in gezonde controles. In de 
HS laesionale huid waren de eiwitniveaus van IL-16, IL-17A, CXCL-8, IL-12/23p40, 
CCL-4 en CXCL-10 significant hoger dan in de controlehuid. Bovendien was er sterke 
immunohistochemische aankleuring voor CCL-4, CXCL-10 en CCL-26 in het HS infil-
traat. Interessant genoeg was er geen significante correlatie tussen eiwitniveaus in het 
plasma en de laesionale huid van HS patiënten, waarbij de correlatiecoëfficiënten 
varieerden tussen −0.53 en +0.42. Samenvattend concluderen wij dat het geïdentifi-
ceerde cytokine- en chemokine-profiel, waaronder de nieuwe markers IL-16, CCL-4, 
CXCL-10 en CCL-26, de aanhoudende inflammatie in HS patiënten weerspiegelt. 
Bovendien kan de lokale en systemische verhoging van CCL-26 in patiënten met HS 
verklaard worden door de hoge pruritusscore in HS. Tenslotte tonen onze resultaten 
aan dat cytokine- en chemokinewaarden in plasma een beperkte reflectie geven van 
het geactiveerde lokale inflammatoire milieu.
In Hoofdstuk 4 hebben we getracht de anti-inflammatoire potentie van de momen-
teel beschikbare biologics gericht tegen TNF-α, IL-17A, IL-12/23p40 of CD20 te 
kwantificeren in een ex vivo ziektemodel. Real-time kwantitatieve PCR en cytokine 
bead-arrays werden gebruikt voor het meten van het remmende effect van adali-
mumab, infliximab, secukinumab, ustekinumab, rituximab en prednison (positieve 
controle) op cytokines en AMP’s in laesionale HS huid in vergelijking met gezonde 
controlehuid. De relatieve mRNA-expressie van alle geteste cytokinen en AMP’s werd 
significant verlaagd door alle anti-inflammatoire middelen (p < 0.0001). De afgifte 
van de belangrijke pro-inflammatoire cytokinen TNF-α, IFN-γ, IL-1ß, IL-6, IL-17A 
werd significant geremd door adalimumab, infliximab, ustekinumab, prednison 
(allen p < 0.0001) en rituximab (p = 0.0071), maar niet door secukinumab (p = 
0.0663). Daarnaast verminderden adalimumab, infliximab en prednison een bredere 
mix van individuele cytokines dan secukinumab, ustekinumab en rituximab. Onze 
resultaten suggereren dat anti-TNF-α biologics en prednison de krachtigste rem-
mers zijn van pro-inflammatoire cytokines en AMP’s in laesionale HS huid. Verder 
151
Nederlandse samenvatting
vormt ons ex vivo huidkweeksysteem een  adequaat model voor studies naar nieuwe 
kandidaat-geneesmiddelen voor HS en voor het personaliseren van een behandeling 
bij specifieke HS patiënten.
In Hoofdstuk 5.1 zijn de effectiviteit en korte-termijn veiligheid van apremilast bij 
patiënten met matige HS onderzocht. Apremilast is een small molecule geneesmiddel 
dat specifiek fosfodiësterase-4 remt, waardoor de expressie van een verscheidenheid 
aan pro-inflammatoire en ontstekingsremmende mediatoren wordt gemoduleerd. In 
totaal werden 20 patiënten met matig HS gerandomiseerd in een 3 : 1 ratio voor 
een  geblindeerde behandeling met apremilast 30 mg tweemaal daags of placebo 
gedurende 16 weken. De Hidradenitis Suppurativa Clinical Response (HiSCR) op 
week 16 werd bereikt bij 8 van de 15 (53.3%) patiënten in de apremilast-groep en 
geen van de 5 (0%) patiënten in de placebogroep (p = 0.055). Daarnaast verbeter-
den andere klinische scores significant gedurende 16 weken in de patiënten met 
apremilast ten op zichte van patiënten met placebo: abcessen en inflammatoire nodi 
(gemiddeld verschil, −2.6; 95% CI, −6.0 tot −0.9; p = 0.011), NRS voor pijn (gemid-
deld verschil, −2.7; 95% CI, −4.5 tot −0.9; p = 0.009) en jeuk (gemiddeld verschil, 
−2.8; 95% CI, −5.0 tot −0.6; p = 0.015). Er was geen significant verschil in de DLQI 
tussen de twee behandelgroepen (gemiddeld verschil, −3.4; 95% CI, −9.0 tot 2.3; p 
= 0.230). De meest frequent gemelde bijwerkingen waren lichte tot matige hoofdpijn 
en gastro-intestinale symptomen, die niet tot drop-outs hebben geleid. Concluderend 
is apremilast een veelbelovende nieuwe behandeloptie voor HS. Studies met grotere 
populaties en met een langere follow-up zijn nodig om de effectiviteit en het veilig-
heidsprofiel van apremilast in HS verder te onderzoeken.
In Hoofdstuk 5.2 beoordeelden we de verandering in de expressie van inflammatoire 
markers in de laesionale huid van HS patiënten die behandeld werden met twee-
maal daags apremilast 30 mg of placebo. Op baseline werden 5 mm stansbiopten 
verkregen van een indexlaesie (HSL) en de niet-laesionale huid (HSN) in hetzelfde 
anatomische gebied. Daaropvolgende HSL biopten in week 4 en week 16 werden 
zo dicht mogelijk bij de eerder gebiopteerde locatie genomen. Elk huidbiopt werd 
gesplitst; de ene helft werd verwerkt voor in vivo mRNA-analyse met behulp van real-
time kwantitatieve PCR en de andere helft werd gekweekt voor ex vivo eiwitanalyse 
met behulp van een proximity extension assay (Olink). Op baseline werden 17 eiwit-
ten geïdentificeerd met een fold change >2 in HSL versus HSN huid bij 20 patiënten. 
De top-5 bestond uit IL-17A (5), S100A12, CST5, IL-12/23p40, CD6 (1) met een fold 
change variërend van respectievelijk 6.6 tot 1638 (FDR < 0.044). Het eiwitgehalte 
van S100A12 nam af in de apremilast-groep in vergelijking met de placebogroep (p = 
0.014, FDR = 0.186). Geen van de 14 genen vertoonden significante veranderingen 
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in de tijd, hoewel een duidelijke neerwaartse trend in relatieve mRNA-expressie 
van IL-17A en IL-17F werd aangetoond bij patiënten die apremilast ontvingen. Onze 
bevindingen benadrukken de uitdaging om de farmacodynamiek te beoordelen in de 
huid van een ontstekingsziekte met een sterk fluctuerend natuurlijk beloop.
In Hoofdstuk 6.1 evalueerden we het effect van ontharing met behulp van een 
long-pulsed 1064-nm Nd:YAG-laser op het beloop van de ziekte in een case serie 
van 15 patiënten met milde HS. Een vragenlijst werd gebruikt om verscheidene 
patiënt-gerapporteerde uitkomsten te beoordelen. Nd:YAG ontharing resulteerde in 
een afname van het aantal maandelijkse opvlammingen (p = 0.019). Daarnaast was 
de gemiddelde (± SD) HS ziekte-ernst na ontharing significant lager dan vóór de 
behandeling, respectievelijk NRS 6.4 ± 2.8 versus NRS 3.6 ± 3.5 (p = 0.010). De 
meerderheid van de patiënten rapporteerde een 51-75% afname van de haargroei na 
behandeling. De algehele tevredenheid over de behandeling werd beoordeeld met 
een NRS-score van 6.7 ± 2.4 en twee derde van de patiënten zou Nd:YAG ontharing 
aanbevelen aan andere HS patiënten. Onze resultaten suggereren dat laserontharing 
een nieuwe therapeutische benadering kan zijn om progressie van de ziekte te voor-
kómen of de symptomen te verminderen, vooral bij HS patiënten met het folliculaire 
subfenotype. De gevonden resultaten kunnen echter vertekend zijn door natuurlijke 
fluctuaties in het ziektebeloop. Gerandomiseerde onderzoeken zijn gerechtvaardigd 
om het werkingsmechanisme en de lange-termijn effectiviteit van laserontharing in 
milde HS te bevestigen.
In Hoofdstuk 6.2 onderzochten we de werkzaamheid en veiligheid van ablatieve the-
rapie met microwaves, gebruikmakend van het miraDry-apparaat, voor milde axillaire 
HS in een randomised intrapatient-controlled trial. Slechts 8 van de 20 HS patiënten 
werden (volledig) behandeld met de miraDry omdat negatieve klinische uitkomsten 
tijdens de wervingsperiode in de beslissing resulteerde om het onderzoek voortijdig 
te beëindigen. Twee patiënten bereikten de HiSCR in de miraDry-behandelde axilla 
en twee patiënten bereikten de HiSCR in de contralaterale axilla (p = 1.00). In totaal 
vertoonden 5 van de 8 patiënten verslechtering van hun ziekte na behandeling met 
miraDry. Bovendien was de mediane (IQR) NRS-score voor pijn in de met miraDry 
behandelde axilla 7.0 (2.0-8.0) versus 0 (0-5.0) in de onbehandelde axilla na 3 maan-
den (p = 0.07). Het aantal haarfollikels na 3 maanden was numeriek lager in de met 
miraDry behandelde axilla, mediaan 4.0 (3.0-5.0)/cm2, een daling van 50.9% ten op-
zichte van baseline, vergeleken met de onbehandelde axilla, mediaan 8.5 (6.0-10.0)/
cm2, een daling van 2.0% ten opzichte van baseline (p = 0.07). Omdat de microwave 
energie bestaande en subklinische of microscopische HS voorloper-laesies (cysten) 
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kan activeren, is het de vraag of er in de dagelijkse praktijk een toegevoegde waarde 
is voor het gebruik van deze techniek bij patiënten met HS.
In Hoofdstuk 7 hebben we een algemeen overzicht gegeven van de belangrijkste 
bevindingen, de klinische implicaties van deze bevindingen besproken, en sug-
gesties voor toekomstig onderzoek gedaan. Er zijn vier kernthema’s voortgekomen 
uit dit proefschrift. Ten eerste is gebleken dat jeuk een frequent voorkomend en 
hinderlijk symptoom is bij patiënten met HS. Hierbij identificeerden we verschil-
lende pathofysiologische substraten die de HS-gerelateerde jeuk kunnen verklaren. 
Ten tweede detecteerden we verhoging van verscheidene pro-inflammatoire cyto-
kinen en chemokinen in de HS laesionale huid, wat de ontwikkeling van effectieve 
anti-inflammatoire HS-therapieën rechtvaardigt. Ten derde konden we de potentie 
en effectiviteit van nieuwe anti-inflammatoire geneesmiddelen voor HS aantonen 
met behulp van respectievelijk laboratorium- en klinische studies. Ten vierde waren 
er ambigue resultaten voor twee behandelstrategieën die zich (primair) richten op 
destructie van de haarfollikels. Tot slot is meer onderzoek naar uiteenlopende aspec-





ADL activities of daily living
AE adverse event
AhR aryl hydrocarbon receptor
AMP antimicrobial peptide
AN abscesse and nodule
BMI body mass index
CCL CC chemokine ligand
CD cluster of differentiation
CI confidence interval
CRP C-reactive protein
CXCL CXC chemokine ligand
DAMP damage-associated molecular pattern
DLQI Dermatology Life Quality Index
EDTA ethylenediaminetetraacetic acid
EQ-5D EuroQoL-5D, a standardised instrument 
for measuring generic health status
FDR false discovery rate
GM-CSF granulocyte-macrophage colony-
stimulating factor
HBD human beta defensin
HE haematoxylin and eosin
HiSCR Hidradenitis Suppurativa Clinical 
Response
HS hidradenitis suppurativa
HS-PGA Hidradenitis Suppurativa Physician’s 
Global Assessment
IBD inflammatory bowel disease
IFN interferon
IL interleukin
IMID immune-mediated inflammatory disease
IQR interquartile range
IRB institutional review board




mRNA messenger ribonucleic acid
MWA microwave ablation
Nd:YAG neodymium-doped yttrium aluminium 
garnet
NRS numeric rating scale, ranging from 0 to 
10
PAC pyoderma, acne, colitis ulcerosa
PAMP pathogen-associated molecular pattern
PASH pyoderma gangrenosum, acne, 
suppurative hidradenitis
PCR polymerase chain reaction
PG pyoderma gangrenosum
PI3K phosphoinositide 3-kinase
PROM patient-reported outcome measure
SD standard deviation
TGF tissue growth factor
Th T helper
TIMP tissue inhibitor of metalloproteinase
TLR toll like receptor
TNF tumour necrosis factor
VAS visual analogue scale
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- Meeting Hidradenitis Patiënten Vereniging in Utrecht – Hidradenitis 
suppurativa 
2016 0.5 ECTS 
- 5th conference of the EHSF in Berlin – Waist to hip ratio in HS 2016 1.0 ECTS 
Other
- Project leader of the HiScreen Registry & Biobank, Erasmus MC and 
DermaHaven
2016 - present 100 hours
- Research meetings: ‘Methodology’ and ‘Journal Club’, department of 
Dermatology of the Erasmus MC 
2015 - 2018 50 hours 
2. Teaching
Lecturing
- Minor Inflammunity for medical students 2018 0.5 ECTS
- Auto-immune diseases of the skin for medical interns 2018 1.0 ECTS 
- National EIDON meetings on HS for dermatologists and (plastic) 
surgeons 
2017 - 2018 2.0 ECTS 
- International EIDON meetings on HS for dermatologists and (plastic) 
surgeons 
2016 - 2018 1.0 ECTS 
Tutoring
- Tutor ‘Kennismaking Beroeps Praktijk’ – Geneeskunde jaar 1, Erasmus 
MC 
2016 - 2017 10 hours 
Supervising students
- Master thesis of medical student Seth Dykstra 2017 - 2018 1.0 ECTS 
- Research project of medical student Marinka Terian 2016 - 2017 0.5 ECTS 
- Master thesis of medical student Annelien Schoenmakers 2016 1.0 ECTS 
Occasional reviewer for
- European Journal of the European Academy of Dermatology and 
Venereology 
2018 4 hours 
- Journal of Investigative Dermatology 2018 4 hours 
- British Journal of Dermatology 2017-2018 8 hours 
- Experimental Dermatology 2017 4 hours 




Allard Vossen werd op 20 februari 1989 geboren te Groningen. Niet veel later 
verhuisde hij met zijn ouders naar het Noord-Brabantse Halsteren alwaar hij zijn 
verdere jeugd doorbracht. In 2007 behaalde hij zijn gymnasium diploma aan het 
R.K. Gymnasium Juvenaat H. Hart te Bergen op Zoom. Hetzelfde jaar startte hij met 
het mr.drs.-programma (Economie en Recht) aan de Erasmus Universiteit Rotterdam 
nadat hij was uitgeloot voor de studie Geneeskunde. Een jaar later behaalde hij zijn 
propedeuse Economie en werd hij via decentrale selectie alsnog aangenomen om 
Geneeskunde te studeren. Het was tijdens zijn coschap Dermatologie in het Erasmus 
Universitair Medisch Centrum, onder begeleiding van dr. M.B.A. van Doorn, dat zijn 
interesse voor dit specialisme werd gewekt. Na het behalen van het artsexamen in 
2014 heeft hij als arts-assistent niet in opleiding op de afdeling Heelkunde van het 
Reinier de Graaf Gasthuis te Delft gewerkt om klinische ervaring op te doen. Eind 
2015 startte hij met zijn promotieonderzoek op de afdeling Dermatologie in het 
Erasmus Universitair Medisch Centrum onder begeleiding van promotor prof. dr. E.P. 
Prens en copromotor dr. H.H. van der Zee. Naast zijn promotieonderzoek werkte 
hij mee aan meerdere klinische trials en zette hij zich in voor de reguliere zorg 
van patiënten met hidradenitis suppurativa. Verder was hij medeorganisator van het 
European Hidradenitis Suppurativa Foundation (EHSF) congres te Rotterdam in 2018, 
en is hij werkgroeplid van de nationale (NVDV) en internationale (HS ALLIANCE) 
behandelrichtlijn voor hidradenitis suppurativa. In januari 2019 begint hij aan de 





Dit proefschrift was niet tot stand gekomen zonder de hulp van velen. Graag wil ik 
een aantal hiervan in het bijzonder bedanken. 
Prof. dr. E.P. Prens, beste Errol, ik kan onze eerste kennismaking in september 2015 
op het laboratorium nog goed herinneren: jij enthousiast vertellende over transla-
tionele studies − ik nog klinisch werkende bij de Heelkunde met de ambitie om 
dermatoloog te worden. Na een week bedenktijd besloot ik de uitdaging van een 
promotietraject aan te gaan en daar heb ik geen moment spijt van gehad. Onze goede 
samenwerking is in mijn ogen het fundament geweest voor de totstandkoming van 
mijn proefschrift. Ik kon altijd bij je binnenlopen en de laatste maanden – sinds de 
verhuizing naar de nieuwbouw – kwam je minstens zo vaak langs op de onderzoeks-
kamer. Ik bewonder je enorme drive, je creatieve klinische en wetenschappelijke 
visie, en het feit dat je in elk denkbare situatie de rust bewaart. Je bent een waardig 
leermeester en een inspirator voor velen. 
Dr. H.H. van der Zee, beste Hessel, exact 7 jaar na jouw promotiedatum verdedig 
ik mijn proefschrift over dezelfde aandoening. Als mijn dagelijks begeleider ben ik je 
dankbaar voor de scherpe adviezen over tal van praktische onderzoeks-gerelateerde 
zaken. Met name je frisse kijk op de opbouw van een manuscript heb ik gewaardeerd. 
Bovendien hebben je routinebezoeken aan de onderzoekskamer op de woensdag-
ochtend (“kan ik nog wat voor je nakijken?”) er mede voor gezorgd dat ik in 3 jaar 
kon promoveren. 
Dr. M.B.A. van Doorn, beste Martijn, onder jouw begeleiding, tijdens het coschap 
Dermatologie in het Erasmus MC, ben ik enthousiast geworden over dit specialisme. 
Bedankt dat je me de kans gaf om onderzoek op te starten, en – nog belangrijker – dat 
je me in contact bracht met Errol. Daarnaast ben ik je dankbaar voor je kritische blik 
op meerdere manuscripten.
Prof. dr. T.E.C. Nijsten (secretaris), prof. dr. P.M. Verhagen en dr. B. Horváth, har-
telijk dank voor de bereidheid om zitting te nemen in de kleine promotiecommissie 
en voor het in een kort tijdsbestek doornemen en beoordelen van mijn proefschrift. 
De leden van de grote commissie, prof. dr. G.B.E. Jemec, prof. dr. J.D. Laman, dr. 
M.B.A. van Doorn en dr. R.J.B. Driessen, hartelijk dank voor uw aanwezigheid op 
deze bijzondere dag en het wisselen van gedachten over mijn proefschrift. 
De patiënten die hebben deelgenomen aan onze onderzoeken wil ik in het 
bijzonder bedanken. Zij hebben vrijwillig vragenlijsten ingevuld, experimentele 
behandelingen ondergaan en/of lichaamsmateriaal afgestaan voor onderzoek naar 
hidradenitis suppurativa. 
Kelsey, Christine, HS buddy’s, onze samenwerking bij tal van gemeenschappelijke 
projecten is altijd vlekkeloos verlopen – van statistiek tot het uitvoeren van ex vivo 
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experimenten en qPCR, van het schrijven van artikelen en richtlijnen tot het orga-
niseren van de EHSF2018 en EIDON. Bedankt voor jullie gezelligheid en hulp bij 
verscheidene klinische en wetenschappelijke activiteiten. 
Mijn kamergenoten (Nd-212), Jill, Linde, Joanne, Christine, Kelsey, met jullie 
aanwezigheid was mijn promotietraject in alle fasen leuker en makkelijker. Een kof-
fiemomentje, een inhoudelijk overleg, lunchen in het museumpark, de afleiding als 
iemand op de achtergrond met een patiënt aan het bellen was, de altijd beschikbare 
SPSS hulplijn van Jill of Kelsey – alles op de kamer zorgde ervoor dat ik beter kon 
presteren. Daarnaast bedankt dat jullie de hoofdstukken van mijn proefschrift hebben 
doorgelezen voor een opmaak- en spellingscheck. 
Het research team, Manon, Denise, Annelies, en studenten Mike, Benthe, Tessa, 
Charlotte, jullie zijn de drijvende kracht achter de uitvoering van alle klinische onder-
zoeken op de afdeling. Bedankt voor jullie hulp bij de SMASH en WAVE trial. Loes, 
dank voor alle statistische lessen en je enthousiasme tijdens de research meetings en 
journal clubs. Ik heb hier veel geleerd. 
Het Dermatologie-Reumatologie laboratorium, Erik, Eddy, Nadine, Patrick, Anne 
Marie, Xiaofei, Wida, Wendy, Marlieke, Hannah, bedankt voor het bijbrengen van 
de fijne kneepjes van het pipetteren en de delicate manier van werken op een onder-
zoekslaboratorium – liever een trippelcheck dan een dubbelcheck.  
Alle arts-onderzoekers, arts-assistenten, stafleden, doktersassistenten, secretaresses 
van de afdeling Dermatologie van het Erasmus MC, bedankt voor de gezellige en 
leerzame jaren en de jaren die gaan komen. Barbera en Natasja, dank voor de suc-
cesvolle samenwerking tijdens de organisatie van de EHSF2018. En ook niet te verge-
ten zijn de (vrijdagmiddag)borrels − deze zullen we met het vaste clubje voortzetten. 
In 2007 begon mijn tijd in Rotterdam en inmiddels zijn er vele vriendschappen ont-
staan.  De mannen van JC Duke, Huize Pinkeltje, Leonidas H5, maten uit Rotterdam 
en Bergen op Zoom, de Suriname clan, met elkaar hebben we mooie herinneringen 
opgebouwd − dat er nog vele mogen volgen.
Ewout en Roelant, broeders, door dik en dun zijn wij er voor elkaar. Bedankt voor 
de hechte band die wij hebben. Trots ben ik dat jullie mij als paranimfen flankeren 
tijdens de verdediging van mijn proefschrift − dit betekent veel voor mij.  
Papa en mama, jullie zijn geweldige ouders en geven me veel liefde en waardering. 
Ik kan alles met jullie bespreken en ik waardeer het dat jullie er altijd voor me zijn. 
Door jullie diepgaande interesse in school, studie en werk en daaruit voortvloeiende 
adviezen kon ik de juiste keuzes maken. Mede daarom sta ik hier vandaag.
Jeanne-Marie, in het afgelopen jaar is er echt wat moois ontstaan tussen ons − wat 
fijn dat ik jou aan mijn zijde heb. Dankjewel voor de liefde die je me geeft en dat je 
altijd voor me klaar staat.
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